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Abstract 
Current techniques to identify growth-restricted fetuses, at risk of health 
complications, have limited accuracy. Placental insufficiency is a key 
pathological process in fetal growth restriction (FGR). I investigated the 
potential clinical benefit of placental biomarkers to identify pregnancies 
delivering small for gestational age (SGA) infants in pregnancies with suspected 
pre-eclampsia and in those with reduced symphysis-fundal height measurement 
using delivery of an SGA infant as a surrogate measure of FGR.  
 
Suspected pre-eclampsia (PELICAN-PE study) 
In a large multicentre prospective cohort study investigating diagnostic accuracy 
of placental growth factor (PlGF) in women with suspected pre-eclampsia, I 
assessed test performance of 47 biomarkers and ultrasound parameters to 
identify women delivering an SGA infant. 
 
PlGF measurement outperformed all other biomarkers and currently used tests 
in predicting delivery of an SGA infant. Combinations of biomarkers added 
minimal value.  
 
Reduced symphysis-fundal height measurement (PELICAN-FGR study) 
I assessed the ability of PlGF and ultrasound parameters to predict delivery of 
an SGA infant in women with reduced symphysis-fundal height (current UK 
standard to identify pregnancies at risk of SGA) in a second multinational 
prospective cohort study.  Test performance statistics were calculated for all 
parameters in isolation and combination. 
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Ultrasound parameters had modest test performance for predicting delivery of 
an SGA infant. PlGF performed no better. Incorporating PlGF with ultrasound 
parameters provided modest improvements. 
 
In women presenting with suspected pre-eclampsia, PlGF measurement is a 
potentially useful adjunct to current practice in identifying those at risk of SGA. 
The findings of the PELICAN-FGR study cannot support the use of PlGF to risk 
stratify women referred with reduced symphysis-fundal height. The prevalence 
of FGR in the two studies differed, with a high number of normal pregnancies in 
those presenting with reduced symphysis-fundal height. The pathological 
process in normotensive versus hypertensive SGA may differ, potentially 
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1.1: Being born small-for-gestational-age (SGA): The 
scope of the problem 
 
The small-for-gestational-age infant is defined as an being born with a birth 
weight below a pre-specified threshold, commonly the third or tenth birth weight 
centiles (Robson et al., 2013). Being born SGA is a global health problem with 
an estimated 18 million babies born SGA per annum, contributing to 60-80% of 
neonatal deaths (UNICEF, 2004). These infants are at increased risk of life-
threatening complications compared to those born with birth weights 
appropriate-for gestational-age (AGA), even when born at term (Malin et al., 
2014), likely secondary to the high incidence of fetal growth restriction (failure of 
a fetus to fulfill their growth potential) (FGR) amongst SGA infants.  
 
These complications originate in the antenatal period and include stillbirth 
(Moraitis et al., 2014). As part of “The Lancet stillbirth series” Lawn et al. 
reported FGR (sometimes referred to as intrauterine growth restriction (IUGR)) 
and placental insufficiency as the highest attributable cause of stillbirth in high-
income countries (including, Australia, Canada, The Netherlands, Norway, UK 
and USA), (present in 32% of antenatal and 26% of intrapartum stillbirths) and 
identified FGR as one of the five main targets to achieve a reduction in stillbirth 
globally (Lawn et al., 2011). FGR, secondary to placental insufficiency, has 








Complications of being delivered SGA are not limited to the antenatal period but 
extend into adult life. These include perinatal and neurodevelopmental 
complications and long-term health complications, such as coronary heart 
disease, hypertension and type 2 diabetes mellitus. Maternal factors that 
predispose to SGA are discussed in detail in section 1.1.3.1. 
 
To reduce the short and long-term health complications associated with being 
born SGA, it is paramount that pregnancies at risk are identified early in the 
antenatal period, allowing targeted monitoring and potentially early intervention. 
However, accurately identifying at-risk pregnancies, diagnosing FGR 
antenatally and optimising management of this high-risk group remains 
challenging. This largely relates to a lack of understanding of the pathological 
mechanisms underlying FGR and limited sensitivity of current screening tools 
and diagnostic tests to accurately identify those at risk. In clinical practice, SGA 
is the target of most screening tools currently employed, which partly explains 
the limited sensitivity of these tools as pregnancies complicated by SGA are a 
heterogenous group including those that are constitutionally small in addition to 
a proportion of pregnancies with FGR. Using SGA as a surrogate for FGR leads 
to the inevitable over investigation and possible intervention, including 
iatrogenic delivery and its ensuing complications, in constitutionally small 








Within the Lancet stillbirth series, Flenady et al. highlighted ‘the need for further 
research into the underlying mechanisms of fetal growth restriction facilitating 
early detection and effective management of women at increased risk’ (Flenady 
et al., 2011b) and Goldenberg et al. included; ‘improving antenatal screening for 
risk factors for stillbirth, such as fetal growth restriction’, as a high priority 
research theme in the concluding article of the series (Goldenberg et al., 2011).  
 
There is no doubt of the importance of the risks associated with delivering a 
growth restricted infant on an individual and global scale and the impact of this 
on healthcare resources. Accurately predicting those at risk of delivering a 
growth restricted infant, enabling targeted intervention, has the potential to 
improve outcome and avoid some of the devastating consequences linked to 
this condition, whilst also avoiding intervention in the group of constitutionally 
small infants.  
 
1.1.1 Clinical importance of identifying the SGA infant antenatally 









1.1.1.1 Short term complications 
1.1.1.1.1 Perinatal complications 
Two North American population studies (including 12,317 and 19,759 
pregnancies who delivered preterm) observed increased rates of respiratory 
distress syndrome, intraventricular haemorrhage and necrotising enterocolitis in 
those born SGA compared to those delivering AGA (McIntire et al., 1999, 
Bernstein et al., 2013). In term SGA infants, increased incidence of fetal 
acidosis (McIntire et al., 1999), seizures within the first week of life (Bukowski et 
al., 2003) and perinatal stroke have been reported (Wu et al., 2004), although 
generalisation and reproducibility of the findings of the latter two studies may be 
limited due to their small sample size and study design (single site nested case-
control study). Polycythaemia, hyperbilirubinaemia and hypoglycaemia have 
also been cited as more common in growth-restricted infants, possibly 
secondary to chronic hypoxia and reduced hepatic glycogen stores (Mayer and 
Joseph, 2013). 
 
1.1.1.1.2 Neurodevelopmental complications 
SGA infants have been found to be at increased risk of cerebral palsy 
compared to those born AGA. This risk is reported as decreasing with 
advancing gestational age (Surveillance of Cerebral Palsy in Europe, 2000). A 
population based case-control study in Sweden compared rates of cerebral 
palsy in SGA infants to those born AGA. They found that the risk of cerebral 






infants, incidence of cerebral palsy, was not more common with SGA 
(Jacobsson et al., 2008).  
McCormick et al. reported poorer academic performance, lower intelligence, 
poor social interaction and behavioural problems amongst those born SGA in 
two cohorts of 8-10 year olds, with differing birth weights (McCormick et al., 
1996). However they suggest that this relationship may occur due to the 
presence of risk factors for delivering an SGA infant rather than a direct effect 
from low birth weight. Pryor et al. and Walker et al. published similar findings 
with the addition of defects in short-term memory in infants born SGA, 
compared to those born AGA (McCormick et al., 1996, Schothorst and van 
Engeland, 1996, Pryor et al., 1995, Walker and Marlow, 2007). Strauss et al. 
analysed data from the National Collaborative Perinatal Project, a large 
multicentre cohort study, and concluded that there were significant differences 
in IQ at age seven between those born SGA and their AGA counterparts 
(Strauss and Dietz, 1998). However, when they compared the growth and 
development of 220 similar-sex term sibling pairs where one sibling was born 
SGA, they found no significant difference in IQ unless there was associated low 
head circumference. These findings suggest that genetic and environmental 
factors play a significant role in the differences observed in IQ when the whole 







1.1.1.1.3 Stillbirth and neonatal death 
Whilst acknowledging that stillbirth is uncommon in high income countries, a 
systematic review and meta analysis reported SGA as having the highest 
population attributable risk of all pregnancy specific disorders (23%) (Flenady et 
al., 2011a). A large cohort study of 92,218 singleton pregnancies (including 389 
stillbirths) reported that if SGA (birth weight <10th customised centile) was not 
recognised antenatally, the risk of stillbirth increased five-fold, emphasising the 
importance of antenatal detection (Gardosi et al., 2013b). A recent multinational 
study evaluated the effects of preterm and SGA delivery on neonatal and 
postnatal mortality in a pooled analysis of data from low and middle-income 
countries. The relative risk of neonatal mortality in babies born SGA at term was 
1.83 (CI 1.32-2.50) and 6.82 (CI 3.56-13.07) for those born preterm. In babies 
born preterm and SGA, the risk was much higher (15.42 (CI 9.11-26.12)) (Katz 
et al., 2013). Improved recognition of SGA would allow appropriate surveillance 
and timing of delivery. A large Swedish retrospective cohort study including 
26,968 women (681 with SGA infants detected antenatally) concluded that 
instigating a structured antenatal surveillance program for pregnancies 
identified as SGA antenatally resulted in a lower risk of fetal adverse outcome 
(Lindqvist and Molin, 2005).  
 
In 1992, Gardosi et al. proposed that use of customised growth centiles, as 
opposed to population derived centiles, improved detection of the SGA fetus 
(Gardosi et al., 1992). In 2009 they published a retrospective analysis on a 






concluded that use of customised birth weight centiles more accurately 
identified those at most risk of adverse outcome, including stillbirth (Gardosi and 
Francis, 2009). However, in a population of women at high-risk of 
uteroplacental insufficiency, use of customised fetal weight limits only detected 
68% of cases antenatally who subsequently delivered an SGA infant, 
highlighting the need for further improvement in identifying those at risk (De 
Jong et al., 2000). Customised birth weight centiles are discussed in more detail 
in section 1.1.2.1.  
 
 
1.1.1.2 Long-term health complications 
1.1.1.2.1 Complications in childhood 
Two large cohort studies, in New Zealand and North America, have reported 
heights and weights of children who were born SGA, to be significantly less 
than those born AGA and this difference persisted into adulthood (Strauss and 
Dietz, 1998, Pryor et al., 1995).  
!
1.1.1.2.2 Complications in adulthood 
Multiple large cohort studies have reported increased incidence of coronary 
heart disease (Frankel et al., 1996, Leon et al., 1998, Bonamy et al., 2011), 
hypertension (Eriksson et al., 2000, Curhan et al., 1996, Huxley et al., 2000) 






Edwards et al., 1999, Newsome et al., 2003) in adults who were born SGA, 
compared to those born AGA.  
 
A possible explanation for these associations involves the concept of 
‘developmental plasticity’, where the fetus adapts in response to the intrauterine 
environment and nutrition in early life (Barker, 2006). One such adaptation is 
insulin resistance, which is associated with the development of type 2 diabetes 
mellitus and hypertension in adult life. This is thought to occur secondary to 
persistence of a protective fetal metabolic adaptation to ensure adequate 
glucose supply to developing organs in a harsh intrauterine environment 
(Phillips, 1996).  
Another possibility is the presence of a maternal genetic susceptibility to 
cardiovascular disease, which may contribute to delivery of an SGA infant, who 
may also inherit this trait. Women with a genetic predisposition to 
cardiovascular disease may have impaired haemodynamic changes in 
pregnancy, resulting in placental dysfunction and inadequate oxygen and 
nutrient supply to the developing fetus. Such women are at increased risk of 
vascular complications, including hypertensive disorders and pre-eclampsia, 
with the ensuing complications of preterm delivery and FGR. This offers some 
explanation why women who give birth to SGA infants have a higher risk of 







Possible mechanisms for these associations remain speculative and it remains 
unclear whether intervention would reduce incidence or improve outcome from 
these multifactorial conditions (Mayer and Joseph, 2013). 
 
1.1.2: Defining the small for gestational age (SGA) infant 
The SGA infant is defined as an infant born with a birth weight below a pre-
specified threshold, commonly the third or tenth birth weight centiles (Robson et 
al., 2013). Other thresholds for defining SGA have been used, including the 
2.5th, 5th and 20th centiles, but the 10th birth weight centile derived from 
appropriate healthy populations is the most frequently reported. This definition 
includes both constitutionally small infants and those with FGR. The latter refers 
to any fetus that fails to fulfill their growth potential, and represents a group at 
high risk of adverse outcome. Figure 1.1 illustrates the relationship between 








Figure 1.1 Venn diagram displaying the relationship between SGA and FGR 
The circle depicting FGR is dotted to represent the uncertainty of the proportion 
of SGA infants who have FGR. 
 
FGR, fetal growth restriction 
 
SGA infants are at increased risk of neonatal morbidity (Bernstein et al., 2013, 
McIntire et al., 1999) and mortality (Frøen et al., 2004, Lawn et al., 2005, 
Lackman et al., 2001), compared to their AGA counterparts, likely secondary to 






which threshold is most appropriate for defining SGA, as this affects the 
proportion of infants within the group that are growth restricted.  
 
If a threshold of the 10th centile from a healthy population is used to define 
SGA, it would be expected that 10% of normal pregnancies (i.e. constitutionally 
small infants) will be included in this group. These pregnancies are not at 
increased risk of adverse outcome (Alfirevic et al., 2010) but by inclusion in this 
definition of SGA they would be subject to extra surveillance which may lead to 
unnecessary anxiety and intervention. Using a lower threshold, such as the 
third centile from a healthy population will reduce the proportion of normal 
pregnancies included to 3%, but would potentially omit cases of FGR, included 
if a higher threshold is employed. Whilst use of any population based threshold 
will omit some cases of FGR it is proposed that those cases of FGR at most risk 
of adverse outcome are likely to be those with low birth weight, and therefore 
using a population based threshold such as the 10th centile offers the best 
probability to identify most cases at risk.  
 
1.1.2.1 Customised birth weight centiles 
Historically, SGA has been defined according to thresholds derived from 
healthy populations. In 1992, Gardosi et al. published data comparing use of 
customised growth centiles to population-based centiles for defining SGA. 
Customised charts incorporated data on maternal height, weight, ethnicity and 






differentiating those SGA fetuses who are growth restricted from those who are 
constitutionally small. They concluded that 28% of babies identified as SGA 
using population based centiles, were within normal limits for that individual 
woman if customised centiles were used, whilst 24% of babies assigned as 
SGA using customised centiles were missed using conventional unadjusted 
centiles (Gardosi et al., 1992). Subsequent studies have shown that use of 
customised centiles improves identification of small babies at high-risk of 
adverse outcomes, including stillbirth (Odibo et al., 2011) and neonatal death 
(Clausson et al., 2001) and that a threshold of the 10th centile provides a high 
detection rate for SGA and its related perinatal complications (Gardosi and 
Francis, 2009, Clausson et al., 2001, Figueras et al., 2007, De Jong et al., 
2000). However, there remains some controversy regarding widespread 
adoption of customised centiles into clinical practice. At earlier gestational ages, 
the customised centiles are calculated using Hadlock’s proportionality formula, 
in contrast to conventional birth weight charts, which use the weights of live 
births. Hadlock’s formula uses measurements of head circumference, 
abdominal circumference and femur length to estimate fetal weight (Hadlock et 
al., 1985). It has been proposed that this, rather than incorporation of maternal 
characteristics into the model, causes the improved detection of those most at 
risk (Hutcheon et al., 2008).  
 
A further concern relates to the inclusion of ethnicity as a component of the 
customised fetal growth charts. The recently published Intergrowth 21st project 






geographically diverse areas when other factors affecting fetal growth were 
controlled for (e.g. nutritional intake, maternal health and level of antenatal 
care). They evaluated fetal growth and newborn size in eight geographically 
diverse urban areas and suggested that genetic variation has little effect on 
fetal growth (Villar et al., 2014). The World Health Organisation (WHO) 
Multicentre Growth Reference Study (MGRS) has previously reported very 
similar patterns of infant growth across six sites in Europe, Africa, India, The 
Middle East and North and South America, when there was little variation in 
environmental, health and nutritional status. This led to construction of 
International growth standards from birth to five years of age (WHO., 2006b, 
WHO., 2006a, WHO., 2006c). The authors of the Intergrowth 21st project 
suggest that previously reported differences in fetal growth in diverse 
populations are more likely due to socioeconomic and environmental factors 
rather than genetic variation. These data are currently being analysed to 
construct standardised International prenatal and neonatal growth standards, 
with the aim of integrating these with the standards derived from the WHO 
Multicentre Growth Reference Study.  
 
The UK Royal College of Obstetrics and Gynaecology Guideline: The 
Investigation and Management of the SGA Fetus, published in 2011, prior to 
Intergrowth, suggests that use of customised fetal weight references may 
improve prediction of a SGA neonate and an adverse perinatal outcome 






1.1.3 Causes of fetal growth restriction 
FGR is a multifactorial condition and risk factors can broadly be divided into, 
maternal, fetal and placental factors. Maternal factors predisposing to placental 
dysfunction account for the largest proportion of cases, with fetal and other 
placental factors playing a much smaller role. 
1.1.3.1 Maternal factors 
1.1.3.1.1 Pre-eclampsia and Placental dysfunction!
Pre-eclampsia is a pregnancy specific condition which is classically defined as 
new onset of hypertension after 20 weeks’ gestation with documented 
proteinuria (≥ 300 mg/day or urinary protein/creatinine ratio ≥ 30 mg/mmol) 
(Brown et al., 2001). The condition occurs when there is failure of adequate 
trophoblast invasion of the maternal spiral arteries leading to impaired placental 
blood flow and episodes of placental ischaemia, and oxidative stress (Huppertz, 
2008, Kaufmann et al., 2003, Poston et al., 2011). Redman et al. suggest that 
proinflammatory mediators are released into the maternal circulation, triggering 
a widespread inflammatory response with alteration in concentrations of many 
acute phase proteins (Redman and Sargent, 2009). This combination of 
systemic inflammation and placental hypoxia leads to maternal endothelial 
dysfunction and the resulting non-specific clinical presentations of pre-
eclampsia.  
 
In addition to the mechanisms outlined above, increased vascular resistance 






deposition and placental infarction and abruption) lead to the frequent 
coexistence of FGR. The relationship between pre-eclampsia and FGR has 
been reported extensively, with severity of pre-eclampsia and gestation at onset 
correlating with presence and severity of FGR. Odegard et al. reported in a 
population based study, a 5% reduction in birth weight in pregnancies 
complicated by pre-eclampsia. This increased to a 12% reduction in birth weight 
with severe pre-eclampsia and birth weight was 23% lower than expected if 
there was early onset of disease (defined as delivery before 32 weeks’ 
gestation). The risk of delivering an SGA infant was four times higher in cases 
complicated by pre-eclampsia compared to controls (Odegard et al., 2000). The 
relationship between late-onset pre-eclampsia and coexistence of FGR is less 
clear with a large Canadian retrospective cohort study including 97,270 
pregnancies reporting that in women delivering beyond 37 weeks’ gestation, 
infant birth weights were similar for women with pre-eclampsia compared to 
those who remained normotensive (Xiong et al., 2002). This supports the theory 
that abnormal uteroplacental perfusion plays a larger role in the pathogenesis of 
early onset pre-eclampsia compared to late onset disease.  
 
Current NICE guidance on the Management of hypertensive disorders during 
pregnancy recommends that all women diagnosed with pre-eclampsia who are 
to be managed conservatively should be offered ultrasound scan to assess fetal 
growth, liquor volume and umbilical doppler measurement (National Institute for 
Health and Clinical Excellence, 2010). However, as discussed in section 






outcome is limited, even when customised centiles are used. There is a need 
for an accurate test to detect SGA antenatally, particularly in high-risk 
populations such as women with early onset pre-eclampsia, to identify women 
at increased risk of adverse perinatal outcome. 
 
Several chronic maternal conditions including hypertensive and renal disease, 
diabetes mellitus, systemic lupus erythematous and antiphospholipid syndrome 
are associated with an increased risk of FGR and pre-eclampsia, mainly 
considered to be secondary to placental dysfunction (Howarth et al., 2007, Fink 
et al., 1998, Yasmeen et al., 2001, Yasuda et al., 1995). A large Canadian 
population based study, including 135,466 pregnancies, reported that women 
with any hypertensive disorder in pregnancy were 1.6 times more likely to 
deliver an SGA infant compared to those who remained normotensive (Allen et 
al., 2004).  
It is hypothesised that procoagulant conditions, such as thrombophilias, lead to 
an increased risk of placental thrombosis with altered uteroplacental blood flow 
contributing to the development of FGR and in severe cases to fetal loss (Facco 
et al., 2009, Arias et al., 1998). Acquired thrombophilias such as anticardiolipin 
antibodies and lupus anticoagulant are associated with FGR and development 
of pregnancy complications such as pre-eclampsia and stillbirth (Yasuda et al., 
1995), but evidence of association with inherited thrombophilias is limited and 







1.1.3.1.2 Other maternal factors!
The association between smoking and FGR has been long established. A large 
international prospective cohort study, including 3513 nulliparous women, 
reported that smoking at 15 weeks’ gestation was associated with a 30-40% 
increased risk of SGA for every 5 cigarettes smoked per day, irrespective of 
whether the pregnancy was complicated by hypertension (19.2% of women 
delivering an SGA infant were smokers compared to 10% in those delivering an 
AGA infant) (McCowan et al., 2010). McCowan et al. published that cessation of 
smoking prior to 15 weeks’ gestation gave a risk of delivering an SGA infant 
comparable to a non-smoking population, highlighting the reversibility of this 
risk (McCowan et al., 2009). Smoking causes impaired uterine blood flow and a 
reduction in oxygen carrying capacity. The latter mechanism is also thought to 
contribute to the increased incidence of FGR in women who live at high altitude 
(Krampl, 2002), or have cyanotic heart disease (Patton et al., 1990), 
haemoglobinopathies or anaemia (Barfield et al., 2010). 
 
A systematic review and meta analysis including 78 studies, involving over one 
million women, reported that singleton pregnancies born to underweight women 
were at higher risk of preterm delivery (both spontaneous and iatrogenic) and 
being born SGA compared to those of normal weight (Han et al., 2011). A paper 
included in this systematic review by Ronnenberg et al. proposed reduced fetal 
nutrition as the mechanism of action (Ronnenberg et al., 2003). Low weight 
gain during pregnancy has also been linked to development of FGR (Lang et 






currently recommended (National Institute for Health and Clinical Excellence, 
2008). 
 
Fetal exposure to both prescription and recreational drugs can lead to FGR. 
Use of heroin or cocaine has been associated with delivery of an SGA infant in 
50% and 27% of cases respectively (Naeye et al., 1973, Fulroth et al., 1989). 
This could be partially attributed to the increased risk of chronic placental 
abruption with cocaine use and the coexisting poor nutrition often observed with 
drug misuse. The later is supported by data published by Naeye et al. where 
severity of SGA correlated with degree of malnutrition (Naeye et al., 1973). 
Alcohol consumption in pregnancy has also been linked to FGR and a large 
prospective study including 31,604 pregnancies reported that this risk is dose 
dependent (Mills et al., 1984). However a recent systematic review and meta-
analysis suggested that light to moderate alcohol intake had no effect on risk of 
delivering an SGA infant and that a dose dependent association was only 
established when daily intake exceeded 10g alcohol (one alcoholic drink) per 
day (Patra et al., 2011). Current national guidelines in the UK, issued prior to 
the systematic review discussed above, advise abstinence during pregnancy, 
perhaps related to the risks of alcohol, although there is little evidence that very 
low consumption (less than 1-2 international units of alcohol less than 1-2 times 
per week) affects fetal growth (Fraser, 2006). 
 
There are numerous additional maternal factors, which have been linked with 






(estimated to increase risk more than two-fold) (Tejani, 1982, Bakketeig et al., 
1993), low socioeconomic status (Wilcox et al., 1995), use of artificial 
reproductive techniques (independent of multiple gestation) (Jackson et al., 
2004, Schieve et al., 2002), short inter-pregnancy interval (Zhu et al., 1999), 
maternal periodontal disease (Khader and Ta'ani, 2005) and extremes of 
maternal age (Lee et al., 1988),. Lee et al. conducted a population study 
including 184,567 women with singleton pregnancies, evaluating the effects of 
maternal age on incidence of low birth weight in women delivering at term. They 
concluded that women under 17 years of age and those over 35 years of age 
were more likely to deliver a SGA infant. They hypothesised that poor 
sociodemographic and prenatal care in women under 17 years of age and 
biologic ageing of maternal tissues and systems in those over 35 years of age 
may contribute to this finding (Lee et al., 1988). The findings of the About 
Teenage Eating (ATE) study support this hypothesis in teenagers. Baker et al. 
reported lower micronutrient intake (including iron, folate and vitamin D) in 
adolescents who delivered SGA infants compared to those delivering AGA 
(Baker et al., 2009). In the Screening for Pregnancy Endpoints (SCOPE) cohort 
(prospective multicentre cohort study including 3513 nulliparous women), 
increasing maternal age was identified as an independent risk factor for 
delivering an SGA infant. This group also reported a correlation between 
maternal dietary intake and risk of SGA, with a high fruit and vegetable intake 
being protective, whilst low fruit intake pre-pregnancy was identified as an 
independent risk factor (McCowan et al., 2010). The exact protective agents in 






micronutrients (including folate, ascorbate, carotenoids and magnesium) and 
dietary fibre and other phytochemicals may play a role. Alternatively they 
suggest that higher fruit and vegetable intake may merely reflect a healthier 
lifestyle (McCowan et al., 2010). Other groups have published on the 
contribution of micronutrient concentrations to delivering an SGA infant (Mistry 
and Williams, 2011). Mistry et al. measured concentrations of selenium, copper 
and zinc in 126 adolescent pregnant women recruited to the ATE study. Third 
trimester concentrations of selenium were lower in those delivering an SGA 
infant compared to their AGA counterparts, whereas differences in 
concentrations of zinc and copper were not significant (Mistry et al., 2014). 
Selenium is a cofactor for several important enzymes involved in antioxidant 
defence. The authors suggest that low maternal concentrations of selenium 
reduce this defence mechanism, leading to restriction of fetal growth. Whilst 
encouraging, large intervention trials would be needed to assess the impact of 
micronutrient supplementation on incidence of SGA prior to consideration of 
clinical adoption. 
1.1.3.2 Fetal factors 
Chromosomal defects are associated with FGR but the reported incidence of 
chromosomal abnormalities is this group varies between 5-20% (Sabogal, 
2007). One study including 458 fetuses with suspected SGA in the second and 
third trimester, reported an incidence of chromosomal abnormality of 19% in 
cases of severe SGA (abdominal circumference (AC) and estimated fetal weight 






commonest abnormality in fetuses prior to 26 weeks’ gestation with trisomy 18 
(Edward’s syndrome) after 26 weeks in this study (Snijders et al., 1993). Other 
aneuploidies and several genetic syndromes also have associations with 
delivery of an SGA infant. 
 
Congenital malformations in the absence of genetic disorders are a rare cause 
of SGA (accounting for 1-2% of cases), but presence of multiple malformations 
has been reported to increase risk (Khoury et al., 1988).  
 
Fetal infections have been reported in up to 5% of cases delivering an SGA 
infant (Hendrix and Berghella, 2008). Cytomegalovirus (CMV), toxoplasmosis, 
malaria and syphilis are the most commonly cited pathogens, whilst cases 
complicated by rubella infection, have decreased since widespread vaccination 
was adopted in developed countries (Hendrix and Berghella, 2008). However, a 
European multicentre prospective cohort study investigating the association 
between toxoplasmosis and subsequent delivery of a SGA infant found no 
causal relationship (Freeman et al., 2005).  
 
A recent small case control study investigated the presence of congenital CMV 
in 19 pregnancies (nine uncomplicated pregnancies (controls), seven cases of 
idiopathic FGR and three cases of pre-eclampsia) and found evidence of 
congenital CMV infection with abnormal placental pathology in five cases of 
idiopathic FGR (three recurrent and two primary infections) (Pereira et al., 






results suggest that subclinical antenatal infections could be responsible for a 
proportion of idiopathic FGR. Larger studies are warranted to substantiate these 
findings. 
 
It has been reported that approximately 3% of cases of FGR are associated 
with multiple pregnancy, with approximately 15-30% of twin pregnancies at risk 
of FGR (Resnik, 2002). FGR in one or more fetuses is associated with neonatal 
adverse outcome (Hendrix and Berghella, 2008).   
 
Whilst many fetal factors can contribute to delivery of an SGA infant, as a group 
fetal factors are causal in only a relatively small number of cases. 
 
1.1.3.3 Placental factors 
Placental abnormalities including placental abruption, infarction, and tumours 
(Zalel et al., 2002, Pham et al., 2006) have all been associated with increased 
risk of SGA likely secondary to reduced uteroplacental blood flow. A large 
American retrospective cohort study including 53,371 pregnancies reported 
SGA (birth weight <10th centile for gestational age) in 14.3% of pregnancies 
complicated by placental abruption compared to 8.1% in controls (Ananth et al., 
1999). Cord malformations, such as velamentous insertion and single umbilical 
artery have also been linked to delivery of an SGA infant. A Finnish 
retrospective cohort study reported increased risk of low birth weight and SGA 






controls (Heinonen et al., 1996). They suggest that velamentous insertion may 
be a compensatory mechanism counteracting impaired early placentation. If the 
primary implantation site has poor vascularity, they propose that the placenta 
migrates to a better site leading to a velamentous cord insertion. 
 
Placenta praevia and accreta have been quoted in review articles as increasing 
risk of delivering an SGA infant (Mayer and Joseph, 2013, Maulik, 2006), but a 
large retrospective cohort study including 59,149 women, (724 of whom had a 
placenta praevia) found no association (Harper et al., 2010). 
 
1.1.4 FGR and placental pathology  
Placental dysfunction, largely due to maternal factors, accounts for the greatest 
proportion of cases of FGR. Improved knowledge of placental pathology has 
facilitated identification of several pathological processes, which underpin the 
development of FGR. In 2008, Redline published a complex classification 
involving five chronic patterns of placental injury, which occur more frequently in 
the placentae from FGR infants (Redline, 2008). These included three 
categories affecting the maternal and fetal vasculature (maldevelopment, 
obstruction or loss of integrity) and two categories involving inflammatory 
processes (infectious and idiopathic). The idiopathic category included chronic 
histiocytic intervillositis and villitis of unknown aetiology (VUE). In VUE, a large 
maternal immune response is cited, predominately through activation of T 






unknown but high grade VUE is associated with significant perinatal morbidity 
and mortality (Redline, 2005, Redline and O'Riordan, 2000).  
Redline suggested that VUE is more common in normotensive term gestations 
with FGR whereas maternal vascular disorders are the most frequent finding in 
preterm deliveries and maternal hypertensive disease with FGR. 
 
Redline’s classification is not widely accepted. Vedmedovska et al. published a 
case series of placental pathology from 50 pregnancies complicated by 
placental disease (including FGR) and reported no differences in perivillous 
fibrin deposition between cases and controls (Vedmedovska et al., 2011).  
Perivillous fibrin deposition was classified by Redline as a maternal vasculature 
maldevelopment, observed in the placentae of women with pre-eclampsia. 
Huppertz et al. have proposed a different model for understanding differing 
placental pathologies for pre-eclampsia and FGR, involving dysregulation of 
trophoblast differentiation. Timing of dysregulation influences development of 
pre-eclampsia or FGR or coexistence of these conditions; it is proposed that 
early dysregulation of trophoblast development results in a combination of pre-
eclampsia and FGR whilst later dysregulation of syncytiotrophoblast leads to 
pre-eclampsia and dysregulation of cytotrophoblast development results in 
isolated FGR (Huppertz, 2011).   
 
Both Redlines and Huppertzs models, propose that different pathological 






This may be relevant when considering potential diagnostic tools for FGR, as 
concentrations of markers may be altered in normotensive FGR compared to 
FGR with hypertension and different markers may be more useful in these two 
distinct groups. The theory of differing pathological mechanisms in women with 
pre-eclampsia compared to those remaining normotensive but delivering an 
SGA infant is supported by the findings of Pecks et al. (Pecks et al., 2012). This 
group evaluated the oxidative state of low-density lipoproteins (LDL) in FGR 
and pre-eclampsia. Several authors have previously reported an increased 
maternal plasma oxidised LDL concentration in pre-eclampsia (Kim et al., 2007, 
Uzun et al., 2005). Pecks et al. proposed that oxidised LDL impairs trophoblast 
invasion affecting remodeling of the spiral arteries contributing to poor 
placentation and the sequelae of pre-eclampsia, and assumed a similar pattern 
would be evident in those pregnancies complicated by delivering an SGA infant. 
However the authors reported an inverse relationship with low concentrations of 
oxidised LDL in pregnancies delivering an SGA infant (Pecks et al., 2012). 
 
1.1.5 Summary 
Being born SGA is a global health problem, associated with significant neonatal 
morbidity and mortality with complications extending into adult life. Identifying 
pregnancies at risk remains challenging but integration of maternal and fetal 







FGR is a multifactorial condition, but placental dysfunction secondary to 
maternal disease is the underlying pathological process in the majority of cases.  
Improvements in the understanding of the pathophysiological processes 
underlying placental disease has aided the identification of upstream markers 
altered early in the pathological process allowing earlier detection and targeted 
intervention. 
 
1.2 Current clinical practice for identifying the SGA 
infant in a low-risk population 
 
Antenatal identification of infants who are subsequently delivered SGA remains 
challenging. Currently in the UK, healthcare professionals routinely conduct 
abdominal palpation and measurement of symphysis-fundal height from 24 
weeks’ gestation to assess fetal size and wellbeing and therefore reduced 
symphysis fundal height measurement was chosen as the inclusion criteria for 
the PELICAN FGR study. Several studies have demonstrated that abdominal 
palpation has limited accuracy (sensitivity 16-50%, specificity 45-95%) for 
detecting the SGA fetus, with Kean et al. publishing a false positive rate of 51% 
from their cohort of 2060 women (Bais et al., 2004, Kean and Liu, 1996, Hall et 
al., 1980, Rosenberg et al., 1982). This high false positive rate results in 
unnecessary follow up, incurring significant costs to the health service whilst 






remains part of routine clinical assessment as it provides information regarding 
fetal lie and possible abnormalities in amniotic fluid volume (e.g. oligo- or 
polyhydramnios). 
 
1.2.1 Symphysis fundal height (SFH) measurement 
Symphysis-fundal height measurement is easily performed in the community 
setting as it does not require expensive equipment, but the test performance of 
this technique is low (sensitivity 27% and specificity 88%) (Persson et al., 
1986).  Use of customised symphysis-fundal height charts, which adjust for 
maternal characteristics including maternal height, weight, parity and ethnic 
group, may improve detection of a SGA neonate whilst also reducing 
intervention. However, antenatal detection rates for SGA  <10th birth weight 
centile with use of customised fundal height charts have been reported as only 
48% (Gardosi and Francis, 1999). Similar findings have been reported in an 
Australian study where only approximately half of all cases of SGA (44/87) were 
being detected antenatally with customised symphysis-fundal height charts 
(Roex et al., 2012). Despite these results, implementation of customised charts 
in conjunction with accredited training has been associated with a reduction in 
stillbirth rates in areas of high uptake but these findings are yet to be 
substantiated in a randomised control trial (Gardosi et al., 2013a). A Cochrane 
systematic review identified only one randomised control trial of 1639 women, 
comparing symphysis-fundal height measurement to abdominal palpation. The 






height measurement was less accurate than abdominal palpation at identifying 
women who subsequently delivered an SGA infant (28% and 48% sensitivity 
respectively) and adoption of this technique had no significant effect on 
perinatal outcome, symphysis-fundal height measurement should not be 
discarded as a screening tool without a much larger trial verifying these findings 
(Neilson, 2000).  
 
1.2.2 Screening by routine ultrasound assessment 
In women with high body mass index (BMI), large fibroids, multiple pregnancy, 
abnormal fetal lie or polyhydramnios, symphysis-fundal height measurement is 
even less accurate and an alternative technique, such as serial ultrasound 
assessment should be considered. Current UK national guidance does not 
advocate screening all women using routine ultrasound to detect SGA due to 
reported low sensitivities (21-54%) (Ben-Haroush et al., 2007, Secher et al., 
1987, Souka et al., 2012, David et al., 1996, Lindqvist and Molin, 2005) with no 
evidence of improved perinatal outcome (Bricker et al., 2008). However, the 
preliminary findings of a recent prospective cohort study in an unselected 
nulliparous population including 4006 women compared routine sonography in 
the third trimester to current practice of selective sonography. Improved 
detection of SGA was reported with routine sonography at 28 and 36 weeks’ 
gestation (sensitivity to detect SGA 57% for routine sonography and 20% for 
selective sonography) (Sovio et al., 2014). Whilst this study suggests that 






of SGA, test sensitivity is limited, with nearly half of cases still remaining 
undetected in this study population. Ultrasound scanning requires expensive 
equipment and highly trained operators; there is therefore a need to evaluate its 
introduction as a screening approach through a randomised controlled trial prior 
to widespread adoption of routine third trimester scanning. This should consider 
the impact on adverse perinatal outcomes and cost implications to the health 
service.  
 
1.2.3 Doppler measurement 
A systematic review investigating the ability of second trimester uterine artery 
Doppler measurement to predict delivery of an SGA infant concluded that in 
low-risk women, an increased pulsatility index alone or with diastolic notching 
best predicted delivery of an SGA infant. However the authors commented that 
for a test to be clinically useful, it should ideally have a high positive likelihood 
ratio (>10) and low negative likelihood ratio (<0.10) and whilst increased 
pulsatility index and bilateral notching are the most promising indices to reach 
these parameters, their inclusion into a low-risk screening program would incur 
considerable cost, limiting use in a low resource setting. Inclusion of the test in 
settings where routine anomaly scanning is undertaken in the second trimester 
should be achievable, but this would lead to the inevitable identification of false 
positive cases. This could cause unnecessary anxiety in those who test positive 
but do not have the condition and more concerning, as this test has a negative 






which would be unacceptable for a stand-alone “rule out” screening tool 
(Cnossen et al., 2008). Whilst highly specific for predicting delivery of an SGA 
infant, the pooled sensitivity of increased pulsatility index and bilateral notching 
(12%) is lower than other proposed or currently used screening tools (routine 
ultrasound scan 21-54%, symphysis-fundal height measurement 27%). In 
isolation Doppler studies are unlikely to be of benefit but in combination with 
other parameters test performance could be improved. A further systematic 
review evaluating the effects of routine second trimester uterine artery Doppler 
measurement on pregnancy outcome reported no improvement in maternal or 
neonatal outcome, but only two studies were included in this review (Stampalija 
et al., 2010). At present, there is insufficient conclusive evidence to support the 
routine screening of a low-risk population using this technique. Similar 
conclusions are reported in a systematic review assessing the effects of routine 
umbilical artery measurement on pregnancy outcome in low-risk populations 
and therefore routine screening with this technique is not currently 
recommended (Alfirevic et al., 2010). 
 
In high-risk populations, second trimester uterine artery Doppler measurement 
(specifically increased resistance index >90th gestation specific centile) has 
been shown to have a moderate prediction for delivery of a severely SGA infant 
(sensitivity 82% (CI 76–87%), specificity 92% (CI 92–93%), positive likelihood 
ratio (LR) 10.9 (CI 10.4–11.4%), negative LR 0.20 (CI 14–26%)) (Cnossen et 
al., 2008). Current UK guidance therefore recommends this technique for 








Current clinical practice in the UK to identify pregnancies at risk of delivering an 
SGA infant in a low risk population relies on techniques with limited test 
performance. Whilst other tests, such as routine third trimester screening with 
ultrasound assessment or second trimester uterine artery Doppler assessment 
show promise as screening tools in the low risk population, they are not 
currently recommended either due to limited test performance, cost implications 
or lack of data regarding effect on adverse perinatal outcome. At present, there 
is a need for a cost effective screening tool, which will accurately identify those 








1.3 Diagnosing the SGA fetus 
 
UK national guidelines suggest that any woman with a symphysis-fundal height 
measurement below the 10th centile or serial measurements that show 
diminished or static growth should be referred for ultrasound assessment of 
fetal size. Abdominal circumference (AC) and/ or estimated fetal weight (EFW) 
are routinely measured; the 10th centile has been quoted as the optimal 
threshold for predicting delivery of an SGA infant and adverse outcome 
(customised EFW for prediction of SGA in a high-risk population sensitivity 
68%, specificity 89%, positive predictive value (PPV) 72%, negative predictive 
value (NPV) 86%, AC for prediction of SGA sensitivity 48-64%, false positive 
rate 38-55%) (Chang et al., 1992, De Jong et al., 2000). However, a recent 
large multicentre prospective observational study reported that EFW less than 
the 3rd centile was more strongly associated with adverse perinatal outcome 
(Unterscheider et al., 2013). Measurement of EFW, in addition to AC, has the 
benefit of allowing use of customised EFW centiles, which may improve 
detection of those pregnancies at greatest risk of adverse outcome (discussed 
in section 1.1.2.1).  
 
However, despite the reported improvement in identifying SGA infants using 
customised centiles, a large proportion are still not detected antenatally. 
DeJong et al. published a series of 215 high-risk pregnancies (defined as 






history of FGR or hypertensive disorder of pregnancy) and reported that despite 
use of customised EFW centiles, 32% of those who delivered an SGA infant 
were not detected antenatally (De Jong et al., 2000). Gardosi et al. conducted a 
cohort study in the West Midlands between 2009 and 2011, to investigate 
maternal and fetal risk factors for stillbirth. Of the 389 cases of stillbirth, 195 
were SGA (with birth weight <10th customised centile for gestational age) but 
82% of these cases were not detected antenatally, despite use of customised 
EFW centiles. In pregnancies where SGA was detected antenatally the risk of 
stillbirth was 9.7 compared to 19.8 in those where SGA was not known, 
emphasising the importance of antenatal detection (Gardosi et al., 2013b). On 
further investigation, it was reported that adherence to guidelines on use of 
customised EFW charts and levels of training varied between recruiting centres, 
which may explain why this study reported detection rates below those 
previously noted (Gardosi et al., 2013b). 
 
In addition to assessing fetal size, the amniotic fluid volume is routinely 
assessed. This is usually reported as a single deepest vertical pocket 
measurement or amniotic fluid index (AFI). The latter is calculated by the sum of 
the deepest vertical liquor pool depth in each of the four quadrants. Whilst low 
AFI has been correlated with delivery of an SGA infant (Hashimoto et al., 2013), 
it has low predictive accuracy (sensitivity 14-45% and specificity 57-97%) and is 
a poor predictor of adverse perinatal outcome (Chauhan et al., 2008, Niknafs 







AFI is one of five factors (AFI, fetal breathing, movements, tone and 
cardiotocograph) assessed in the calculation of biophysical profile  (BPP). BPP 
has a maximum score of 10 (each factor scored out of two) and low scores 
have been associated with perinatal mortality (Manning, 2002). However, its 
clinical implementation, even in high-risk pregnancies, has not been shown to 
improve perinatal outcome, or reduce perinatal death, limiting its utility as a 
surveillance tool in SGA (Lalor et al., 2008). 
 
1.3.1 Summary 
Current practice to diagnose the SGA fetus relies on techniques with limited 
diagnostic capability. From the current literature, customised estimated fetal 
weight measurement appears to perform best but still misses a large proportion 
of cases. Given the extent and severity of the morbidity associated with being 
born SGA, and the limitations of current diagnostic tools to identify whose at 
risk, there is a need for a cost effective, accurate test which could improve 
detection. Whilst the pathophysiology of FGR is multifactorial, placental 
dysfunction plays a key role. With improved knowledge of the pathophysiology 
of placental disease, multiple biomarkers have been identified which reflect 
placental function. These could provide a useful adjunct to current techniques in 








1.4 Biomarkers in placental disease 
 
A biomarker has been defined as “any substance, structure or process that can 
be measured in bio specimens and may be associated with health-related 
outcomes” (Gallo et al., 2011). Biomarkers relating to specific cellular and 
molecular events can inform of early biological mechanisms often prior to 
clinical manifestation of disease. Altered concentrations of biomarkers could 
therefore be utilised to identify those at particular risk of specific diseases and 
would be especially useful where current diagnostic tools are limited, such as 
FGR. 
 
In conditions where the aetiology is multifactorial, the level of understanding of 
the complex pathological processes implicated may dictate which biomarkers 
are selected for prediction. If a final common pathway from the differing 
aetiologies has been identified, then measurement of a single downstream 
biomarker may be appropriate. Alternatively measurement of multiple 
biomarkers chosen to reflect the numerous biological processes associated with 
that particular condition maybe more accurate. The causes of placental 
dysfunction and subsequent FGR are numerous, utilising multiple biological 
pathways. This section will focus on proposed biomarkers of placental disease, 
subdivided according to the biological process with which they are associated. 






Table 1.1: Biomarkers and mechanism of action 
Biomarkers Biomarker full name Mechanism of action !  or "  in 
placental disease 
Angiogenic factors 
PlGF Placental Growth Factor  Angiogenic marker produced by trophoblastic tissues. "  
VEGF-C Vascular endothelial growth factor C Angiogenic marker produced by trophoblastic tissues. "  
sFlt-1 Soluble fms-like tyrosine kinase-1 Also known as sVEGFR1. Binds VEGF reducing plasma 
concentrations.  
!  
Endoglin Endoglin Anti-angiogenic cell surface glycoprotein. "  TGFβ binding " 
nitric oxide signaling leading to " angiogenesis. 
!  
Angiogenin Angiogenin  Potent angiogenic factor which interacts with endothelial cells 
facilitating migration, invasion, proliferation and formation of 
tubular structures 
!  
C-Met Tyrosine kinase  Proto-oncogene encoding a protein, hepatocyte growth factor 








Biomarkers Biomarker full name Mechanism of action !  or "   
Endothelial function/damage 
Arginase-1 Arginase 1 Enzymes which compete with nitric oxide synthase (NOS) for l-
arginine, " NO formation and ! superoxide formation by NOS 
!  
Endothelin Endothelin Potent vasoconstricting peptide produced by the endothelium. 
Modulates blood pressure. 
!  
NGAL Neutrophil gelatinase-associated lipocalin Renal factor. Protein released post ischaemic damage or sepsis !  
HIF Hypoxia inducible factor 1-alpha inhibitor Inhibits transcription factor HIF-1alpha, which mediates cellular 
responses to hypoxia, preventing tissue repair. 
!  
PODXL Podocalyxin Renal marker expressed in glomerular podocytes and vascular 









Biomarkers Biomarker full name Mechanism of action !  or "   
Cell invasion/ adhesion 
ADAM 9 Disintegrin and metalloproteinase 
domain-containing protein 9 
Modulates cell-cell interactions possibly affecting trophoblast 
invasion and spiral artery formation. Role in angiogenesis. Marker 
in renal and prostate cancers 
!  
CPA-4 Carboxypeptidase A4 Metallocarboxypeptidase, which cleaves angiotensin-1, a potent 
vasoconstrictor. Low concentrations in normal tissue 
"  
ESAM-1 Endothelial Cell-selective adhesion 
molecule 
Junctional type cellular adhesion molecule expressed by vascular 
endothelium. Regulates angiogenesis and endothelial 
permeability. 
"  
ICAM-1 Intercellular adhesion molecule 1 SIgnalling protein involved in immune activation. !  
VCAM Vascular cell adhesion molecule SIgnalling protein involved in immune activation. !  
Kunitz-2 (HAI-2)  Kunitz-type protease inhibitor 2  Trans-membrane serine proteases inhibitor inhibits clotting factors 
and hepatic growth factor activation.  
"  
MMP-9 Matrix metalloproteinase-9 Expressed by cytotrophoblast and aids trophoblast invasion and 








Biomarkers Biomarker full name Mechanism of action !  or "   
TIMP-1 Metalloproteinase Inhibitor 1 Inhibits matrix metalloproteases, therefore inhibiting trophoblast 
invasion. Interacts with MMP-12# increasing 
plasminogen#angiostatin which inhibits angiogenesis 
!  
Cell apoptosis 
Caspase Caspase  Cysteine protease involved in apoptosis. Expressed in 
syncytiotrophoblast cytoplasm. Key role in cell digestion. Linked to 
increased apoptosis in placental disease. 
!  
FAS Tumor necrosis factor receptor 
superfamily member 6 
Chemokine that when bound activates cascade of caspases 
mediating apoptosis 
!  
FasL Tumor necrosis factor ligand superfamily 
member 6 
Chemokine that when bound causes apoptosis !  
TNFR1A Tumor necrosis factor receptor 
superfamily member 1A 
TNF a binds to this receptor stimulating IL-1 activation and 








Biomarkers Biomarker full name Mechanism of action !  or "   
Markers of inflammation 
CRP C reactive protein Non-specific inflammatory marker raised in the acute phase 
immune response. CRP activates the complement system 
!  
CXCL10 CXC motif chemokine 10 Immune activator released by endothelial cells. !  
Elafin Elafin Elastase-specific protease inhibitor involved in inflammation. !  
IL-1ra  Interleukin 1 receptor antagonist Competitive inhibitor of IL-1, which activates inflammatory 
response with release of prostaglandins. 
"  
MIF Macrophage migration inhibitory factor  Pro-inflammatory cytokine "  
PCT Procalcitonin Precursor of calcitonin. Involved in calcium homeostasis (" 
plasma [calcium]) and raised in inflammation. 
!  
ST2 Interleukin-1 receptor-like 1  Receptor for IL33 detected in liver, kidney, pancreas, prostate, 
spleen, small intestine and placenta, (particularly in the 
syncytiotrophoblast). Activation produces modulatory cytokines.  
!  
TGFβ-R2 Transforming growth factor beta- 
receptor 2 
Receptor for TGFβ a multifunctional protein controlling 








Biomarkers Biomarker full name Mechanism of action !  or "   
Markers of coagulation 
PAI-1 and -2  Plasminogen activator inhibitor 1 and 2 Produced by trophoblasts, inhibits fibrinolysis. PAI-1 is pro-
angiogenic and modulates coagulation, cell adhesion & migration. 
PAI-2 "  
Pentraxin-3 Pentraxin-related protein PTX3  Involved in the activation of the complement system. Role in 
innate resistance to pathogens. 
!  
Metabolic markers 
PAPP-A  Pregnancy specific plasma protein A Metalloprotease produced by the syncytiotrophoblast, which 
cleaves IGFBP-4, increasing IGF-1, which is anti-apoptotic and 
promotes fetal and placental growth. 
"  
IGF-1 Insulin growth factor 1 IGF-1 enhances substrate uptake and suppresses catabolism in 
fetal tissues.  
"  
Leptin Leptin Protein product of Ob gene. Released by the placenta and 
stimulates growth and inhibits apoptosis. Produced in response to 









Biomarkers Biomarker full name Mechanism of action !  or "   
Renal and cardiovascular biomarkers 
ANP  Natriuretic peptide A Cardiac hormone causing vasodilatation. Released by the atria in 
response to stretch 
!  
BNP Natriuretic peptide B Cardiac hormone causing vasodilatation, and inhibition of renin 
and aldosterone. Synthesised in ventricle in response to volume 
expansion and pressure overload. 
!  
Nephrin Nephrin Renal marker essential for normal glomerular function and 
cardiovascular development.  
!  





1.4.1 Biomarkers relating to angiogenesis 
Establishing a successful healthy pregnancy is dependent on adequate 
trophoblast invasion of the maternal spiral arteries, forming a low resistance 
feto-maternal circulation. Angiogenesis is the process of new blood vessel 
formation and is essential in facilitating this process. Placental growth factor 
(PlGF) and vascular endothelial growth factor (VEGF), members of the platelet-
derived growth factor family of cysteine knot growth factors, are potent 
angiogenic factors (Clark et al., 1998a, Clark et al., 1998b, Maglione et al., 
1991), which share 53% identity (Iyer et al., 2001, Maglione et al., 1991). PlGF 
is a 149 amino acid long protein, encoded by a single gene, the PlGF gene, on 
chromosome 14 and is expressed by placental trophoblastic tissue (Maglione et 
al., 1993, Clark et al., 1998b, Maglione et al., 1991). There are four isotopes of 
PlGF; PlGF-1 and PlGF-3 are non-heparin binding isoforms, whilst PlGF-2 and 
PlGF-4 have additional heparin binding domains (Hauser and Weich, 1993, 
Yang et al., 2003). PlGF binds directly to VEGFR-1, a tyrosine kinase receptor 
(also known as Flt-1), activating a number of pro-angiogenic genes (Schoenfeld 
et al., 2004, Autiero et al., 2003b).  
 
VEGF is a protein, key for the regulation of angiogenesis. VEGF binds to the 
same tyrosine kinase receptor as PlGF, but also to VEGFR-2, (also known as 
Flk-1), for which it has higher affinity (Bates, 2011). Binding results in a transient 
calcium influx, which triggers a rapid increase in permeability (Bates et al., 
2002). The overall affects increase vascular permeability, angiogenesis and 
vasodilatation (Bates and Harper, 2002). 
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Figure 1.2: Molecular mechanisms of placental growth factor and vascular 
endothelial growth factor. Reproduced from (Fischer et al., 2008) 
 
In addition to direct angiogenic effects, PlGF also displaces VEGF-A from 
VEGFR-1 (Flt-1), allowing it to bind to VEGFR-2, which indirectly enhances 
angiogenesis (Park et al., 1994). PlGF also up regulates the expression of 
several other angiogenic factors (Roy et al., 2005, Marcellini et al., 2006).  
 
Reduced maternal concentrations of PlGF and VEGF have been correlated with 
delivery of an SGA infant in numerous studies prior to onset of disease (Tjoa et 
al., 2001, Bersinger and Odegard, 2004, Thadhani et al., 2004, Espinoza et al., 
2007, Stepan et al., 2007, Diab et al., 2008, Erez et al., 2008, Poon et al., 
2008b, Asvold et al., 2011, Vandenberghe et al., 2011, Benton et al., 2012, 
Chappell et al., 2013, Bersinger and Odegard, 2005).  Both factors bind to 
soluble VEGF receptor-1 (sVEGFR-1) (also known as soluble fms-like tyrosine 
kinase-1 (s-Flt-1)), which prevents interaction of PlGF and VEGF with 
membrane bound Flt-1 in vascular tissues, leading to endothelial dysfunction 
 58 
(Autiero et al., 2003a). VEGF has higher affinity for s-Flt-1 than Flk-1 and 
therefore if low concentrations of PlGF are expressed then VEGF preferentially 
binds to sFlt-1 and Flt-1, which induces only weak tyrosine kinase activity, 
reducing angiogenic activity. Three studies measuring s-Flt-1 in the second 
trimester have correlated increased maternal s-Flt-1 concentrations with 
delivery of an SGA infant (Stepan et al., 2007, Diab et al., 2008, Asvold et al., 
2011). The first two studies published test performance statistics (sensitivity 64-
89% and specificity 54-62%) to detect SGA but were limited by very small case 
numbers (n=9, n=11) and part of the inclusion criteria for both studies was 
abnormal second trimester uterine artery Doppler measurement, a risk factor for 
delivery of an SGA infant. 
 
Further biomarkers involved in angiogenesis include soluble endoglin (s-Eng), 
angiogenin and C-met. S-Eng is an anti-angiogenic soluble TGF-ß co-receptor, 
which inhibits TGF-ß binding, leading to reduced nitric oxide signaling, with 
associated reduction in angiogenesis (Venkatesha et al., 2006). Three small 
case-control studies have reported increased maternal concentrations of S-Eng 
in cases delivering an SGA infant (Erez et al., 2008, Asvold et al., 2011, 
Romero et al., 2008). Two of these studies compared S-Eng concentrations 
between the first two trimesters whilst the third investigated concentrations 
throughout pregnancy. None of the studies commented on whether 
concentration of S-Eng correlated with severity of disease. Angiogenin is a 
potent angiogenic factor, which interacts with endothelial cells facilitating 
migration, invasion, proliferation and formation of tubular structures. Raised 
maternal concentrations of angiogenin have been correlated with pre-eclampsia 
and co-existing SGA but there were no cases of normotensive SGA in this 
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study (n=91) (Shaarawy et al., 2005). In contrast, Yamashiro et al. found no 
difference in maternal or fetal plasma concentrations of angiogenin at delivery 
between SGA and AGA pregnancies (Yamashiro et al., 2000). Both studies 
were case-control design and limited by small sample sizes (n=91 and n=61 
respectively). Larger prospective studies would be necessary to further evaluate 
a possible relationship between angiogenin concentrations and delivery of an 
SGA infant. C-met, also known as hepatocyte growth factor receptor (HGFR), 
binds to HGF and promotes angiogenesis. Zeng et al. published the results of a 
small prospective case-control study (n=44) evaluating the ability of soluble C-
met measured in the second and third trimester to predict pre-eclampsia. When 
sampled between 25-30 weeks’ gestation, the ROC area under the curve (AUC) 
for C-met to predict development of pre-eclampsia was 0.95 (CI 0.9-1.0) (Zeng 
et al., 2009). However, they did not include delivery of an SGA infant as an 
endpoint and to date there are no published data regarding the ability of C-met 
concentrations to predict this outcome. 
 
Conde-Agudelo et al. conducted a systematic review and meta analysis of 
biomarkers for predicting intrauterine growth restriction (IUGR, which they 
defined as failure of the fetus to achieve its optimal growth potential) and 
reported that the overall predictive accuracy of angiogenic biomarkers for IUGR 
was minimal (Conde-Agudelo et al., 2013). The review included 53 studies, 
evaluating 37 biomarkers, including thirteen studies reporting on PlGF, one on 
VEGF, three on s-Flt-1 and two on s-Eng. The overall summary ROC curve of 
PlGF to predict FGR gave an AUC of 0.66 (95% CI 0.44-0.87). However, there 
were multiple limitations to this review. The ROC curve calculation of PlGF to 
predict FGR did not stratify for gestational age at sampling and the only attempt 
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made by the authors to further subdivide according to gestational age split 
these data according to sampling before or after 20 weeks’ gestation. The ROC 
area did improve if sampling occurred after 20 weeks, but only two of the five 
studies in this calculation included women sampled in the third trimester, where 
a predictive test would be particularly helpful to aid decisions regarding timing of 
delivery. All of these studies were case-control design with the exception of one 
prospective cohort study (Espinoza et al., 2007) where the primary outcome 
was pre-eclampsia rather than delivery of an SGA infant. Whilst the authors 
acknowledged the difficulty in defining IUGR, there was great heterogeneity in 
definitions of FGR which included; delivery of an infant with birth weight <5th or 
<10th centiles with or without additional clinical or pathological evidence of FGR 
and IUGR requiring delivery before 34 weeks’ gestation. Many of the studies in 
this review used delivery of an SGA infant (I.e. birth weight <5th or <10th centiles 
for gestational age) as a surrogate for FGR with the inherent problem of 
including constitutionally small infants within this definition. Only six of the 53 
studies used an appropriate reference standard that included birth weight 
centile and additional clinical or pathological evidence of FGR. Only three 
studies fulfilled all five criteria of methodological quality for inclusion in the 
analysis and thresholds for determining an abnormal result differed between 
studies when the same biomarker was being evaluated.  
 A small case-control study (n=88), included in the systematic review and 
fulfilling all five criteria for methodological quality, defined SGA according to 
birth weight, additional clinical data (second trimester uterine artery Doppler 
notching, or absent/reversed umbilical artery end diastolic flow or 
oligohydramnios) and placental pathology. This group reported much more 
encouraging test performance than the pooled ROC AUC published in the 
 61 
meta-analysis by Conde-Agudelo et al. (sensitivity 100% (CI 66–100%), 
specificity 86% (CI 42–100%)) (Benton et al., 2012). This is supported by the 
findings of a recent large, prospective, multicentre observational study in 
women presenting with suspected pre-eclampsia (n=625). In this study, low 
PlGF concentrations <5th centile predicted delivery of an infant with birth weight 
<3rd centile in those sampled before 35 weeks’ gestation, with high sensitivity 
(90%; CI 82 to 95%) and negative predictive values (91%; CI 85 to 96%) 
(Chappell et al., 2013). In addition to the limitations of the systematic review 
and meta-analysis by Conde-Agudelo et al. outlined above, other explanations 
for the improved performance seen in these two studies include the use of a 
PlGF assay that measured the PlGF-1 isoform with minimal cross-reactivity for 
PlGF-2, with proven higher sensitivity and specificity than assays used in the 
other studies (Benton et al., 2011), and both studies sampling high-risk 
populations. Further investigation is required in the general antenatal 
population, prior to considering routine incorporation of PlGF into clinical 
practice. 
 
1.4.2 Biomarkers relating to endothelial function/ oxidative stress/ 
inflammation and coagulation 
The multiple causes of poor uteroplacental blood flow outlined in sections 
1.1.3.1 and 1.1.3.3 (maternal and placental factors), lead to a chronic hypoxic 
state in the placenta and intermittent flow with reperfusion results in widespread 
damage and systemic oxidative stress (a disturbance in the balance between 
reactive oxygen species production and clearance). Nevo et al. and Yinon et al. 
suggest that in in vivo and in vitro models, hypoxia up-regulates anti-angiogenic 
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markers including s-Flt (Nevo et al., 2006) and S-Eng (Yinon et al., 2008). Up-
regulation of s-Flt is mediated by Hypoxia Inducible Factor (HIF-1), which has 
been proposed as a possible biomarker to identify pregnancies at risk of pre-
eclampsia, but was not found to be a good predictor of those with SGA (Rolfo et 
al., 2010, Rajakumar et al., 2007).  
 
It is proposed that oxidative stress up-regulates xanthine oxidase and NAD(P)H 
oxidase in the placenta producing superoxides and oxygen free radicals, which 
cause localised cell injury. Associated release of cytokines (e.g. IL-1, IL-6 and 
TNF-α) activate neutrophils and have direct effects on endothelial cell activation 




Figure 1.3: Summary of pathways involving placental oxidative stress 
leading to maternal endothelial dysfunction. Reproduced from (Raijmakers 




Several biomarkers released by the endothelium have been proposed as 
potential diagnostic tools for SGA and pre-eclampsia. These include endothelin, 
arginase, Neutrophil gelatinase-associated lipocalin (NGAL) and podocalyxin. 
Endothelin is a potent vasoconstrictor and it is suggested that increased release 
contributes to hypertension observed in pre-eclampsia. Raised maternal 
concentrations are reported prior to onset of pre-eclampsia, but association with 
SGA has not been established (Shaarawy and Abdel-Magid, 2000). Arginase 
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competes with nitric oxide synthase (NOS) for L-arginine and reduces nitric 
oxide formation with increased superoxide formation by NOS (Sankaralingam et 
al., 2009). Associations have been made with pre-eclampsia, but not reported 
for SGA. NGAL is a protein released post ischaemic damage and sepsis; 
elevated plasma concentrations have been correlated with the presence and 
severity of pre-eclampsia, but not with birth weight (Kim et al., 2013). A recent 
small case-control study evaluated the changes in NGAL urinary concentrations 
in normal pregnancy and pre-eclampsia and reported that whilst the 
NGAL/creatinine ratio was lower in pre-eclampsia than in healthy pregnancies, 
urinary NGAL was not a valuable early marker for pre-eclampsia (Odum et al., 
2014).  
 
Podocalyxin is a renal marker expressed in podocytes and vascular 
endothelium, which is important in maintaining glomerular filtration slit patency.  
Concentrations are raised in several cancers (Nielsen and McNagny, 2009). 
Given the association between hypertensive disorders, renal disease and 
placental dysfunction, podocalyxin may be a useful marker in placental 
disorders although as association with delivery of an SGA infant is yet to be 
reported. 
 
Endothelial cell activation leads to increased expression of adhesion molecules 
such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule (VCAM) and a further increase in cytokine release, establishing a 
positive feedback loop, further increasing xanthine and NAD(P)H oxidase 
release (Raijmakers et al., 2004). This cycle is key to the ensuing endothelial 
dysfunction reported in placental disease.  
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1.4.2.1 Markers involved with cell adhesion 
A range of markers involved in cell adhesion have been proposed as potential 
targets for prediction of pre-eclampsia and delivery of an SGA infant. In addition 
to ICAM and VCAM, discussed above, data have been published on matrix 
metalloproteinase 9 (MMP9) regarding its suitability as a marker of placental 
dysfunction. MMP9 is expressed by the cytotrophoblast and aids trophoblast 
invasion and remodeling of the spiral arteries (Rahimi et al., 2013). HIgher 
concentrations measured in the first trimester have been reported with placental 
disease, specifically pre-eclampsia compared to controls (Poon et al., 2009), 
but this has not been substantiated in later trimesters and association with SGA 
is less well established (Myers et al., 2005).  High concentrations of an MMP-9 
variant have been reported in cases of severe pre-eclampsia, but SGA was not 
assessed independently in the study (Rahimi et al., 2013). Carboxypeptidase 
A4 (CPA-4) is a metallocarboxypeptidase, which cleaves angiotensin-I, a potent 
vasoconstrictor (Wang et al., 2006, Lipscomb et al., 1970). Low concentrations 
are found in healthy tissue but currently there is no published data relating 
concentrations to FGR. The ADAM (disintegrin and metalloprotease) family of 
proteins is involved with cell-to-cell interactions and potentially affect 
trophoblast invasion and spiral artery formation. There are at least 33 identified 
family members and there is most detail in the literature regarding the ability of 
ADAM-12 to predict placental disease. In a retrospective case-control study, 
Spencer et al. measured ADAM-12 in the first and second trimesters of 
pregnancy and reported reduced first trimester serum concentrations in those 
women who developed pre-eclampsia, but elevated concentrations in the 
second trimester compared to gestation matched controls (Spencer et al., 
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2008). Subsequent to this, Poon et al. published the findings of a case-control 
study evaluating first trimester ADAM-12 concentrations to predict adverse 
pregnancy outcome, including delivery of an SGA infant. They reported that 
measurement of first trimester ADAM-12 did not provide useful prediction of 
SGA bringing into question the clinical utility of this biomarker to determine this 
endpoint (Poon et al., 2008a). 
 
1.4.2.2 Markers involved with cell apoptosis 
Apoptosis is the natural process of programmed cell death, ensuring control of 
cell numbers within a multicellular organism. If excessive, this process results in 
tissue atrophy. Concentrations of several markers involved in cell apoptosis 
have been linked to development of placental disease. Caspase is a serine 
protease expressed in the syncytiotrophoblast cytoplasm that increases cell 
apoptosis. Several isoforms have been identified and one small case control 
study (n=20) reported elevated serum concentrations of caspase-3 in women 
with pre-eclampsia (Park et al., 2008), Activation of tumour necrosis factor 
receptor superfamily member 6 (FAS) by tumour necrosis factor ligand 
superfamily member 6 (FasL), triggers a cascade of caspase release, resulting 
in cell death. Two small case-control studies (n= 20-38) have reported 
increased maternal concentrations of FAS and FasL in women with pre-
eclampsia and severe FGR (Kuntz et al., 2001, Laskowska et al., 2006), but 




1.4.2.3 Markers of inflammation 
Normal pregnancy induces a systemic inflammatory response and the 
processes outlined above exaggerate this effect. Multiple molecules, which 
have been identified as key to this process (including those listed in Table 1.1) 
are therefore altered in placental disease and are attractive potential diagnostic 
tools as their concentrations change early in the disease process. However, 
due to the multitude of activators of this process, they are often non-specific 
making them less suited to clinical application in identifying those at risk of 
delivering an SGA infant.  
 
1.4.2.4 Markers of coagulation 
The exaggerated inflammatory response observed in placental dysfunction is 
generated by the systemic inflammatory network, which involves not only 
activation of immune cells, but also the clotting and complement systems and 
metabolic changes. Alterations in concentrations of modulators of coagulation, 
such as low plasminogen activator inhibitor 1 and 2 (PAI-1 and 2), have been 
reported in pre-eclampsia and SGA but this study only included 17 women who 
delivered an SGA infant (Chappell et al., 2002). Pentraxin-3 is involved in 
activation of the complement system and plays a role in innate resistance to 
pathogens. Maternal concentrations have been shown to be elevated at time of 
diagnosis of pre-eclampsia and SGA and in one small study (n= 23) 
concentrations correlated to severity, but further evidence from larger cohorts 




1.4.2.5 Metabolic markers  
The insulin like growth factor (IGF) system is the main regulator of fetal growth. 
Factors include IGF-I and II and their binding proteins (IGFBP1-6). The IGFs 
are small polypeptides, which have structural similarity to proinsulin. They are 
mainly bound to IGFBPs in extracellular tissues, and activity is restricted to the 
unbound fraction. They are produced by maternal and fetal tissues. Fetal IGF-1 
production is mainly regulated by fetal insulin production. IGF-1 enhances 
substrate uptake and suppresses catabolism in fetal tissues. Fetal serum IGF-1 
concentrations have been correlated with birth weight, with lower fetal 
concentrations in SGA fetuses (Maulik et al., 2006). A prospective cohort study 
including 153 women evaluated IGF-1 concentrations in maternal serum and 
reported a significantly lower concentration in those women who delivered a 
preterm SGA infant (median [IQR]: 134 [99–181] µg/L, P <0.05) compared with 
AGA pregnancies (200 [181–221] µg/L), but this association was not significant 
in women delivering at term (Chiesa et al., 2008). A review of the endocrine 
regulation of fetal growth summarised conflicting data regarding altered 
maternal serum concentrations of IGF-1 in cases of FGR. They concluded that 
at present there are no clear data supporting measurement of maternal serum 
IGF-1 as a screening tool for FGR (Murphy et al., 2006). 
 
IGF-II modulates early embryonic growth and overexpression leads to 
excessive growth. Unlike IGF-1, there has been little association with SGA. In 
addition to the insulin growth factors, other metabolic markers have been 
proposed. Dessi et al. have recently published a review article evaluating the 
ability of myo-inositol to predict FGR (Dessi and Fanos, 2013). Myo-inositol is a 
stereoisomer of inositol, a naturally occurring sugar alcohol. This group 
 69 
proposed that in the growth restricted state, insulin concentrations are reduced 
as an adaptive mechanism allowing preservation of fetal energy stores with a 
consequent increased excretion of inositol into the extracellular compartment 
and increased concentrations of metabolites in maternal plasma. This review 
article included six small case-control studies (n=8-56) with four reporting a 
statistically significant increase in concentrations of myo-inositol in the plasma 
of cases complicated by FGR. However, only two of these studies were in 
humans and given the small numbers included, larger cohort studies are 
needed to further investigate these findings.  
 
Pregnancy specific plasma protein A (PAPP-A) is a metalloprotease produced 
by the syncytiotrophoblast, which cleaves IGFBP-4, increasing the free fraction 
of IGF-1 and thus promoting fetal growth. Multiple studies have investigated the 
role of PAPP-A, mainly when measured in the first trimester to determine 
pregnancies at risk of placental dysfunction. Low maternal concentrations have 
been reported in both pre-eclampsia and SGA (Cowans and Spencer, 2007, 
Smith et al., 2002, Vandenberghe et al., 2011, Bersinger and Odegard, 2004) 
but a systematic review and meta analysis assessing the ability of serum 
Down’s syndrome screening markers to predict pre-eclampsia and SGA 
concluded that in isolation, PAPP-A had low predictive accuracy for delivery of 
an SGA infant. This review included 10 studies investigating SGA (seven where 
measurement was in first trimester), and concluded that the most accurate 
predictor for determining a birth weight <10th centile was PAPP-A <1st centile 
(even then with a modest positive LR of 3.50 (2.53-4.82)) (Morris et al., 2008). 
Another ADAM-like metalloprotease has been identified, PAPP-A2, but an 
accurate immunoassay for this marker has not been available and reference 
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ranges in pregnancy had not been established. Kløverpris et al. have recently 
evaluated an immunoassay for PAPP-A2 and have published normal ranges in 
pregnancy (Kloverpris et al., 2013). Assessment of the performance of PAPP-
A2 performance as a marker of placental disease is now awaited.   
 
In addition to the IGF family, increased expression of leptin, a placental protein 
that stimulates growth and inhibits apoptosis, has been reported in pre-
eclampsia, however, differences in maternal concentrations between 
pregnancies delivering an SGA infant and those delivering an AGA infant were 
not statistically significant (Chappell et al., 2002). In addition, leptin 
concentrations are affected by BMI making clinical application more 
challenging, and this itself could be a potential confounder.  
 
1.4.3 Renal and cardiovascular biomarkers 
Given the association of hypertensive and renal disorders with placental 
dysfunction, established markers of these disease processes may be useful in 
identifying those at risk of placental disease. Raised maternal concentrations of 
the cardiac markers natriuretic peptides A and B  (ANP and BNP) have been 
observed in pre-eclampsia (Szabo et al., 2011, Ringholm et al., 2011). BNP is 
synthesized in the ventricle in response to volume expansion and pressure 
overload and causes vasodilatation and inhibition of renin and aldosterone. 
ANP is released by the atria in response to stretch and also results in 
vasodilatation. However, to date there are no published data to support an 
association with delivery of an SGA infant.  
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Several markers of renal function have been linked to placental dysfunction. 
Cystatin is a low molecular weight protein, which is filtered from the 
bloodstream by the glomerulus. Any deterioration in glomerular filtration rate 
leads to increased plasma concentrations of cystatin. Cystatin is also an 
inhibitor of cysteine proteinases and may therefore affect regulation of 
trophoblast invasion by proteinases. Raised maternal cystatin concentrations 
have been correlated with subsequent development of pre-eclampsia 
(Thilaganathan et al., 2009, Thilaganathan et al., 2010, Saleh et al., 2010), 
however, an association with SGA is yet to be established. Nephrin is a 
transmembrane protein that is a structural component of glomerular filtration 
slits. It is essential for normal glomerular function and cardiovascular 
development. Nephrin concentrations are closely correlated to glomerular 
filtration rate (Zheng et al., 2011) and it is proposed that high urinary 
concentrations could be observed in pre-eclampsia. However, there is no 
current evidence to link this marker to placental disease. 
 
1.4.4 Summary 
To date, the ability of an isolated biomarker to accurately identify pregnancies at 
risk of delivering an SGA infant has been debated but from the current literature 
the angiogenic group of factors, specifically PlGF, offers the most promise.  
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1.5 Combinations of clinical parameters and 
biomarkers for determining the SGA infant 
 
Whilst none of the parameters discussed so far have, in isolation, been 
recommended for use in clinical practice to identify the pregnancy at risk of 
SGA, a combined approach may offer improved detection. Several studies have 
evaluated the utility of first trimester biomarker panels for determining delivery 
of an SGA infant (Pihl et al., 2008, Poon et al., 2009), but none have reported 
sufficient test performance to warrant recommendation for use in clinical 
practice. The findings of a systematic review evaluating the predictive 
capabilities of combinations of serum biomarkers measured in the late first and 
early second trimesters (as part of screening for chromosomal disorders) to 
determine subsequent delivery of an SGA infant corroborate this as they report 
low test performance (Hui et al., 2012). However, this review was hampered by 
the heterogeneity of studies included; the authors concluded that large cohort 
studies, with standardised screening test parameters and outcomes, should be 
undertaken to better evaluate these combinations (Hui et al., 2012).  
 
Other studies have incorporated maternal characteristics and/ or ultrasound 
parameters (Karagiannis et al., 2011, Poon et al., 2008b, Poon et al., 2013, 
Papastefanou et al., 2012). However the most promising combinations of 
markers and clinical characteristics proposed had only modest predictive ability 
in determining delivery of an SGA infant; e.g. for a combination of mean arterial 
pressure, maternal characteristics, uterine artery pulsatility index, PAPP-A and 
PlGF, sensitivity was 55.5% for preterm SGA <37 weeks’ gestation for 10% 
false positive rate (Poon et al., 2013). Whilst detection rates of SGA are 
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improved in these studies, compared to those combining biomarkers alone, 
combinations include ultrasound measurements requiring highly skilled 
operators, which may limit acceptability for women and preclude adoption in a 
low resource setting. 
   
1.6 Who and when to screen for SGA 
 
Given the morbidity and mortality associated with being born SGA, identifying 
those at risk and allowing appropriate follow up and timing of delivery may 
improve outcome. However, deciding the most appropriate population to screen 
for SGA is problematic. A population-based approach would be costly and may 
lead to false identification of cases, resulting in increased anxiety and 
potentially unnecessary follow-up and intervention in this group. Consideration 
of the economic implications of adopting a population based approach is also 
important as screening a large population has significant financial implications 
for detection of a condition that whilst common, has poor outcome in only a 
small subgroup. Given the multifactorial nature of SGA, it is unlikely that a low 
cost test with sufficient sensitivity and specificity to identify those at increased 
risk of FGR within a large, low-risk population will be identified.  
 
An alternative approach is to screen a more defined population already 
identified as being at increased risk (e.g. previous history of delivery of an SGA 
infant or reduced symphysis fundal height measurement). Whilst the latter is 
currently utilised to identify those within the antenatal population who warrant 
further investigation for SGA, its low sensitivity and specificity to detect the 
condition lead to true cases being missed. However, this is likely to be a more 
cost effective option than a population based screening program.  
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Timing of screening is also challenging. Assessment early in pregnancy has the 
benefit of identifying women at risk early, allowing appropriate follow-up, but the 
further the time interval from assessment to development of the condition 
generally leads to a reduction in any test performance. Ideally assessment of 
risk should be late enough to minimise false positive and false negative results, 
but early enough to identify cases with sufficient time to plan appropriate follow-
up and timing and place of delivery. To date, most studies assessing biomarker 
panels in predicting subsequent delivery of an SGA infant have involved 
sampling in the first and second trimesters of pregnancy, where test 
performance was insufficient to recommend incorporation into clinical practice. 
It is possible that sampling in the third trimester, closer to time of delivery 
maybe an appropriate alternative.  
 
1.7 Chapter Summary 
 
Whilst numerous biomarkers have been proposed as potential tools for 
identifying those at risk of placental disease, sufficient test performance for 
adoption into clinical algorithms to identify pregnancies at risk of SGA has not 
yet been established. Of all the mechanistic groups discussed, there are most 
published data on the angiogenic factors. The data relating to PlGF and 
prediction of delivery of an SGA infant in a high-risk population are promising, 
but further evaluation is required before recommendations can be made for 
widespread deployment.  
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Whilst acknowledging its limitations (as discussed in section 1.4.1), a recent 
systematic review concluded that at present there is no individual clinically 
useful biomarker for predicting SGA in women with singleton pregnancies 
(Conde-Agudelo et al., 2013). They give the multifactorial nature of SGA as a 
possible explanation for this finding. It is suggested that combining 
measurement of multiple biomarkers, covering a variety of pathological 
processes contributing to delivery of an SGA infant may provide a more 
promising test. However, from the current data summarised in section 1.5, the 
ideal combination providing sufficient test performance for clinical practice, 
whilst also maintaining clinical acceptability, is still elusive. This may be partially 
related to the timing of sampling as most studies reported on samples taken in 
the first and second trimesters, where changes in these markers may be too 
subtle to be detected by current assays or alterations in concentrations may 
occur at later gestations. There is a paucity of evidence assessing 
measurement of third trimester biomarker panels, covering a wide range of 
pathological processes, to determine delivery of an SGA infant. Considering this 
is the most frequent time of presentation with suspected SGA and is closer to 
time of delivery, it seems logical to evaluate tests within this timeframe.  
 
Given the limitations of current parameters for identifying the SGA infant, and 
the current evidence summarised above, there is an acute need for improved 







1. To assess the ability of third trimester biomarkers and ultrasound 
parameters to determine delivery of a SGA infant in women with 
suspected pre-eclampsia 
 
2. To assess the diagnostic accuracy of PlGF and ultrasound parameters to 
predict the SGA infant in women presenting with suspected SGA.  
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1.9 Hypotheses 
In this work, I collected data from two cohorts (the first with suspected pre-
eclampsia and the second with suspected SGA fetuses) to test the following 
hypotheses: 
1. A combination of biomarkers, identified from 47 biomarkers, selected for 
their biological plausibility, can accurately identify women at risk of 
delivering an SGA infant from a cohort presenting with signs and 
symptoms, but not proven pre-eclampsia (suspected pre-eclampsia). 
 
2. PlGF can more accurately determine delivery of an SGA infant in women 
presenting with suspected SGA (i.e. reduced symphysis fundal height 
measurement, the current clinical tool for referral for further investigation 










Chapter 2: Biomarkers and 






Whilst numerous individual biomarkers have been proposed as potential 
diagnostic tools to identify pregnancies at risk of delivering an SGA infant, there 
is currently insufficient evidence to recommend incorporating any of these tests 
into routine clinical practice (Conde-Agudelo et al., 2013). It is suggested that 
given the multifactorial nature of SGA, a combination of biomarkers, which 
reflect a variety of pathological pathways key to development of SGA, may 
provide a more promising approach. A test early in pregnancy for distant 
prediction of delivering an SGA infant would allow appropriate follow up and 
planning of delivery. However, numerous studies measuring biomarker panels 
in the late first and early second trimesters of pregnancy have failed to identify 
women at risk of delivering an SGA infant with sufficient accuracy. This may be 
due to changes in these factors occurring beyond the first and second 
trimesters, alterations being below the level of detection for the selected 
biomarker assays at the time of testing, or lack of discrimination between 
subsequent cases and those with normal pregnancy outcome when measured 
many weeks prior to manifestation of the growth restriction.  
 
Measuring biomarker panels at later gestations may offer more accurate 
prediction, as testing closer to the onset of any condition generally yields 
improved test performance; variation in certain biomarker concentrations 
between those who deliver an appropriate for gestational age infant and those 
whose pregnancies are complicated by SGA may become more marked at later 
gestations, while providing clinical information at a time that influences 
immediate management. Biomarker measurement in the late second and third 
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trimesters of pregnancy to identify those at greatest risk of delivering an SGA 
infant may be especially useful in high-risk pregnancies, such as those with 
hypertensive disorders, as this could provide additional information to aid 
decision making regarding level of monitoring and timing of delivery.  
 
At present there are few published data regarding performance of individual 
biomarkers or panels measured at later gestations to predict delivery of an SGA 
infant.  
 
We identified a large group of biomarkers with either a biological role in 
placental function, known association with pre-eclampsia or involvement with 
placental disease. These biomarkers were measured in women with suspected 
pre-eclampsia, a group at high-risk of placental dysfunction with the aim of 
developing a biomarker panel capable of accurately identifying those at risk of 
delivering an SGA infant. 
 
2.1.1 Involvement with the study 
The primary aim of the PELICAN-PE study was to assess the diagnostic 
accuracy of placental growth factor (PlGF) to determine need for delivery for 
confirmed pre-eclampsia in women presenting with suspected pre-eclampsia. I 
acted as study coordinator for the PELICAN-PE study from August 2011, until 
study completion (February 2012). This involved liaising with all study sites and 
conducting regular site visits, providing database training for new members of 
staff and coordinating study teleconferences to provide updates. I received 
training in use of the PlGF Triage meter and accompanied the study monitor on 
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site visits and assisted in assessing quality control of the meters at enrolling 
sites. In addition to my role as study coordinator, I also recruited over 100 
women from the day assessment unit, antenatal ward and delivery suite at St 
Thomas’ Hospital, London and coordinated and inputted study data. I was a 
member of a panel of expert adjudicators who reviewed all final maternal 
diagnoses to assign final adjudicated diagnoses, adjudicating for sites other 
than where I enrolled women. I was involved in the statistical analysis plan for 
the study and contributed to the first manuscript (as a co-author) arising from 
the results, published in the peer-reviewed journal, Circulation, in November 
2013 (published manuscript in appendix). 
 
In addition to the primary aim of the PELICAN-PE study I also assessed the 
ability of a large panel of biomarkers to determine pre-eclampsia and delivery of 




Data presented in this chapter are taken from the PELICAN-PE study. Women 
were recruited from seven consultant-led maternity units in the United Kingdom 
and Ireland, between January 2011 and February 2012. Ethical approval was 
granted by East London Research Ethics Committee (ref. 10/H0701/117).  
 
Women presenting with signs or symptoms of suspected pre-eclampsia, 
between 20+0 and 40+6 weeks’ gestation with a singleton or twin pregnancy and 
aged ≥16 years were eligible for inclusion in the study. Written informed consent 
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was obtained from participants. A study-specific database was created and 
baseline demographic and pregnancy-specific information were entered. At 
study enrolment, blood was drawn into ethylenediamine tetra-acetic acid and 
samples were labelled, and transported to the laboratory where they were spun 
at 3000 rpm for 10 minutes. Plasma was extracted and stored at -80oC until 
analysis. All cases were adjudicated by a panel of experts to assign a final 
maternal diagnosis using definitions defined below in 2.2.1. All diagnoses were 
assigned without knowledge of any biomarker values. 
 
2.2.1 Definitions 
Definitions were pre-defined by the PELICAN study co-investigator group in 
collaboration with a neonatologist to reflect adverse perinatal outcomes relevant 
to pre-eclampsia, particularly that requiring preterm delivery. A decision was 
made to include the consequences of prematurity rather than preterm delivery 
itself.  
Definitions for maternal hypertensive disorders of pregnancy were taken from 
the American College of Obstetricians and Gynecologist’s practice bulletin 
available at the time of study design and adjudication (ACOG Practice Bulletin, 
2002) and are as follows: 
 
Mild gestational hypertension: 
Systolic BP 140-159 mmHg and/or DBP 90-109 mmHg on two occasions 
4 hours to 1 week apart presenting after gestational week 20 without proteinuria 
or markers of severe pre-eclampsia. 
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Severe gestational hypertension: 
Systolic BP ≥ 160 mmHg or DBP ≥ 110 mmHg on two occasions at least 4 
hours to one week apart presenting after gestational week 20 without 
proteinuria or markers of severe pre-eclampsia. 
 
Chronic hypertension: 
Documented presence of chronic non-gestational hypertension (systolic BP 
>140 mm Hg and/or DBP > 90 mm Hg) prior to this pregnancy, 
or  




Any of the following*: 
1) Urine protein ≥300 mg/24 hours (or 165mg/12hr) from a timed urine 
collection (preferred definition, if results from 24-hour timed urine collection 
available); 
2) Protein: Creatinine ratio ≥ 30 (mg/mmol). 
3) Urinary protein 1+ on dipstick on two occasions at least 4 hours apart. 
4) Urinary protein ≥2+ on dipstick on one occasion. 




De novo proteinuria after 20+0 weeks’ gestation (with a negative proteinuria 
assessment prior to 20+0 weeks’ gestation).
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Chronic proteinuria: 
Proteinuria noted prior to 20+0 weeks; or proteinuria that fails to resolve by 6 
weeks postpartum. 
 
Pre-eclampsia (Traditional Definition): 
Gestational hypertension plus gestational proteinuria.  
Mild pre-eclampsia: 
Mild gestational hypertension plus gestational proteinuria that does not 
meet the criteria for severe pre-eclampsia as stated below. 
 
Severe pre-eclampsia: 
Presence of pre-eclampsia as defined above plus one or more of the 
following: 
• Systolic BP ≥ 160 mmHg or DBP ≥ 110 mmHg on two occasions at 
least 6 hours apart while the patient is on bed rest;  
• Proteinuria of 5 g or higher in a 24-hour urine specimen or 3+ or 
greater on two random urine dipstick assessments collected at least 4 
hours apart; 
• Oliguria of less than 500 mL urine output in 24 hours; 
• Cerebral or visual disturbances; 
• Pulmonary edema or cyanosis; 
• Epigastric or RUQ pain; 
• Impaired liver function (2x upper limit of normal for AST and/or ALT); 
• Thrombocytopenia (platelet count <100,000/mm3); 




Superimposed pre-eclampsia (Traditional definition): 
Chronic hypertension plus gestational proteinuria (defined as urine protein ≥ 
300 mg/24 hours from a timed urine collection). 
 
Superimposed pre-eclampsia (Atypical): 
• Chronic hypertension plus abnormal laboratory test (low platelets or 
elevated liver enzymes). 
• Chronic proteinuria plus gestational hypertension. 
 
Atypical pre-eclampsia: 
In the absence of proteinuria: 
Gestational hypertension plus any of the following: 
• Haemolysis (elevated total bilirubin >1.2 mg/dl); 
• Thrombocytopenia (platelet count <100,000/mm3); 
• Elevated liver function tests (2X upper limit of normal for AST and/or 
ALT). 
• Fetal growth restriction (birth weight <10% percentile) 
 
In the absence of hypertension:        
Gestational proteinuria plus any of the following: 
• Haemolysis (elevated total bilirubin >1.2 mg/dl); 
• Thrombocytopenia (platelet count <100,000/mm3); 
• Elevated liver function tests (2X upper limit of normal for AST and/or 
ALT). 




The presence of new-onset grand mal seizures in a woman with pre-eclampsia 
or gestational hypertension in the absence of all of the following: 
• Known seizure disorder; 
• Chronic treatment with anti-seizure medications; 
• Known intra-cerebral pathology. 
 
HELLP syndrome: 
Gestational hypertension and/or gestational proteinuria plus elevated liver 
enzymes (2X upper limit of normal), elevated LDH (2X upper limit of normal), 
thrombocytopenia (platelet count <100,000/mm3) and evidence of Haemolysis 
(elevated total bilirubin >1.2 mg/dl). 
 
Delivery of a small for gestational age infant was defined as birth weight <3rd 
and <10th customised centile, calculated using the Gestation Related Optimal 
Weight (GROW) method (Gardosi et al., 1992).  
 
Adverse perinatal outcome was defined as presence of any of the following 
complications: antepartum/intrapartum fetal or neonatal death, neonatal unit 
admission for >48 hrs at term, intraventricular haemorrhage, periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis. 
 
Adverse maternal outcome was defined as presence of any of the following 
complications: maternal death, eclampsia, stroke, cortical blindness or retinal 
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detachment, hypertensive encephalopathy, systolic blood pressure ≥160mmhg, 
myocardial infarction, intubation (other than for caesarean section), pulmonary 
oedema, platelets <50×10⁹/l (without transfusion), disseminated intravascular 
coagulation, thrombotic thrombocytopenic purpura/haemolytic uraemic 
syndrome, hepatic dysfunction (alanine transaminase ≥70iu/l), hepatic 
haematoma or rupture, acute fatty liver of pregnancy, creatinine >150 µmol/l, 
renal dialysis, placental abruption, major postpartum haemorrhage, major 
infection. 
 
2.2.2 Biomarker selection and measurement  
A detailed literature review was undertaken, in consultation with medical 
experts, to identify potential biomarkers for assessment. The 47 biomarkers 
selected had either a known association with pre-eclampsia and/or a 
biologically plausible role in placentation, or a role in the pathophysiology of 
placental disease e.g. angiogenesis, inflammation, coagulation. A full list of the 
57 biomarker assays with abbreviations, units and assay information are 
displayed in Tables 2.1 and 2.2. 
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Table 2.1: List of Biomarker abbreviations and units 
Biomarker Biomarker full name Units 
PlGF Placental Growth Factor pg/ml 
ADAM 9 Disintegrin and metalloproteinase domain-
containing protein 9 
pg/ml 
Angiogenin Angiogenin  µg/ml 
ANP  Natriuretic peptide A ng/ml 
Arginase-1 10a Arginase 1  ng/ml 
Arginase-2 11a Arginase 2  ng/ml 
BNP Brain natriuretic peptide ng/ml 
Caspase Caspase  ng/ml 
CCL23 MIP3, C motif chemokine 23 ng/ml 
C-Met-109a Tyrosine kinase  ng/ml 
C-Met-111a Tyrosine kinase  ng/ml 
CPA-4 Carboxypeptidase A4 ng/ml 
CRP C reactive protein µg/ml 
CXCL10 CXC motif chemokine 10 ng/ml 
Cystatin Cystatin ng/ml 
Elafin-131 Elafin  ng/ml 
Elafin-132 Elafin  ng/ml 
Endoglin Endoglin ng/ml 
Endothelin Endothelin pg/ml 
Ephrin Ephrin pg/ml 
ESAM-1 Endothelial Cell-selective adhesion molecule ng/ml 
FAS Tumor necrosis factor receptor superfamily 
member 6 
ng/ml 
FasL Tumor necrosis factor ligand superfamily 
member 6 
ng/ml 
HIF  Hypoxia inducible factor 1-alpha inhibitor ng/ml 
HbF  Haemoglobin Fetal ng/ml 
ICAM-1 Intercellular adhesion molecule 1 ng/ml 
IL-1ra  Interleukin 1 receptor antagonist pg/ml 
Kunitz-2 (HAI-2) 34a Kunitz-type protease inhibitor 2  ng/ml 
Kunitz-2 (HAI-2) 35b Kunitz-type protease inhibitor 2  ng/ml 
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Biomarker Biomarker full name Units 
Kunitz-2 (HAI-2) 40b Kunitz-type protease inhibitor 2  ng/ml 
Leptin Leptin  ng/ml 
Leptin receptor Leptin receptor  ng/ml 
MIF-49a Macrophage migration inhibitory factor  ng/ml 
MIF-49b Macrophage migration inhibitory factor  ng/ml 
MMP-9 Matrix metalloproteinase-9 ng/ml 
Nephrin-100a Nephrin  ng/ml 
Nephrin-101a Nephrin  ng/ml 
NGAL-MT Neutrophil gelatinase-associated lipocalin ng/ml 
PAI-1 (active)  Plasminogen activator inhibitor 1 ng/ml 
PAI-2 Plasminogen activator inhibitor 2 ng/ml 
PAPP-A  Pregnancy specific plasma protein A ng/ml 
PCT-95a Procalcitonin  pg/ml 
PCT-99b Procalcitonin  pg/ml 
Pentraxin-3-64a Pentraxin-related protein PTX3  ng/ml 
Pentraxin-3-67a Pentraxin-related protein PTX3  ng/ml 
Periostin Periostin ng/ml 
PODXL-74b Podocalyxin ng/ml 
sFlt-1 Soluble fms-like tyrosine kinase-1 ng/ml 
ST2-116b Interleukin-1 receptor-like 1  ng/ml 
ST2-75b Interleukin-1 receptor-like 1  ng/ml 
TGFβ Transforming growth factor beta-1 ng/ml 
TIMP-1 Metelloproteinase Inhibitor 1 ng/ml 
TNFR1A Tumor necrosis factor receptor superfamily 
member 1A 
ng/ml 
VEGF-C Vascular endothelial growth factor C ng/ml 
Visfatin-82a Visfatin ng/ml 
WAP4C-HE4-85b WAP four disulfide core domain protein 2  ng/ml 



















PlGF 12 3000 13 Sandwich, Luminex 
ADAM-9 38.07 7913.74 11 Sandwich, Luminex 
Angiogenin 0.14 61.24 7 Competitive, Luminex 
ANP  0.048 71.93 13 Sandwich, Luminex 
Arginase-1 10a 0.035 30.50 9 Sandwich, Luminex 
Arginase-2 11a 1.318 378.14 15 Sandwich, Luminex 
BNP 0.007 5.83 18 Sandwich, Luminex 
Caspase 0.292 114.29 13 Sandwich, Luminex 
CCL23 0.009 3.52 7 Sandwich, Luminex 
C-Met 109a 7.999 453.54 11 Sandwich, Luminex 
C-Met 111a 77.147 1035.48 7 Sandwich, Luminex 
CPA-4 0.119 19.14 5 Sandwich, Luminex 
CRP 0.07871 141.96 5 Competitve, Luminex 
CXCL10 0.006 5.81 10 Sandwich, Luminex 
Cystatin 165.009 9072.87 21 Competitive, 
Microtitre 
Elafin-131 28.670 42668.61 10 Competitve, Luminex 
Elafin-132 21.159 42668.61 5 Competitve, Luminex 
Endoglin 1.981 654.84 18 Sandwich, Microtitre 
Endothelin-1  0.704 901.9 13 Sandwich, Luminex 
Ephrin 43.71 4009.97 20 Sandwich, Luminex 
ESAM-1  1.073 32.77 9 Sandwich, Luminex 















FasL 0.156 30.20 11 Sandwich, Luminex 
FIH  0.003 18.50 6 Sandwich, Luminex 
HbF  0.848 386.32 18 Sandwich, Microtitre 
ICAM-1 106.275 30231.73 6 Competitive, Luminex 
IL-1ra  0.477 1434.20 9 Sandwich, Luminex 
Kunitz-2-34a 0.016 10.17 19 Sandwich, Luminex 
Kunitz-2-35b 0.140 57.15 13 Sandwich, Luminex 
Kunitz-2-40b 0.159 57.38 7 Sandwich, Luminex 
Leptin-43a 5.509 148.56 11 Sandwich, Luminex 
Leptin-46b 2.244 1079.61 9 Sandwich, Luminex 
MIF-49a 3.912 25.99 10 Sandwich, Luminex 
MIF-49b 0.414 70.85 9 Sandwich, Luminex 
MMP-9 4.542 202.82 5 Sandwich, Luminex 
Nephrin-100a 0.517 19.98 25 Sandwich, Luminex 
Nephrin-101a 0.094 19.74 22 Sandwich, Luminex 
NGAL-MT 0.625 2924.00 22 Sandwich, Microtitre 
PAI-1-52b 0.194 103.48 12 Sandwich, Luminex 
PAI-2 0.047 77.90 5 Sandwich, Luminex 
PAPP-A  0.189 812.10 7 Sandwich, Luminex 
PCT-95a 12.22 9165.34 14 Sandwich, Luminex 
PCT-99b 9.55 3982.50 14 Sandwich, Luminex 
Pentraxin-3-64a 0.221 91.01 10 Sandwich, Luminex 
Pentraxin-3-67a 0.940 59.41 16 Sandwich, Luminex 















Podocalyxin 0.075 20.79 15 Sandwich, Luminex 
sFlt-1 0.006 27.86 10 Sandwich, Luminex 
ST2-116b 0.038 21.25 14 Sandwich, Luminex 
ST2-75b 0.075 44.63 6 Sandwich, Luminex 
TGF 0.040 63.98 9 Sandwich, Luminex 
TIMP-1 9.127 1917.45 5 Competitive, Luminex 
TNFR-1A 0.230 31.02 18 Sandwich, Luminex 
VEGF-C 0.527 74.07 5 Sandwich, Luminex 
Visfatin 2.535 1738.71 13 Sandwich, Luminex 
WAP4C-HE4-85b 0.129 89.71 11 Sandwich, Luminex 




All samples were analysed for PlGF at the recruiting sites by laboratory staff, 
trained in measurement of plasma PlGF using the Triage®
 
PlGF Test (Alere, 
San Diego, CA). The test utilises a quantitative fluorescence immunoassay, 
measuring free PlGF. A fluorescently labelled murine monoclonal antibody 
against PlGF is fixed within the test device. When the plasma sample is added 
to the test device, free PlGF binds to the fixed antibody and the triage meter 
quantifies the concentration of plasma PlGF by measuring the degree of 
fluorescence. The lower level of detection of the assay is 12 pg/ml. The cost of 
the Alere Triage meter is £2,500 and each PlGF test is priced at £40. 
 
The additional 56 biomarker assays were measured at a single central 
laboratory (Alere, San Diego, CA). Stored samples were thawed to room 
temperature prior to the assays being performed. All immunoassays were either 
antibody sandwich assays or competitive assays (using biotinylated antigen), 
using either Luminex or ELISA technology. For all Luminex assays, the primary 
antibody (mouse-derived recombinant Fab fragment) was conjugated to 
magnetic Luminex beads, which were added to 384-well assay plates. The 
plates were placed on a magnetic ring stand to avoid the beads being removed 
during washing. For Luminex sandwich assays the plasma sample was then 
added and incubated for one hour and then washed. A biotinylated secondary 
antibody was then added and incubated prior to a further wash to remove any 
unbound detection antibody. Streptavidin-conjugated phycoerythrin (which 
binds to biotin on the detection antibody) was then added and washed prior to 
reading using a Luminex 200 reader. 
 
For Luminex competitive assays the initial steps were as above but the plasma 
sample was mixed with a biotinylated antigen prior to transfer to the plate 
 94 
containing the primary antibody. After addition and incubation, washing 
removed any unbound biotinylated antigen. Streptavidin-labelled phycoerythrin 
was then added, which binds to biotin on the detection antigen. The degree of 
fluorescence was then measured using a Luminex 200 reader. 
 
The micro-titre ELISA assays used a streptavidin-coated plate and biotin or 
fluorescein conjugated recombinant Fab fragments. The ELISA sandwich assay 
used a biotin-conjugated recombinant Fab as the capture antibody and a 
fluorescein-conjugated recombinant Fab as the detection antibody. Capture 
antibody was coated on the plate, incubated, washed and sample added. After 
sample incubation, the plate was washed and then incubated with detection 
antibody. Following washing, the plate was incubated with anti-fluorescein 
antibody conjugated to alkaline phosphatase, washed, fluorescent substrate 
added and then read using a Tecan infinite F200 reader. 
 
The ELISA competitive assay used a biotin-conjugated antigen as the capture 
and a fluorescein-conjugated recombinant Fab as the detection antibody. The 
plate was coated with capture antigen, incubated and washed. Addition of 
sample was immediately followed by addition of the detection antibody and 
incubated. The final steps were the same as the ELISA sandwich.  
 
All assays were performed in 384-well microtitre plates using a Perkin-Elmer 
Minitrak robotic liquid handling system for all liquid handling steps. For all 
sandwich assays, one concentration in each set of calibrators included 
neutralizing antibody for correction of endogenous antigen present in the 
plasma pool. Each assay used an eight-point dose curve prepared 
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gravimetrically in EDTA plasma or buffer. Plasma samples were added to the 
384-well plate, containing wells for a calibration curve consisting of multiple 
analyte concentrations and control samples. Calibration curves were prepared 
gravimetrically in plasma from healthy donors.  
 
All results were concealed until a final adjudicated diagnosis had been made 
and laboratory staff were masked to the clinical diagnosis. Results were not 
revealed until all participants had delivered. 
 
Table 2.3 contains individual biomarker median concentrations displayed 
according to birth weight within the study group.   
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Table 2.3: Individual median biomarker concentrations (quartiles) in 
women presenting before 35 weeks’ gestation  
 
Biomarkers Women with SGA 
infant <3rd centile 
(n = 96) 
Women with SGA 
infant <10th centile 
(n = 130) 
Women with infant 
≥ 10th centile  
(n = 144) 
ADAM 9 * 89.6% below limit 
of detection 
91.5% below limit 
of detection 





(7.71 to 19.3) 
11.2  
(7.56 to 18.7) 
9.44  
(6.56 to 15.1) 
ANP (ng/ml) 1.28  
(0.52 to 3.39) 
1.06  
(0.53 to 3.04) 
0.83  




(0.43 to 1.09) 
0.65  
(0.43 to 1.10) 
0.70  




 (8.70 to 20.1) 
13.9  
(8.70 to 19.2) 
10.2 
(6.63 to 14.1) 
BNP (pg/ml) 0.15  
(0.10 to 0.22) 
0.14  
(0.08 to 0.19) 
0.09  
(0.06 to 0.14) 
CCL23 (ng/ml) 0.22  
(0.17 to 0.33) 
0.23  
(0.17 to 0.33) 
0.28  
(0.21 to 0.35) 
CRP (µg/ml) 17.9  
(8.98 to 33.0) 
15.7 
(7.53 to 32.5) 
12.6   
(6.52 to 23.3) 
CPA-4 (ng/ml) 2.41  
(1.84 to 2.80) 
2.45  
(1.85 to 2.99) 
2.82  




(1.90 to 8.48) 
4.08  
(1.81 to 8.29) 
3.10  
(1.45 to 6.08) 
CXCL10 (ng/ml) 0.23  
(0.15 to 0.33) 
0.23  
(0.16 to 0.32) 
0.22  




(2234 to 5271) 
3158  
(2230 to 5309) 
2789  




(92.7 to 147) 
126  
(94.2 to 152) 
136  




(291 to 426) 
373  
(294 to 441) 
398  
(341 to 494) 
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Biomarkers Women with SGA 
infant <3rd centile 
(n = 96) 
Women with SGA 
infant <10th centile 
(n = 130) 
Women with infant 
≥ 10th centile  




(98.1 to 191) 
133  
(96.0 to 180) 
128  




(41.13 to 121.35) 
61.40  
(40.54 to 112.69) 
65.51  




(67.5 to 243) 
126  
(55.5 to 216) 
33.6  
(16.5 to 104) 
ESAM-1 (ng/ml) 4.97  
(3.99 to 6.11) 
4.97  
(4.18 to 6.15) 
5.29  




(0.91 to 2.40) 
1.42  
(0.87 to 2.40) 
1.61  
(1.04 to 2.53) 
Ephrin (pg/ml) * 94.8% below limit 
of detection 
95.6% below limit 
of detection 
97.2% below limit 
of detection 
HbF (ng/ml) 50.9 
(26.0 to 90.9) 
50.7  
(25.6 to 88.7) 
46.0  
(23.1 to 72.7) 
HIF (ng/ml) 0.18  
(0.08 to 0.41) 
0.19  
(0.07 to 0.40) 
0.13  
(0.06 to 0.30) 
ICAM-1 (ng/ml) 679  
(538 to 932) 
665 
(517 to 914) 
609  
(478 to 828) 
IL1RA (pg/ml) 19.7  
(13.4 to 30.8) 
19.0 
 (13.1 to 31.1) 
23.8  
(16.6 to 34.5) 
ST2 116 (ng/ml) 1.43  
(0.76 to 2.43) 
1.21  
(0.68 to 2.18) 
0.78  
(0.53 to 1.70) 
ST2 75b (ng/ml) 6.74  
(4.81 to 12.4) 
6.39  
(4.49 to 10.2) 
5.86  
(3.17 to 9.15) 
Kunitz 2 34a 
(ng/ml) 
0.42 
 (0.30 to 0.55) 
0.42  
(0.30 to 0.54) 
0.41  
(0.29 to 0.56) 
Kunitz 2 35b 
(ng/ml) 
0.25  
(0.12 to 0.39) 
0.26  
(0.12 to 0.40) 
0.29  
(0.15 to 0.46) 
Kunitz 2 40b 
(ng/ml) 
0.14  
(0.14 to 0.31) 
0.15 
 (0.14 to 0.31) 
0.24  




(14.1 to 22.9) 
17.2  
(13.7 to 22.7) 
17.3  
(10.3 to 25.8) 
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Biomarkers Women with SGA 
infant <3rd centile 
(n = 96) 
Women with SGA 
infant <10th centile 
(n = 130) 
Women with infant 





(104 to 178) 
140  
(105 to 182) 
154 
(113 to 199) 
MIF 49a (ng/ml) 10.7  
(8.97 to 13.1) 
10.5 
(8.96 to 13.1) 
11.3  
(9.76 to 12.9) 
MIF 49b (ng/ml) 8.95  
(5.73 to 14.0) 
8.78  
(5.72 to 13.7) 
7.88  
(5.31 to 11.6) 
MMP-9 (ng/ml) 40.3 
(30.3 to 54.6) 
39.7  
(29.5 to 55.7) 
41.6  
(31.5 to 58.4) 
TIMP-1 (ng/ml) 132 
(94.9 to 187) 
126  
(94.7 to 180) 
110 
 (83.6 to 155) 
Nephrin 100a 
(ng/ml) * 
72.9% below limit 
of detection 
74.6% below limit 
of detection 





(0.26 to 0.73) 
0.38  
(0.26 to 0.66) 
0.30  
(0.16 to 0.49) 
NGAL (ng/ml) 48.24  
(35.0 to 75.6) 
46.2  
(34.2 to 71.0) 
38.7  




(40.6 to 154) 
90.0  
(40.6 to 156) 
135  
(67.4 to 224) 
Pentraxin 3 64a 
(ng/ml) * 
77.1% below limit 
of detection 
77.7% below limit 
of detection 
72.9% below limit 
of detection 
Pentraxin 3 67a 
(ng/ml) 
3.32  
(1.71 to 5.10) 
2.97 
 (1.68 to 5.03) 
1.97  




(6.86 to 11.3) 
9.07  
(6.78 to 11.1) 
8.53  
(6.29 to 10.7) 
PlGF (pg/ml) 11.6  
(5.01 to 33.1) 
16.7  
(6.11 to 58.2) 
195  
(33.2 to 494) 
PAI-1 (ng/ml) 0.50  
(0.24 to 0.81) 
0.45  
(0.24 to 0.78) 
0.46  
(0.26 to 0.73) 
PAI-2 (ng/ml) 9.18  
(7.39 to 11.9) 
9.93  
(7.63 to 12.3) 
11.9  
(9.42 to 14.3) 
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Biomarkers Women with SGA 
infant <3rd centile 
(n = 96) 
Women with SGA 
infant <10th centile 
(n = 130) 
Women with infant 
≥ 10th centile  




(0.09 to 0.29) 
0.14  
(0.07 to 0.28) 
0.10  




(44.6 to 128) 
67.1  
(41.2 to 122) 
45.8  




(5.63 to 28.9) 
11.5  
(5.63 to 28.5) 
11.4  




(1.32 to 2.18) 
1.81  
(1.35 to 2.30) 
1.99  
(1.62 to 2.43) 
FasL (ng/ml) * 72.9% below limit 
of detection 
74.6% below limit 
of detection 





(5.01 to 11.6) 
7.67  
(5.48 to 11.5) 
7.50  
(5.92 to 10.6) 
FAS (ng/ml) 2.7  
(2.1 to 3.5) 
2.71  
(2.10 to 3.53) 
2.72  
(2.01 to 3.66) 
VEGF-C (ng/ml) 15.2  
(12.9 to 18.3) 
15.1  
(12.9 to 18.0) 
14.1  
(12.1 to 16.6) 
sFlt-1 (ng/ml) 3.60  
(1.54 to 5.82) 
2.74  
(1.33 to 5.38) 
0.95  
(0.50 to 2.49) 
Visfatin (ng/ml) 2.37  
(1.62 to 3.32) 
2.35  
(1.61 to 3.29) 
1.93  




(1.15 to 2.65) 
1.65  
(1.12 to 2.63) 
1.40  




 (12.0 to 17.1) 
13.9  
(12.2 to 16.8) 
13.3  
(11.1 to 15.7) 
 
* Meaningful quartiles cannot be calculated as the concentrations in most 
samples were below the lower limit of assay detection. 
  
 100 
2.2.3 Statistical analysis  
I undertook the statistical analysis with the medical statistician having devised 
the statistical plan with the study Chief investigator and Principal Investigator at 
St Thomas’ Hospital.  
 
The first part of this analysis evaluated the ability of 47 biomarkers to determine 
subsequent delivery of an SGA infant. Logged values of all 57 biomarker 
assays were used as standard distributional checks showed high levels of 
skewness, which were consistent with underlying log normal distributions. Prior 
to disclosure of pregnancy outcomes, factor analysis of biomarker data was 
undertaken on the whole data set, reducing the 57 biomarker assays to a 
smaller number of highly correlated groups, solely on the basis of the 
correlations between the biomarkers and without reference to outcome. 
Consideration of scree plots and Eigen-values (> two) identified the most 
important factors (Costello and Osborne, 2005) which were rotated (orthogonal 
varimax method) so that each factor related strongly (correlation >0.6) to a 
small number of biomarkers only. Scores were calculated on each factor for 
each subject.  
 
The principal outcome for this analysis was delivery of an SGA infant (defined 
as birth weight less than the 3rd or 10th customised centile). The factor scores 
were entered into a multiple logistic regression model for prediction of 
subsequent SGA. The best performing factors (and their biomarkers) were 
investigated further by using stepwise logistic regression (a parametric method) 
to determine which of the biomarkers within these factors, appeared to provide 
additional information beyond that derived from PlGF (known to be a good 
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predictor of need for delivery for pre-eclampsia) (Chappell et al., 2013). 
Prediction scores were extracted for the best combinations.  
 
Some biomarkers, with high uniqueness scores, were not strongly associated 
with any factor. To investigate whether any of these biomarkers had predictive 
power in addition to that provided by PlGF and biomarkers identified earlier, 
stepwise logistic regression was undertaken. To avoid excluding a biomarker 
that may be of potential value, a standard multiple-testing correction to p-
values, such as Bonferroni was not used. However, for a biomarker to be 
considered useful, it had to pass a series of tests, so that the chance of a false 
positive was greatly reduced. These included: being a component of a 
significant factor (or having high uniqueness and not appearing in any factor), 
being a significant predictor in logistic regression both alone and after allowing 
for PlGF, having a ROC area for the combined score significantly greater than 
PlGF alone, being a useful predictor for both definitions of SGA. A comparison 
of Receiver Operated Curves (ROC) areas (a non-parametric method) of 
individual biomarkers and combinations was made to see if any of the additional 
information was both consistent and large enough to be clinically useful.  
 
The analysis was initially conducted on samples from women enrolled prior to 
35 weeks’ gestation as maternal plasma PlGF concentrations decline towards 
the end of the third trimester reducing test performance beyond 35 weeks’ 
gestation. This was then repeated in women enrolled between 35+0 and 36+6 
weeks’ gestation.  
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The second part of this analysis compared the best performing biomarker(s) to 
currently utilised ultrasound parameters. To allow this comparison data was 
restricted to women who had an ultrasound within 14 days of enrolment (when 
blood was drawn for biomarker analysis). The sensitivity, specificity and 
predictive values were calculated for three ultrasound parameters (estimated 
fetal weight (EFW) or abdominal circumference (AC) <10th centile, absent or 
reversed end diastolic flow in the umbilical artery (AREDF) and oligohydramnios 
(defined as amniotic fluid index <5th centile)) and the best performing biomarker 
to allow comparison. The performance of these parameters was assessed in 
isolation and combination, to determine both delivery of an SGA infant and 
adverse perinatal outcome. 
 
Statistical analysis was carried out in the statistical package Stata (version 
11.2), College Station Texas, USA. Formal significance was taken at p<0.05. 







649 women presenting with suspected pre-eclampsia between 20+0 and 40+6 
weeks’ gestation were recruited across seven sites between January 2011 and 
February 2012. 17 of these women did not have a valid enrolment plasma 
sample and there was no outcome data available on a further nine women, 
excluding them from any further analysis. Of the remaining 623 women, 29 had 
multi-fetal pregnancies and were excluded from this analysis. 197 women were 
recruited over 37 weeks’ gestation and the samples from these women were 
not analysed further. This decision followed the findings of the HYPITAT study, 
and publication of National Institute of Clinical Excellence (NICE) guidance on 
the management of hypertensive disorders during pregnancy. The HYPITAT 
study concluded that induction of labour in women presenting with gestational 
hypertension or mild pre-eclampsia beyond 37 weeks’ gestation improved 
maternal outcome (Koopmans et al., 2009). Subsequent NICE guidance 
recommended induction of labour in women presenting with pre-eclampsia 
beyond 37 weeks’ gestation (National Institute for Health and Clinical 
Excellence, 2010) and therefore investigating the utility of biomarkers to 
determine placental dysfunction beyond 37 weeks’ gestation was not justified 
as this would not alter clinical management. With particular reference to PlGF, 
maternal plasma concentrations decline after 32 weeks’ gestation with 
convergence of concentrations between normal and pathological pregnancies 
with advancing gestation (Knudsen et al., 2012) and therefore the clinical utility 
of this biomarker beyond 37 weeks’ gestation is likely to be less predictive of 
outcome even if women remained pregnant.  
 
 104 
274 women were recruited prior to 35 weeks’ gestation and 126 of these 
women had an ultrasound scan with all parameters recorded within or at 14 
days of enrolment (where PlGF sample was taken). Of these women, 74 
delivered an SGA infant <10th customised centile and 59 were below the 3rd 
centile. 123 women were recruited between 35+0 and 36+6 weeks’ gestation and 
53 of these women had an ultrasound scan and PlGF measured within or at 14 
days. Of these women, 21 delivered an SGA infant <10th centile and 14 had a 
birth weight below the 3rd centile (Figure 2.1).  
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2.3.1 Women presenting prior to 35 weeks’ gestation (n = 274) 
All descriptive Tables are separated according to subsequent infant birth 
weight.  Characteristics of participants at booking and enrolment are displayed 
in Tables 2.4 and 2.5 respectively. There is little difference between groups at 
booking and enrolment except the presence of new onset proteinuria and 
hypertension, which occurred more frequently at enrolment in women who 
subsequently delivered an SGA infant. A likely explanation for this finding is the 
known association between pre-eclampsia and SGA. Table 2.6 details delivery 
and maternal and neonatal outcomes; delivery by planned caesarean section 
was higher in women with an SGA infant (62% in pregnancies complicated by 
SGA <10th centile) compared to those delivering an infant ≥ 10th centile (32%). 
The median gestation at delivery was much lower in the cases complicated by 
SGA, likely secondary to increased iatrogenic delivery in this group (34.4 
weeks, versus 38.1 weeks’ gestation in women delivering an infant with a birth 
weight ≥10th centile). There were six stillbirths and two neonatal deaths, and 
with the exception of one case, all had a birth weight <3rd customised centile. In 
all cases of stillbirth the PlGF concentration at enrolment was <100 pg/ml and 
predated ultrasound abnormalities by 7 to 39 days and stillbirth by 10 to 53 
days. The prevalence of adverse perinatal outcomes (definition excluded SGA) 
was much higher in the SGA groups compared to those delivering AGA infants, 
emphasising the importance of identifying those at risk (39%, 32% and 13% for 
SGA <3rd centile, SGA <10th centile and birth weight ≥10th centile respectively). 
The most common adverse perinatal outcomes in cases with birth weight <3rd 
customised centile at delivery were respiratory distress syndrome (21/39), 
followed by admission to NICU for >48 hrs at term (6/39) and retinopathy of 
 107 
prematurity (5/39). There were four cases each of bronchopulmonary dysplasia 
and necrotising enterocolitis and one case of intraventricular haemorrhage 
within this group. 
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Table 2.4: Characteristics of participants at booking (grouped by 
subsequent infant birth weight) under 35 weeks’ gestation.  Values given 
are median (quartiles) or n (%) as appropriate.  
 
Characteristics Women with 
SGA infant <3rd 
centile (n = 96) 
Women with 
SGA infant <10th 
centile (n=130) 
Women with 
infant ≥ 10th 
centile (n=144) 
Age (years) 31.9 
(27.2 to 36.2) 
31.9 
(27.4 to 36.4) 
31.7 
(26.3 to 35.6) 
BMI (kg/m2) 26.8 
(24.1 to 31.2) 
28.0 
(23.9 to 32.8) 
29.3 
(24.7 to 34.9) 
White ethnicity 63 (65.6) 87 (66.9) 92 (63.9) 
Highest systolic BP 
(mmHg) 
120 (110 to 130) 121 (110 to 130) 120 (110 to 130) 
Highest diastolic BP 
(mmHg)  
74 (65 to 81) 74 (65 to 81) 75 (68 to 82) 
Smoker at booking 17 (18.5) 24 (19.2) 29 (20.4) 
Quit smoking during 
pregnancy 
10 (10.9) 14 (11.2) 19 (13.4) 





15 (15.8) 18 (14.0) 12 (8.6) 
Chronic hypertension 11 (11.5) 21 (16.2) 23 (16.0) 
SLE or APS 5 (5.2) 6 (4.6) 6 (4.2) 
Pre-existing diabetes 
mellitus 
2 (2.1) 2 (1.5) 4 (2.8) 
Renal disease 6 (6.3) 9 (6.9) 10 (6.9) 
SLE or APS, Systemic lupus erythematosus or Antiphospholipid syndrome 
BP, Blood Pressure 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile   
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Table 2.5: Characteristics of participants at study enrolment under 35 
weeks’ gestation. Values given are median (quartiles) or n (%) as 
appropriate.  
Characteristics Women with 
SGA infant <3rd 
centile (n = 96) 
Women with 
SGA infant <10th 
centile (n=130) 
Women with 
infant ≥ 10th 
centile (n=144) 
Gestational age at 
sampling (weeks) 
31.0 
(27.6 to 33.0) 
31.0 
(27.6 to 33.1) 
31.1 
(28.0 to 33.6) 
Signs or symptoms of suspected pre-eclampsia 
New onset hypertension † 60 (63) 80 (62) 65 (45) 
Worsening of underlying 
hypertension  
16 (17) 24 (19) 32 (22) 
New onset of dipstick 
proteinuria 

















Headaches 24 (25) 32 (25) 49 (34) 
Suspected SGA 
(customised birth weight 
centiles) † 
40 (42) 40 (31) 1 (1) 
Highest systolic BP 
(mmHg) † 
147  
(137 to 160) 
148  
(138 to 160) 
141  
(128 to 156) 
Highest diastolic BP  
(mmHg) † 
94  
(83 to 100) 
94 
(83 to 100) 
90  
(80 to 100) 
Epigastric/ right upper 
quadrant pain 
4 (4) 6 (5) 12 (8) 
Laboratory tests at time of enrolment 
Alanine transaminase 
(U/L) 
15 (11 to 19) 16 (12 to 20) 13 (10 to 19) 
Creatinine (µmol/L)  55 (46 to 64) 55 (46 to 64) 50 (41 to 60) 
Uric acid (µmol/L) † 310  
(217 to 359) 
290  
(195 to 355) 
241  
(184 to 287) 
Platelet count (x109/L) 230  
(199 to 275) 
230  
(191 to 275) 
236  
(202 to 266) 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile (the 
main outcome) to women with infant ≥ 10th centile 
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Table 2.6: Characteristics of delivery, maternal and neonatal outcome for 
women presenting before 35 weeks’ gestation. Values given are median 
(quartiles) or n (%) as appropriate.  
 
Characteristics Women with 
SGA infant <3rd 
centile (n = 96) 
Women with 
SGA infant <10th 
centile (n = 130) 
Women with 
infant ≥ 10th 
centile  
(n = 144) 
Onset of labour 
Spontaneous † 3 (3) 7 (5) 32 (23) 
Induced 29 (30) 42 (33) 64 (45) 
Pre labour caesarean section 
† 
64 (67) 80 (62) 46 (32) 
Mode of delivery 
Spontaneous † 15 (16) 25 (20) 45 (31) 
Assisted vaginal  5 (5) 8 (6) 21 (15) 
Caesarean section † 75 (79) 95 (74) 78 (54) 
Adverse maternal outcome*  44 (46) 61 (47) 56 (39) 
Gestation at delivery (weeks) 
†  
33.8  
(30.8 to 36.1) 
34.4  
(31.4 to 37.3) 
38.1  
(36 to 39.4) 
Fetal death † 5 (5) 5 (4) 1 (1) 
Neonatal death 2 (2) 2 (2) 0 (0) 
Birth weight (g) † 1537  
(1043 to 1910) 
1660  
(1200 to 2310) 
3128  
(2698 to 3545) 
SGA <10th birth weight 
centile 
96 (100) 130 (100) 0 (0) 
SGA <3rd birth weight centile  96 (100) 96 (74) 0 (0) 
SGA <1st birth weight centile  68 (71) 68 (53) 0 (0) 
Adverse perinatal outcome** 
† 
37 (39) 41 (32) 19 (13) 
Maternal diagnosis 
No maternal disease 0 1 (0.8) 21 (15) 
Gestational hypertension 1 (1) 1 (0.8) 25 (17) 
Chronic hypertension 4 (4) 12 (9) 16 (11) 
Pre-eclampsia 86 (90)  106 (81) 59 (41) 
HELLP syndrome 1 (1) 1 (0.8) 1 (0.7) 
Other diagnosis 4 (4) 9 (7) 22 (16) 
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*Adverse maternal outcome defined as presence of any of the following 
complications: maternal death, eclampsia, stroke, cortical blindness or retinal 
detachment, hypertensive encephalopathy, systolic blood pressure ≥160mmhg, 
myocardial infarction, intubation (other than for caesarean section), pulmonary 
oedema, platelets <50×109/l (without transfusion), disseminated intravascular 
coagulation, thrombotic thrombocytopenic purpura/ haemolytic uraemic 
syndrome, hepatic dysfunction (alanine transaminase ≥70iu/l), hepatic 
haematoma or rupture, acute fatty liver of pregnancy, creatinine >150 µmol/l, 
renal dialysis, placental abruption, major postpartum haemorrhage, major 
infection. 
 
**Adverse perinatal outcome defined as: presence of any of the following 
complications: antepartum/ intrapartum fetal or neonatal death, neonatal unit 
admission for >48 hrs at term, intraventricular haemorrhage, periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis. 
 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 




Factor analysis of all 57 biomarkers was performed as described in section 
2.2.3. The results of the factor analysis showing the five largest factors are 
displayed in Table 2.7. Factors three and four had the highest odds ratios in 
women recruited before 35 weeks’ gestation. The biomarkers within factors 3 
and 4 were investigated further by using stepwise logistic regression to 
determine which if any of these biomarkers provided additional information 
beyond that derived from PlGF. Prediction scores were calculated to identify the 
best combinations of biomarkers for further analysis. PlGF was consistently the 
strongest predictor and did not need to be forced into the model. 
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Table 2.7: Odds ratios derived from multiple logistic regression analysis 
of the 5 factors in women presenting before 35 weeks’ gestation (Odds 
ratios are for a change of 1 SD in the factor score). 
 
Factor  Biomarkers contained 
in factor 
Women with SGA 
infant <3rd centile 
Odds Ratio 
(95% CI) 
Women with SGA 
infant <10th centile 
Odds Ratio  
(95% CI) 
1 ANP, Arginase-1, 
CCL23, CPA-4, ESAM-




0.85 (0.64 to 1.13) 0.89 (0.68 to 1.16) 
2 ADAM-9, Ephrin, FasL, 
Kunitz 35b, Kunitz 40b, 
Nephrin, PAI-1, 
Pentraxin-3-64a 
0.79 (0.57 to 1.1) 0.78 (0.58 to 1.03) 




1.67 (1.23 to 2.28) 1.57  (1.18 to 2.07) 
4 PlGF, Endoglin, sFlt-1 2.85 (2.13 to 3.82) 2.38  (1.84 to 3.08) 
5 Angiogenin, Caspase, 
FIH, ICAM-1, MIF, 
TIMP-1 





A summary of the best performing individual biomarkers and combinations 
derived from logistic regression to determine SGA <3rd and <10th birth weight 
centiles are displayed in Table 2.8. PlGF outperformed all other individual 
biomarkers and biomarker ratios in determining delivery of an SGA infant, with a 
ROC area of 0.83 (95% CI 0.78 to 0.88) for SGA <3rd centile and 0.79 (95% CI 
0.73 to 0.84) for SGA <10th centile (Figure 2.2). Biomarker combinations 
incorporating PlGF added little to the test performance of PlGF in isolation, with 
a ROC area of 0.84 (95% CI 0.79 to 0.89) for the most promising combination to 
predict SGA <3rd centile and 0.80 (95% CI 0.74 to 0.85) for SGA <10th centile 
(Figure 2.3). Table 2.9 contains ROC areas for all 57 biomarker assays 
measured in determining SGA <3rd and <10th birth weight centiles. To allow 
comparison of individual biomarker test performance in women enrolled prior to 
35 weeks’ gestation with those women enrolled between 35+0 and 36+6 weeks’ 




Table 2.8: Test performance statistics for individual biomarkers and 
combinations (derived from logistic regression) to predict SGA <3rd 
centile and <10th centile in women presenting before 35 weeks’ gestation 
(ROC areas with 95 confidence intervals). 
 
Biomarkers or combinations SGA <3rd centile SGA <10th centile 
Nephrin 0.63 (0.56 to 0.70) 0.62 (0.55 to 0.69) 
[CPA-4] 0.63 (0.57 to 0.70) 0.62 (0.55 to 0.68) 
PCT 95a  0.67 (0.61 to 0.74) 0.64 (0.57 to 0.71) 
[PAI-2]               0.68 (0.62 to 0.75) 0.66 (0.59 to 0.72) 
BNP 0.69 (0.62 to 0.75) 0.64 (0.58 to 0.71) 
sFlt-1 0.73 (0.67 to 0.79) 0.69 (0.63 to 0.76) 
Endoglin  0.74 (0.68 to 0.80) 0.73 (0.67 to 0.79) 
[PlGF] 0.83 (0.78 to 0.88) 0.79 (0.73 to 0.84) 
[PlGF/s-Flt ratio] 0.80 (0.75 to 0.85) 0.77 (0.71 to 0.82) 
[PlGF/Endoglin ratio] 0.82 (0.77 to 0.86) 0.78 (0.73 to 0.83) 
[PlGF], [CPA-4] 0.83 (0.78 to 0.88) 0.79 (0.74 to 0.84) 
[PlGF], Nephrin 0.84 (0.79 to 0.88) 0.80 (0.74 to 0.85) 
[PlGF], Nephrin, [CPA-4] 0.84 (0.79 to 0.89) 0.80 (0.74 to 0.85) 
 




Figure 2.2 ROC areas of individual biomarkers measured under 35 weeks’ 
gestation to determine: 
SGA < 3rd centile 
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Figure 2.3 ROC areas of biomarker combinations measured under 35 
weeks’ gestation to determine: 
SGA < 3rd centile 
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Table 2.9: Individual biomarker test performance (ROC areas with 95 
confidence intervals) under 35 weeks’ gestation and 35+0 to 36+6 weeks’ 
gestation. 
   
   
< 35 weeks’ gestation 35+0 - 36+6 weeks’ gestation 
(<3rd centile)   (<10th centile)   (<3rd centile)   (<10th centile)   
[PlGF] 0.83  
(0.78 to 0.88) 
0.79  
(0.73 to 0.84) 
0.69  
(0.57 to 0.81) 
0.74  
(0.64 to 0.83) 
ADAM-9 0.52  
(0.48 to 0.56) 
0.54  
(0.50 to 0.58) 
0.55  
(0.49 to 0.62) 
0.56  
(0.50 to 0.62) 
Angiogenin  0.59  
(0.51 to 0.66) 
0.58  
(0.51 to 0.64) 
0.61  
(0.49 to 0.73) 
0.57  
(0.46 to 0.68) 
ANP 0.56  
(0.49 to 0.64) 
0.56  
(0.49 to 0.63) 
0.49  
(0.35 to 0.63) 
0.54  
(0.42 to 0.65) 
Arginase 1 0.51  
(0.44 to 0.58) 
0.51  
(0.44 to 0.58) 
0.61  
(0.48 to 0.73) 
0.54  
(0.42 to 0.65) 
[Arginase 2] 0.64  
(0.56 to 0.71) 
0.63  
(0.57 to 0.70) 
0.67  
(0.55 to 0.79) 
0.64  
(0.54 to 0.75) 
BNP 0.69  
(0.62 to 0.75) 
0.64  
(0.58 to 0.71) 
0.65  
(0.54 to 0.77) 
0.68  
(0.58 to 0.78) 
Caspase  0.56  
(0.49 to 0.63) 
0.56  
(0.49 to 0.62) 
0.58  
(0.46 to 0.70) 
0.52  
(0.42 to 0.63) 
[CCL23] 0.57  
(0.50 to 0.64) 
0.58  
(0.51 to 0.65) 
0.52  
(0.40 to 0.65) 
0.54  
(0.43 to 0.65) 
[CPA-4] 0.63  
(0.57 to 0.70) 
0.62  
(0.55 to 0.68) 
0.72  
(0.61 to 0.83) 
0.72  
(0.63 to 0.82) 
CRP 0.58  
(0.51 to 0.65) 
0.55  
(0.48 to 0.62) 
0.68  
(0.57 to 0.80) 
0.59  
(0.48 to 0.70) 
CXCL10 0.51  
(0.44 to 0.59) 
0.53  
(0.46 to 0.59) 
0.46  
(0.32 to 0.61) 
0.51  
(0.40 to 0.63) 
Cystatin C  0.58  
(0.51 to 0.65) 
0.59  
(0.52 to 0.66) 
0.53  
(0.39 to 0.66) 
0.54  




(0.52 to 0.66) 
0.58  
(0.51 to 0.64) 
0.64  
(0.51 to 0.76) 
0.64  
(0.54 to 0.74) 
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(0.54 to 0.68) 
0.59  
(0.52 to 0.65) 
0.64  
(0.52 to 0.76) 
0.64  
(0.54 to 0.74) 
Elafin 131  0.57  
(0.50 to 0.64) 
0.54  
(0.47 to 0.61) 
0.64  
(0.52 to 0.76) 
0.55  
(0.44 to 0.66) 
Elafin 132  0.48  
(0.41 to 0.55) 
0.47  
(0.41 to 0.54) 
0.60  
(0.49 to 0.72) 
0.52  
(0.42 to 0.63) 
Endoglin  0.74  
(0.68 to 0.80) 
0.73  
(0.67 to 0.79) 
0.58  
(0.46 to 0.70) 
0.65  




(0.45 to 0.60) 
0.54  
(0.48 to 0.61) 
0.57  
(0.45 to 0.70) 
0.55  
(0.45 to 0.66) 
[Ephrin] 0.49  
(0.46 to 0.51) 
0.49  
(0.47 to 0.51) 
0.51 
 (0.50 to 0.52) 
0.51  
(0.49 to 0.52) 
[ESAM-1] 0.55  
(0.48 to 0.63) 
0.55  
(0.48 to 0.62) 
0.67  
(0.55 to 0.79) 
0.66  
(0.55 to 0.76) 
[FAS] 0.53  
(0.45 to 0.60) 
0.49  
(0.42 to 0.56) 
0.53  
(0.40 to 0.65) 
0.55  
(0.45 to 0.66) 
[FasL] 0.52  
(0.46 to 0.58) 
0.54  
(0.48 to 0.59) 
0.52  
(0.41 to 0.62) 
0.54  
(0.45 to 0.62) 
HIF 0.55  
(0.48 to 0.62) 
0.56  
(0.49 to 0.62) 
0.56  
(0.43 to 0.68) 
0.51  
(0.40 to 0.62) 
[HbF] 0.44  
(0.37 to 0.51) 
0.45  
(0.38 to 0.52) 
0.55  
(0.41 to 0.69) 
0.49  
(0.38 to 0.61) 
ICAM-1 0.57  
(0.50 to 0.64) 
0.55  
(0.48 to 0.62) 
0.67  
(0.56 to 0.78) 
0.60  
(0.49 to 0.71) 
[IL-1ra] 0.58  
(0.51 to 0.65) 
0.59  
(0.53 to 0.66) 
0.62  
(0.50 to 0.75) 
0.62  




(0.45 to 0.59) 
0.51  
(0.44 to 0.58) 
0.36  
(0.24 to 0.48) 
0.40  




(0.50 to 0.64) 
0.56  
(0.49 to 0.63) 
0.74  
(0.63 to 0.85) 
0.73  
(0.65 to 0.82) 
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 < 35 weeks’ gestation 35+0 -36+6 weeks’ gestation 




(0.51 to 0.65) 
0.60  
(0.53 to 0.66) 
0.69  
(0.57 to 0.81) 
0.68  
(0.58 to 0.78) 
[Leptin 43a]  0.47  
(0.40 to 0.54) 
0.49  
(0.42 to 0.56) 
0.50  
(0.37 to 0.63) 
0.49  
(0.38 to 0.60) 
[Leptin 46b] 0.59  
(0.52 to 0.66) 
0.56  
(0.49 to 0.63) 
0.65  
(0.52 to 0.78) 
0.62  
(0.51 to 0.73) 
[MIF-49a] 0.54  
(0.47 to 0.62) 
0.58  
(0.51 to 0.65) 
0.57  
(0.45 to 0.70) 
0.57  
(0.46 to 0.68) 
[MIF-49b] 0.55  
(0.47 to 0.62) 
0.54  
(0.47 to 0.61) 
0.48  
(0.36 to 0.60) 
0.49  
(0.38 to 0.59) 
[MMP-9] 0.52  
(0.44 to 0.59) 
0.53  
(0.46 to 0.60) 
0.57  
(0.45 to 0.69) 
0.56 




(0.50 to 0.60) 
0.55  
(0.50 to 0.60) 
0.53  
(0.44 to 0.62) 
0.52  




(0.56 to 0.70) 
0.62  
(0.55 to 0.69) 
0.67  
(0.55 to 0.80) 
0.63  
(0.52 to 0.74) 
NGAL 0.62  
(0.55 to 0.69) 
0.60  
(0.54 to 0.67) 
0.46  
(0.33 to 0.58) 
0.49  




(0.46 to 0.60) 
0.50  
(0.43 to 0.57) 
0.49  
(0.36 to 0.62) 
0.48  
(0.37 to 0.59) 
[PAI-2] 0.68  
(0.62 to 0.75) 
0.66  
(0.59 to 0.72) 
0.67  
(0.56 to 0.79) 
0.65  
(0.55 to 0.75) 
[PAPP-A]  0.60  
(0.53 to 0.67) 
0.64  
(0.57 to 0.70) 
0.62  
(0.50 to 0.74) 
0.66  
(0.56 to 0.77) 
PCT 95a 0.67  
(0.61 to 0.74) 
0.64  
(0.57 to 0.71) 
0.61  
(0.48 to 0.73) 
0.59  
(0.48 to 0.69) 
PCT 99b 0.51  
(0.44 to 0.58) 
0.52  
(0.45 to 0.59) 
0.38  
(0.26 to 0.51) 
0.45  




(0.44 to 0.55) 
0.48  
(0.43 to 0.53) 
0.46  
(0.36 to 0.57) 
0.45  
(0.36 to 0.54) 
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(0.57 to 0.71) 
0.63  
(0.56 to 0.69) 
0.59  
(0.46 to 0.71) 
0.61  
(0.50 to 0.71) 
Periostin  0.56  
(0.48 to 0.63) 
0.54  
(0.47 to 0.61) 
0.50  
(0.37 to 0.63) 
0.57  
(0.46 to 0.68) 
Podocalyxin 0.62  
(0.55 to 0.69) 
0.59  
(0.53 to 0.66) 
0.65  
(0.53 to 0.76) 
0.62  
(0.52 to 0.72) 
sFlt-1 0.73  
(0.66 to 0.79) 
0.69  
(0.63 to 0.76) 
0.57  
(0.45 to 0.70) 
0.61 
 (0.51 to 0.71) 
ST2-116b 0.62  
(0.55 to 0.69) 
0.60  
(0.53 to 0.66) 
0.55  
(0.43 to 0.67) 
0.61  
(0.51 to 0.72) 
ST2 -75b 0.59  
(0.52 to 0.66) 
0.57  
(0.51 to 0.64) 
0.49  
(0.35 to 0.62) 
0.55  
(0.44 to 0.66) 
[TGFβ-1] 0.60  
(0.53 to 0.68) 
0.59  
(0.52 to 0.66) 
0.66  
(0.55 to 0.77) 
0.64  
(0.54 to 0.74) 
TIMP-1 0.60  
(0.53 to 0.67) 
0.56  
(0.49 to 0.63) 
0.56 
 (0.45 to 0.68) 
0.52  
(0.41 to 0.63) 
[TNFR-1A] 0.54  
(0.46 to 0.62) 
0.51  
(0.44 to 0.58) 
0.60  
(0.47 to 0.73) 
0.57  
(0.47 to 0.68) 
VEGF-C 0.57  
(0.50 to 0.65) 
0.58  
(0.51 to 0.64) 
0.42  
(0.29 to 0.56) 
0.46  
(0.35 to 0.58) 
Visfatin  0.56  
(0.49 to 0.63) 
0.56  
(0.49 to 0.62) 
0.46  
(0.35 to 0.57) 
0.49  




(0.55 to 0.69) 
0.60  
(0.53 to 0.66) 
0.52  
(0.39 to 0.66) 
0.55  




(0.48 to 0.63) 
0.57  
(0.51 to 0.64) 
0.40  
(0.27 to 0.53) 
0.47  
(0.35 to 0.58) 
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In addition to analysing the test performance of multiple biomarkers, the ability 
of currently utilised ultrasound parameters to determine delivery of an SGA 
infant was assessed and compared to low PlGF. Tables 2.10 and 2.11 
summarise the sensitivity, specificity, positive and negative predictive values 
and positive and negative likelihood ratios of low maternal plasma PlGF (<100 
pg/ml) and currently measured ultrasound parameters (including EFW/AC <10th 
centile, oligohydramnios (AFI <5cm) and AREDF) to determine delivery of an 
SGA infant <3rd and <10th customised centiles respectively. EFW/AC <10th 
centile had the best performance of currently used ultrasound parameters, with 
a sensitivity of 71.2% (95% CI 57.9 to 82.2%) and NPV 78.5% (95% CI 67.8 to 
86.9%) to determine SGA <3rd centile. However PlGF outperformed all currently 
measured ultrasound parameters with a sensitivity of 93.2% (95% CI 83.5 to 
98.1%) and NPV 89.7% (95% CI 75.8 to 97.1%) to determine SGA <3rd centile 
(Table 2.10). When PlGF was combined with currently used ultrasound 
parameters, sensitivity improved to 96.6% (95% CI 88.3 to 99.6%) with NPV 
94.3% (95% CI 80.8 to 99.3%). 
 
In predicting adverse perinatal outcome (excluding SGA in this definition) PlGF 
had higher sensitivity (89.7%) and negative predictive value (89.7%) than all 
other ultrasound measurements (Table 2.12). If PlGF was combined with fetal 
ultrasound parameters (AC or EFW <10th centile) there was a marginal rise in 
test sensitivity to 92.3% (95% CI 79.1 to 98.4%).   
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Table 2.10: Test performance statistics (with 95% confidence intervals) for individual indicators and in combination to predict 
small for gestational age (SGA) <3rd customised birth weight centile in women presenting before 35 weeks’ gestation (n=126) 






% (95% CI) 
Negative 
predictive value 







AC or EFW <10th centile 71.2 
(57.9 to 82.2) 
92.5 
(83.4 to 97.5) 
89.4 
(76.9 to 96.5) 
78.5 
(67.8 to 86.9) 
9.5      
(4.0 to 22.5) 
0.31      
(0.21 to 0.47) 
Oligohydramnios 18.6 
(9.7 to 30.9) 
98.5 
(92.0 to 100) 
91.7 
(61.5 to 99.8) 
57.9 
(48.3 to 67.1) 
12.5 
(1.7 to 93.9) 
0.83     
(0.73 to 0.94) 
AREDF 20.3 
(11.0 to 32.8) 
98.5 
(92 to 100) 
92.3 
(64 to 99.8) 
58.4 
(48.8 to 67.6) 
13.6      
(1.8 to 102) 
0.81       
(0.71 to 0.92) 
PlGF <100 pg/ml 93.2 
(83.5 to 98.1) 
52.2 
(39.7 to 64.6) 
63.2 
(52.2 to 73.3) 
89.7 
(75.8 to 97.1) 
2.0       
(1.5 to 2.5) 
0.13 
(0.05 to 0.34) 
Combinations 
AC or EFW <10th centile 
or oligo or AREDF 
72.9 
(59.7 to 83.6) 
91.0  
(81.5 to 96.6) 
87.8  
(75.2 to 95.4) 
79.2 
(68.5 to 87.6) 
8.1 
(3.7 to 17.7) 
0.30  
(0.19 to 0.46) 
AC or EFW <10th centile 
or PlGF <100 pg/ml 
96.6 
(88.3 to 99.6) 
49.3 
(36.8 to 61.8) 
62.6 
(51.9 to 72.6) 
94.3 
(80.8 to 99.3) 
1.90       
(1.5 to 2.4) 
0.07       
(0.02 to 0.3) 
AC or EFW, Abdominal Circumference or Estimated Fetal Weight, Oligohydramnios defined as amniotic fluid index <5th centile for 
gestational age, AREDF, Absent or Reversed End Diastolic Flow in umbilical artery  
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Table 2.11: Test performance statistics (with 95% confidence intervals) for individual indicators and in combination to predict 
small for gestational age (SGA) <10th customised birth weight centile in women presenting before 35 weeks’ gestation (n=126) 
Indicator  Sensitivity %  
(95% CI) 




% (95% CI) 
Negative 
predictive value 







AC or EFW <10th centile 58.1 
(46.1 to 69.5) 
92.3 
(81.5 to 97.9) 
91.5 
(79.6 to 97.6) 
60.8 
(49.1 to 71.6) 
7.6       
(2.9 to19.8) 
0.5       
(0.3 to 0.6) 
Oligohydramnios 16.2 
(8.7 to 26.6) 
100 




(36.3 to 55.2) 
0 0.8       
(0.8 to 0.9) 
AREDF 16.2 
(8.7 to 26.6) 
98.1 
(89.7 to 100) 
92.3 
(64.0 to 99.8) 
45.1 
(35.8 to 54.8) 
8.4 
(1.1 to 62.9) 
0.9  
(0.8 to 1.0) 
PlGF <100 pg/ml 83.8 
(73.4 to 91.3) 
51.9 
(37.6 to 66.0) 
71.3 
(60.6 to 80.5) 
69.2  
(52.4 to 83.0) 
1.7       
(1.3 to 2.4) 
0.3      
(0.2 to 0.6) 
Combinations 
AC or EFW <10th centile 
or oligo or AREDF 
60.8 
(48.8 to 72.0) 
92.3 
(81.5 to 97.9) 
91.8 
(80.4 to 97.7) 
62.3 
(50.6 to 73.1) 
7.9  
(3.0 to 20.6) 
0.42  
(0.32 to 0.57) 
AC or EFW <10th centile 
or PlGF <100 pg/ml 
87.8 
(78.2 to 94.3) 
50.0 
(35.8 to 64.2) 
71.4 
(61.0 to 80.4) 
74.3 
(56.7 to 87.5) 
1.8       
(1.3 to 2.3) 
0.24      
(0.12 to 0.48) 
AC or EFW, Abdominal Circumference or Estimated Fetal Weight, Oligohydramnios defined as amniotic fluid index <5th centile for 
gestational age, AREDF, Absent or Reversed End Diastolic Flow in umbilical artery
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Table 2.12: Test performance statistics (with 95% confidence intervals) for 
individual indicators and in combination to predict adverse perinatal 
outcome in women presenting before 35 weeks’ gestation (n=126) 
 
Indicator  Sensitivity 
%  (95% CI) 
Specificity 
%  (95% CI) 
Positive 
predictive 




value %  
(95% CI) 
AC or EFW 
<10th centile 
48.7 
(32.4 to 65.2) 
67.8 
(56.9 to 77.4) 
40.4 
(26.4 to 55.7) 
74.7 
(63.6 to 83.8) 
Oligohydramnios 12.8 
(4.3 to 27.4) 
92.0 
(84.1 to 96.7) 
41.7 
(15.2 to 72.3) 
70.2 
(60.9 to 78.4) 
AREDF 12.8 
(4.3 to 27.4) 
90.8 
(82.7 to 95.9) 
38.5 
(13.9 to 68.4) 
69.9 
(60.6 to 78.2) 
PlGF <100 pg/ml 89.7 
(75.8 to 97.1) 
40.2 
(29.9 to 51.3) 
40.2 
(29.9 to 51.3) 
89.7 
(75.8 to 97.1) 
Combinations 





(37.2 to 69.9) 
67.8 
(56.9 to 77.4) 
42.9 
(28.8 to 57.8) 
76.6 
(65.6 to 85.5) 
AC or EFW 
<10th centile or 
PlGF <100 pg/ml 
92.3 
(79.1 to 98.4) 
36.8 
(26.7 to 47.8) 
39.6 
(29.5 to 50.4) 
91.4 
(76.9 to 98.2) 
 
AC or EFW, Abdominal Circumference or Estimated Fetal Weight 
Oligohydramnios defined as amniotic fluid index <5th centile for gestational age 
ARDEF, Absent or Reversed End Diastolic Flow in umbilical artery   
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2.3.2 Women presenting between 35+0 and 36+6 weeks’ gestation  
(n = 123) 
Of 123 women presenting between 35+0 and 36+6 weeks’ gestation, 39 (31.7%) 
delivered an SGA infant <10th customised centile for birth weight. Patterns in 
demographics at booking and enrolment were similar to those seen in women 
presenting prior to 35 weeks’ gestation (Table 2.13).  
 
Table 2.14 summarises data for delivery and maternal and neonatal outcomes. 
In contrast to women recruited prior to 35 weeks’ gestation, onset and mode of 
delivery and maternal adverse outcome did not vary greatly with infant birth 
weight. However, delivery by caesarean section was very high in the whole 
cohort, at approximately 50%. This is nearly twice that of the current national 
average and may reflect that pregnancies recruited to this study were high risk. 
There were no fetal of neonatal deaths in this group and whilst prevalence of 
adverse perinatal outcomes was higher in pregnancies complicated by delivery 
of an SGA infant compared to those delivering an AGA infant, this was much 
lower than in women recruited prior to 35 weeks’ gestation (12% in women 
recruited between 35+0 and 36+6 weeks and delivering an SGA infant <3rd 
centile compared to 39% in those recruited prior to 35 weeks’ gestation who 




Table 2.13: Characteristics of participants recruited between 35+0 to 36+6 
weeks’ gestation at booking and enrolment (grouped by subsequent 
infant birth weight).  Values given are median (quartiles) or n (%) as 
appropriate.  
 
Characteristics Women with 
SGA infant <3rd 
centile (n = 25) 
Women with 
SGA infant <10th 
centile (n=39) 
Women with 






(25.2 to 36.1) 
 
29.6 
(25.1 to 35.3) 
 
32.4 
(28.0 to 35.0) 
BMI (kg/m2) 28.6  
(25.6 to 30.5) 
28.0  
(24.3 to 30.5) 
28.8  
(24.3 to 32.9) 
White ethnicity 16 (64) 23 (59) 53(63) 
Highest first 
trimester systolic 
BP (mmHg)  
110 (104 to 122) 116 (104 to 122) 120 (110 to 128) 
Highest first 
trimester diastolic 
BP (mmHg)  
70 (60 to 75) 70 (62 to 78) 76 (67 to 80) 
Smoker at booking 6/25 (24) 8/39 (21) 11/80 (14) 
Quit smoking during 
pregnancy 




3 (12) 4 (10) 2 (2) 
Chronic 
hypertension 
2 (8) 3 (7.7) 6 (7) 
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Characteristics Women with 
SGA infant <3rd 
centile (n = 25) 
Women with 
SGA infant <10th 
centile (n=39) 
Women with 
infant ≥ 10th 
centile (n=84) 
At enrolment: 
Gestational age at 
sampling (weeks) 
35.7 
(35.4 to 36.3) 
36 
(35.4 to 36.4) 
36.1 
(35.4 to 36.4) 
New onset 
hypertension † 




1 (4) 3 (7.7) 15 (17.9) 
New onset of 
dipstick 
proteinuria 
18 (72) 28 (71.8) 49 (58.3) 
Suspected SGA 
(customised birth 
weight centiles) † 
8 (32) 8 (20.5) 1 (1.2) 
Highest systolic 
BP (mmHg) 
140 (130 to 151) 145 (131 to 153) 143 (132 to 152) 
Highest diastolic 
BP (mmHg) 
90 (82 to 98) 92 (82 to 99) 94 (87 to 99) 
 
BP, Blood Pressure  
 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile   
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Table 2.14: Characteristics of delivery and maternal and neonatal outcome 
for women recruited between 35+0 and 36+6 weeks’ gestation. Values given 
are median (quartiles) or n (%) as appropriate.  
Characteristics Women with 
SGA infant <3rd 
centile (n = 25) 
Women with 
SGA infant <10th 
centile (n=39) 
Women with 
infant ≥ 10th 
centile (n=84) 
Onset of labour 
Spontaneous 4 (16) 6 (15.4) 17 (20.2) 
Induced 16 (64) 23 (59) 47 (56) 
Pre labour caesarean section 5 (20) 
 
10 (25.6) 19 (22.6) 
Mode of delivery 
Spontaneous 9 (36) 13 (33.3) 37 (44) 
Assisted vaginal  3 (12) 4 (10.3) 7 (8.3) 
Caesarean section 12 (48) 21 (53.8) 40 (47.6) 
Adverse maternal outcome* 6 (24) 11 (28.2) 26 (31) 
Gestation at delivery (weeks) 37.3  
(36.7 to 37.9) 
37.1  
(36.4 to 37.9) 
37.7   
(37 to 39.4) 
Fetal death 0 (0) 0 (0) 0 (0) 
Neonatal death 0 (0) 0 (0) 0 (0) 
Birth weight (g) † 2170  
(2030 to 2340) 
2250  
(2055 to 2480) 
3240  
(2925 to 3525) 
SGA <10th birth weight 
centile 
25 (100) 39 (100) 0 (0) 
SGA <3rd birth weight centile  25 (100) 25 (64.1) 0 (0) 
SGA <1st birth weight centile  11 (44) 11 (28.2) 0 (0) 
Adverse perinatal outcome** 3 (12) 4 (10.3) 5 (6) 
Maternal diagnosis 
No maternal disease 0 0 5 (6) 
Gestational hypertension 0 0 14 (17) 
Chronic hypertension 2 (8) 4 (10) 5 (6) 
Pre-eclampsia 20 (80) 31 (80) 38 (45) 
HELLP syndrome 0 0 0 




*Adverse maternal outcome defined as presence of any of the following 
complications: Maternal death, Eclampsia, Stroke, Cortical blindness or retinal 
detachment, Hypertensive encephalopathy, Systolic blood pressure 
≥160mmHg, Myocardial infarction, Intubation (other than for caesarean section), 
Pulmonary oedema, Platelets <50×10⁹/L (without transfusion), Disseminated 
intravascular coagulation, Thrombotic thrombocytopenic purpura/ haemolytic 
uraemic syndrome, Hepatic Dysfunction (Alanine transaminase ≥70IU/L), 
Hepatic haematoma or rupture, Acute fatty liver of pregnancy, Creatinine >150 
µmol/L, Renal dialysis, Placental abruption, Major postpartum haemorrhage, 
Major infection. 
 
**Adverse perinatal outcome defined as: presence of any of the following 
complications: Antepartum/ intrapartum fetal or neonatal death, Neonatal unit 
admission for >48 hrs at term, Intraventricular haemorrhage, Periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis. 
 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile 
 
 
As described in section 2.3.1, factor analysis of all 57 biomarkers was 
performed and the results showing the five largest factors in women enrolled 
between 35+0 and 36+6 weeks’ gestation is displayed in Table 2.15. Factors 
three and four had the highest odds ratios and the biomarkers within these 
factors were investigated further as described in section 2.3.1. 
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Table 2.15: Odds ratios derived from multiple logistic regression analysis 
of the 5 factors in women presenting between 35+0 and 36+6 weeks’ 




Factor  Biomarkers contained 
in factor 
Women with SGA 
infant <3rd centile 
Women with SGA 
infant <10th centile 
Odds Ratio 
 (95% CI) 
Odds Ratio 
 (95% CI) 
1 ANP, Arginase-1, CCL23, 




0.46 (0.26 to 0.78) 0.42  (0.25 to 0.72) 
2 ADAM-9, Ephrin, FasL, 
Kunitz 35b, Kunitz 40b, 
Nephrin, PAI-1, 
Pentraxin-3-64a 
0.97 (0.36 to 2.56) 0.54  (0.21 to 1.41) 




1.80 (1.03 to 3.16) 1.73  (1.02 to 2.94) 
4 PlGF, Endoglin, sFlt-1 3.54  (1.52 to 8.26) 6.89  (2.88 to 16.4) 
5 Angiogenin, Caspase, 
FIH, ICAM-1, MIF, TIMP-
1 
1.07  (0.61 to 1.90) 0.85  (0.50 to 1.45) 
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Table 2.16 summarises the best performing individual biomarkers and 
combinations in determining delivery of an SGA infant <3rd and <10th 
customised centiles. In determining SGA <10th centile PlGF outperforms all 
other biomarkers measured with a ROC area of 0.74 (0.64 to 0.83) (Figure 2.4). 
Combinations of biomarkers derived from logistic regression improved test 
performance to determine SGA <10th centile, with PlGF, Nephrin and 
Carboxypeptidase A4 (CPA-4) producing a ROC area of 0.81 (0.73 to 0.90) 
(Figure 2.5). In determining SGA <3rd centile Kunitz 2 had the best individual 
test performance (ROC area 0.74 (0.63 to 0.85)) (Figure 2.4) with combinations 
of PlGF, Nephrin and CPA-4 improving test performance to a ROC area of 0.77 
(0.66 to 0.88) (Figure 2.5). The test performance of all individual biomarkers are 
displayed in Table 2.9. 
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Table 2.16: ROC areas (with 95% confidence intervals) for individual 
biomarkers and combinations (derived from logistic regression) to predict 
small for gestational age (SGA) <3rd and <10th customised birth weight 
centiles in women presenting between 35+0 and 36+6 weeks’ gestation. 
 
Biomarkers or combinations SGA <3rd centile SGA <10th centile 
Nephrin 0.67 (0.55 to 0.80) 0.63 (0.52 to 0.74) 
[PAI-2]           0.67 (0.56 to 0.79) 0.65 (0.55 to 0.75) 
[PlGF] 0.69 (0.57 to 0.81) 0.74 (0.64 to 0.83) 
[CPA-4] 0.72 (0.61 to 0.83) 0.72 (0.63 to 0.82) 
Kunitz 2 35b 0.74 (0.63 to 0.85) 0.73 (0.65 to 0.82) 
[PlGF/s-Flt ratio] 0.66 (0.54 to 0.78) 0.70 (0.60 to 0.80) 
[PlGF/Endoglin ratio] 0.66 (0.54 to 0.78) 0.73 (0.63 to 0.82) 
[PlGF], Nephrin  0.73 (0.62 to 0.84) 0.76 (0.67 to 0.85) 
[PlGF], [CPA-4] 0.77 (0.67 to 0.88) 0.81 (0.73 to 0.90) 
[PlGF], Nephrin, [CPA-4] 0.77 (0.66 to 0.88) 0.81 (0.73 to 0.90) 
 




Figure 2.4: ROC areas of individual biomarkers measured between 35+0 
and 36+6 weeks’ gestation to determine: 
SGA < 3rd centile 
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Figure 2.5: ROC areas of biomarker combinations measured between 35+0 
and 36+6 weeks’ gestation to determine: 
SGA < 3rd centile 
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Tables 2.17 and 2.18 compare test performance of currently utilised ultrasound 
parameters and PlGF to determine delivery of an SGA infant <3rd and <10th 
customised centiles respectively. Similar patterns are seen in test performance 
in this group as were observed in women recruited prior to 35 weeks’ gestation. 
EFW/AC <10th centile has the best test performance of any ultrasound 
parameter assessed to determine delivery of an SGA infant (sensitivity 64.3%, 
NPV 88.1% for SGA <3rd centile) but PlGF outperforms all ultrasound 
parameters (sensitivity 85.7% (95% CI 57.2 to 98.2%), NPV 81.8% (95% CI 
48.2 to 97.7%)) in determining subsequent delivery of an SGA infant. Addition 
of PlGF measurement to currently utilized ultrasound parameters increases test 
sensitivity to determine SGA <3rd centile from 71.4% (95% CI 41.9 to 91.6%) to 
92.9% (95% CI 66.1 to 99.8%). Similar patterns are seen in Table 2.19 for 
prediction of adverse perinatal outcomes, where PlGF in isolation has a 
sensitivity of 100% in determining this endpoint. 
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Table 2.17: Test performance statistics for individual indicators and in combination to predict small for gestational age (SGA) 
<3rd customised birth weight centile in women presenting between 35+0 and 36+6 weeks’ gestation (n= 53) 
Indicator  Sensitivity %  
(95% CI) 




% (95% CI) 
Negative 
predictive value 







AC or EFW <10th centile 64.3 
(35.1 to 87.2) 
94.9 
(82.7 to 99.4) 
81.8 
(48.2 to 97.7) 
88.1 
(74.4 to 96.0) 
12.5 
(3.1 to 51.1) 
0.4 
(0.2 to 0.8) 
Oligohydramnios 14.3 
(1.8 to 42.8) 
94.9 
(82.7 to 99.4) 
50.0 
(6.8 to 93.2) 
75.5 
(61.1 to 86.7) 
2.8 
(0.4 to 17.9) 
0.9 
(0.7 to 1.1) 
AREDF 14.3 
(1.8 to 42.8) 
97.4 
(86.5 to 99.9) 
66.7 
(9.4 to 99.2) 
76.0 
(61.8 to 86.9) 
5.6 
(0.6 to 56.8) 
0.9 
(0.7 to 1.1) 
PlGF <100 pg/ml 85.7 
(57.2 to 98.2) 
23.1 
(11.1 to 39.3) 
28.6 
(15.7 to 44.6) 
81.8 
(48.2 to 97.7) 
1.11 
(0.9 to 1.5) 
0.6 
(0.2 to 2.5) 
Combinations 
AC or EFW <10th centile 
or oligo or AREDF 
71.4 
(41.9 to 91.6) 
89.7 
(75.8 to 97.1) 
71.4 
(41.9 to 91.6) 
89.7 
(75.8 to 97.1) 
7.0  
(2.6 to 18.7) 
0.32 
(0.14 to 0.73) 
AC or EFW <10th centile 
or PlGF <100 pg/ml 
92.9 
(66.1 to 99.8) 
23.1 
(11.1 to 39.3) 
30.2 
(17.2 to 46.1) 
90.0 
(55.5 to 99.7) 
1.2 
(1.0 to 1.5) 
0.3 
(0.04 to 2.2) 
AC or EFW, Abdominal Circumference or Estimated Fetal Weight, Oligohydramnios defined as amniotic fluid index <5th centile for 
gestational age, AREDF, Absent or Reversed End Diastolic Flow in umbilical artery  
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Table 2.18: Test performance statistics for individual indicators and in combination to predict small for gestational age (SGA) 
<10th customised birth weight centile in women presenting between 35+0 and 36+6 weeks’ gestation (n=53) 
Indicator  Sensitivity %  
(95% CI) 




% (95% CI) 
Negative 
predictive value 
% (95% CI) 
Positive 
likelihood 




AC or EFW <10th centile 52.4 
(29.8 to 74.3) 
100 
(89.1 to 100) 
100 
(71.5 to 100) 
76.2 
(60.5 to 87.9) 
0 0.5 
(0.3 to 0.8) 
Oligohydramnios 14.3 
(3.0 to 36.3) 
96.9 
(83.8 to 99.9) 
75.0 
(19.4 to 99.4) 
63.3 
(48.3 to 76.6) 
4.6 
(0.5 to 41.1) 
0.9 
(0.7 to 1.1) 
AREDF 9.5 
(1.2 to 30.4) 
96.9 
(83.8 to 99.9) 
66.7 
(9.4 to 99.2) 
62.0 
(47.2 to 75.3) 
3.1 
(0.3 to 31.5) 
0.9 
(0.8 to 1.1) 
PlGF <100 pg/ml 90.5 
(69.6 to 98.8) 
28.1 
(13.7 to 46.7) 
45.2 
(29.8 to 61.3) 
81.8 
(48.2 to 97.7) 
1.3 
(1.0 to 1.6) 
0.3 
(0.1 to 1.4) 
Combinations 
AC or EFW <10th centile 
or oligo or AREDF 
57.1 
(34.0 to 78.2) 
93.8 
(79.2 to 99.2) 
85.7 
(57.2 to 98.2) 
76.9 
(60.7 to 88.9) 
9.14 
(2.3 to 36.8) 
0.46 
(0.3 to 0.8) 
AC or EFW <10th centile 
or PlGF <100 pg/ml 
95.2 
(76.2 to 99.9) 
28.1 
(13.7 to 46.7) 
46.5 
(31.2 to 62.3) 
90.0 
(55.5 to 99.7) 
1.3 
(1.1 to 1.7) 
0.2 
(0.02 to 1.2) 
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Table 2.19: Test performance statistics for individual indicators and in 
combination to predict adverse perinatal outcome in women presenting 
between 35+0 and 36+6 weeks’ gestation (n=53) 
 
Indicator  Sensitivity 
%  (95% CI) 
Specificity 







value %  
(95% CI) 
AC or EFW <10th 
centile  
50.0 
(6.8 to 93.2) 
81.6 
(68.0 to 91.2) 
18.2 
(2.3 to 51.8) 
95.2 
(83.8 to 99.4) 
Oligohydramnios  0 
(0 to 60.2) 
91.8 
(80.4 to 97.7) 
0 
(0 to 60.2) 
91.8 
(80.4 to 97.7) 
AREDF  25.0 
(0.6 to 80.6) 
95.9 
(86.0 to 99.5) 
33.3 
(0.8 to 90.6) 
94.0 
(83.5 to 98.7) 
PlGF <100 pg/ml 100 
(39.8 to 100) 
22.4 
(11.8 to 36.6) 
9.5 
(2.7 to 22.6) 
100 
(71.5 to 100) 
Combinations 





(6.8 to 93.2) 
75.5 
(61.1 to 86.7) 
14.3 
(1.8 to 42.8) 
94.9 
(82.7 to 99.4) 
AC or EFW <10th 
centile or PlGF 
<100 pg/ml 
100 
(39.8 to 100) 
20.4 
(10.2 to 34.3) 
9.3 
(2.6 to 22.1) 
100 
(69.2 to 100) 
 
AC or EFW, Abdominal Circumference or Estimated Fetal Weight, 
Oligohydramnios defined as amniotic fluid index <5th centile for gestational age, 





In women presenting prior to 35 weeks’ gestation, PlGF outperformed all other 
individual biomarkers in its ability to determine delivery of an SGA infant in this 
cohort of women with suspected pre-eclampsia. Combinations of biomarkers 
added only modest rises in ROC area and are unlikely to be clinically useful. 
 
Ultrasound parameters utilised in current clinical practice had modest sensitivity 
in determining delivery of an SGA infant, resulting in 33% of cases of SGA <3rd 
centile in this cohort remaining undetected, compared to only 7% of cases being 
missed if low PlGF concentration had been used as a predictive test. Addition of 
PlGF quantification to ultrasound parameters improved detection rates.  
 
In addition, PlGF had high sensitivity to detect adverse perinatal outcome, 
which included stillbirth. The performance of PlGF to detect adverse perinatal 
outcome was particularly marked in women recruited between 35+0 and 36+6 
weeks’ gestation (100% sensitivity (39.8 to 100%)). However caution should be 
exercised regarding the reproducibility of these results as only 53 women 
recruited between 35+0 and 36+6 weeks’ gestation had ultrasound data available 
for analysis.  
 
Participant characteristics at booking and enrolment were similar for women 
presenting beyond 35 weeks’ gestation to those recruited prior to 35 weeks’, 
with new onset of hypertension and proteinuria reported more frequently in 
women who delivered an SGA infant, compared to those delivering AGA 
infants. However, in contrast to women recruited prior to 35 weeks’ gestation, 
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onset and mode of delivery in women recruited after 35 weeks’ gestation were 
not strongly associated with birth weight. This could be explained by women 
presenting at later gestations having less severe disease or that by presenting 
later, closer proximity to delivery limits disease progression to the same extent 
as in women presenting at earlier gestations. The proportion of women having a 
pre-labour caesarean section was much higher in women enrolled prior to 35 
weeks’ gestation, compared to those entering the study between 35+0 and 36+6 
weeks’ gestation, irrespective of birth weight. In addition to the explanations 
given above, the difficulties with successfully inducing labour at early gestations 
may also have contributed to this finding. 
 
Trends in biomarker test performance in women recruited between 35+0 and 
36+6 weeks’ gestation to determine delivery of an SGA infant were similar to 
those observed in women recruited prior to 35 weeks’ gestation with PlGF 
outperforming other biomarkers (ROC area 0.74 (0.64 to 0.83) for SGA <10th 
centile). However, test performance statistics were less impressive than those 
reported in women recruited prior to 35 weeks’ gestation. Combinations of 
biomarkers achieved only modest improvements in test performance over PlGF 
alone (ROC area for combination of PlGF, Nephrin 101a, CPA-4 0.81; 95% CI 
0.73 to 0.90)).  
 
Further discussion of these findings are detailed in Chapter 4: Discussion. 
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Chapter 3: Biomarkers and 
ultrasound parameters to determine 





Following from the positive findings of the PELICAN-PE study, where PlGF 
accurately predicted delivery of an SGA infant in a high-risk population with 
suspected pre-eclampsia, I sought to investigate whether these findings could 
be replicated in a more general antenatal setting. Within the UK, current clinical 
referral pathways rely on symphysis fundal height measurement to identify 
those suspected of carrying an SGA fetus. Women with reduced symphysis-
fundal height measurement are then referred for further assessment, usually by 
ultrasound scan.  
 
I investigated how measuring PlGF in this group of women, at time of 
presentation for ultrasound scan, compared to current tools and whether this 
could provide additional information to the clinician to improve identification of 
pregnancies complicated by SGA.  
 
3.1.1 Involvement with the study 
I developed the study concept and design for PELICAN FGR in conjunction with 
the PELICAN-PE study chief investigators. I submitted a substantial 
amendment to the research ethics committee (East London) via the Integrated 
Research Application System, to request permission to extend the PELCAN-PE 
study protocol to include recruitment of women with suspected SGA (as defined 
in section 3.2). Approval for these amendments was subsequently granted. A 
standard operating protocol was compiled and circulated to all study sites. The 
plan for statistical analysis was agreed between myself, Mr Paul Seed (medical 




I led design of the database fields needed to collect data for women recruited 
with suspected SGA.  
 
I headed a team, who undertook site initiation visits (SIVs) to train staff on use 
of the database and provided support to all sites as part of my role of study 
coordinator. In this role I worked along side an independent study monitor, who 
was responsible for training laboratory staff in the techniques necessary for 
PlGF measurement and also for downloading PlGF results, which were masked 
to all other staff involved in the study. I received training in the use of the PlGF 
Triage meter and assisted the study monitor with ensuring correct calibration of 
meters at enrolling sites. I also led regular study teleconferences to maintain 
contact and updates with all sites. 
 
I led regular site visits to all participating sites with the exception of Vancouver, 
Canada, with whom I maintained regular contact.  
 
In addition to my work coordinating other sites, I personally recruited over 100 
women to this study from our antenatal clinics, ultrasound scan department and 
day assessment unit at St Thomas’ Hospital, London. Two colleagues under my 
supervision and myself were responsible for inputting all data for the 177 
women recruited at St Thomas’ Hospital. I was responsible for data cleaning 
and adjudication of all final maternal diagnoses, along with senior clinicians. I 
undertook the statistical analysis with the medical statistician, and input from the 




The PELICAN-FGR study was a prospective observational study evaluating the 
ability of placental growth factor (PlGF) and current ultrasound parameters to 
determine delivery of a small for gestational age (SGA) infant in women who 
presented measuring small for dates. Women were recruited from eleven 
consultant-led units across the United Kingdom and Canada between 
December 2011 and July 2013. Ethical approval was granted by East London 
Research Ethics Committee (ref. 10/H0701/117).  
 
Study eligibility required women to be aged 16 years or over, with a singleton 
pregnancy, between 24+0 to 36+6 weeks’ gestation and referred with suspected 
SGA by either: 
1) Symphysis-fundal height (cm) measuring more than 2cm (i.e. 3cm or 
more) under that expected for any given gestational age (completed 
weeks) e.g. measuring 33cm or less at 36 weeks’ gestation. 
Or 
2) Symphysis-fundal height less than the 10th centile on a customised chart. 
The above definitions were selected for eligibility criteria as they constituted the 
current parameters utilised in enrolling sites for further investigation for 
suspected SGA. Symphysis-fundal height was measured according to recruiting 
site protocol for measurement. Women with multi-fetal pregnancies, confirmed 
SGA, major fetal anomaly, or ruptured amniotic membranes were excluded (see 
section 2.2.1 for definitions). Written informed consent was obtained from 
participants. A study specific database was designed and implemented with 
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training provided for all users at recruiting sites, prior to recruitment of the first 
participant. Baseline demographic and pregnancy specific data was entered, 
including ultrasound data at study enrolment. An independent data monitor was 
appointed to ensure accurate reporting and regular data monitoring was 
undertaken at all sites.  
 
At study enrolment blood was drawn into ethylenediamine tetra-acetic acid and 
processed and stored as described in section 2.2. All maternal plasma samples 
were analysed for PlGF at the recruiting site using the Triage®
 
PlGF Test 
(Alere, San Diego, CA) as described in section 2.2.2. All laboratory staff 
received standardised training in sample processing delivered by the study 
monitor. All Triage meters were programmed to produce a masked result and 
only provided confirmation of a satisfactory test.  All laboratory staff were 
masked to the clinical diagnosis and all results were concealed until a final 
adjudicated maternal diagnosis was reached. PlGF results were classified as 
normal (PlGF ≥ 5th centile for gestational age), low (<5th centile) or very low 
(<12 pg/ml) i.e. below the lower limit of detection. To assess assay 
reproducibility, replicate samples were tested at a central laboratory. The total 
precision (coefficient of variation) on plasma controls at concentrations of 85 
pg/ml and 1300 pg/ml were 12.8% and 13.2%, respectively. 
 
Any subsequent hospital attendances were recorded in the study database, 
including repeat ultrasound assessments, details of delivery and adverse 
maternal and perinatal outcomes (defined in 2.2.1). 
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All cases were adjudicated by senior obstetricians (with review by two clinicians, 
and additional review by a third if discordancy in order to reach a consensus), 
without knowledge of PlGF concentrations, and a final maternal diagnosis was 
assigned according to the definitions detailed in 2.2.1 and those given below.  
 
3.2.1 Definitions 
Small for gestational age fetus: 
Fetal abdominal circumference and/ or estimated fetal weight (on ultrasound 
assessment) less than the 10th centile for gestational age. 
 
Small for gestational age infant: 
Birth weight less than the 3rd and 10th centile by customised GROW centile. 
 
Suspected fetal growth restriction: 
Symphysis fundal height (cm) measuring more than 2cm (i.e. 3cm or more) 
under that expected for any given gestational age (completed weeks) e.g. 
measuring 33cm or less at 36 weeks’ gestation 
 
Major fetal anomaly: 
Fetal malformations that affect viability and/ or the quality of life of the fetus and 
require intervention. (European Union Registry Of Congenital Anomalies and 




Amniotic fluid index less than 5 cm. 
 
3.2.2 Sample size and power calculation 
The PELICAN-FGR study was powered for the primary endpoint of delivering 
an SGA infant with birth weight less than the 3rd customised birth weight centile. 
Based on data from St Thomas’ Hospital, London, 8% of women referred with 
suspected SGA delivered an SGA infant with birth weight less than the 3rd 
customised centile. The study was powered on the basis of the number of 
cases needed to reliably distinguish good (80%) from moderate (60%) 
sensitivity. 55 cases of SGA <3rd birth weight centile were needed for 90% 
power and 5% significance. Therefore, the planned sample size was 688. 
During data monitoring (whilst still masked to PlGF concentrations), the 
incidence of SGA <3rd birth weight centile in the study population was noted to 
be 13%. This resulted in recruitment of 78 cases from a total of 601 women, at 
which point the study was closed. 
 
3.2.3 Statistical analysis 
The primary outcome (reference standard) of delivering an SGA infant less than 
the 3rd customised birth weight centile, was calculated using version 6.7 of 
Gestation Related Optimal Weight (GROW) calculator (Gardosi and Francis), 
with maternal weights adjusted for normal BMI (18-30 kg/m2). This threshold 
(3rd centile) was chosen as it includes fewer infants who are constitutionally 
small and has a stronger association with perinatal mortality (Moraitis et al., 
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2014). Delivery of an SGA infant less than the 10th customised birth weight 
centile, and adverse perinatal outcomes were considered as secondary 
outcomes. 
 
Gestational age adjusted centiles have been calculated for PlGF from a large 
low risk antenatal population (Knudsen et al., 2012). A PlGF concentration 
below the 5th centile was taken as abnormal as this has been shown to offer a 
combination of high sensitivity and acceptable specificity for pre-eclampsia and 
SGA (Chappell et al., 2013).  
 
Sensitivity, specificity, positive and negative predictive values and positive and 
negative likelihood ratios (with 95% confidence intervals) were calculated for 
PlGF and three ultrasound parameters (estimated fetal weight <10th centile, 
umbilical artery Doppler pulsatility index (UAPI) > 95th centile and 
oligohydramnios) to determine delivery of an SGA infant <3rd and <10th 
customised centiles, both in isolation and in combination. To provide umbilical 
artery Doppler pulsatility index centiles for this analysis, gestation adjusted 
centiles were calculated for each observed value of UAPI based on a mean 
value of 0.405 -0.0134 x gestational age in weeks’, and a standard deviation of 
0.0794 for the log10 UAPI (Parra-Cordero et al., 2007).  
 
Receiver operator characteristic (ROC) curve areas were also calculated for 
each individual parameter and combinations, and in a pre-defined subgroup 
who delivered within six weeks of PlGF sampling. 
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Variables related to health resource use (number of fetal ultrasounds, neonatal 
bed nights in Special Care Baby Unit or in Neonatal Intensive Care Unit, 
attendances at out-patient clinic/ Day Assessment Unit/ Antepartum Hospital 
Clinic after enrolment, maternal bed nights for suspected fetal compromise after 
enrolment, post-partum bed nights) were presented as means with 95% 
confidence intervals.  Due to non-normal distributions, a bias corrected and 
accelerated bootstrap was used with 10,000 replications (Efron, 1987). 
 
Statistical analysis was carried out in Stata statistical package (version 11.2), 
College Station Texas, USA. Formal significance was taken at p<0.05. 
 
This study was reported in accordance with the STAndards for the Reporting of 





601 women presenting with suspected SGA between 24+0 and 36+6 weeks’ 
gestation were recruited across 11 sites between December 2011 and July 
2013. We recruited all women who were approached, eligible and consented 
but did not document women who declined to participate. No outcome data 
were available on two participants and five women did not have a valid plasma 
PlGF result. A further two women had no ultrasound data at enrolment 
available. After exclusion of these nine cases, 592 women were included in this 
analysis. Of these women 192 delivered an SGA infant with birth weight <10th 
customised centile and 78 had a birth weight <3rd centile (Figure 3.1). 
 
All descriptive tables are subdivided according to subsequent birth weight. 
Characteristics of participants at booking are given in Table 3.1, with higher 
rates of smoking observed in those who delivered an SGA infant <3rd and <10th 
birth weight centiles. Baseline characteristics of participants at study enrolment 
are summarised in Table 3.2, with little difference in maternal factors between 
groups. At enrolment, only 57.9% of women who delivered an SGA infant <3rd 
centile and 47.1% of women who delivered an SGA infant <10th centile had an 
EFW <10th centile. Details of maternal and neonatal outcomes are shown in 
Table 3.3. Overall, maternal and perinatal adverse outcomes were infrequent 
(3.2 and 2.2% respectively) but rates were numerically higher in those who 
delivered an SGA infant <3rd and <10th centile (SGA-3 6.4% and 5.1% and 
SGA-10 4.7% and 3.1% respectively). Induction of labour and caesarean 
section were more common in cases complicated by SGA in comparison to 
those pregnancies delivering AGA. Final maternal adjudicated diagnoses are 
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given in Table 3.4, with the majority of women experiencing no maternal 
complications during their pregnancy (n=555; 94%). Whilst the number of cases 
of pre-eclampsia were small (n=16) most delivered an SGA infant (n=12).  
  
 153 





Birth weight ≥3rd 
centile n=58  
SGA <3rd 
centile n=49 
Birth weight ≥ 3rd 
centile n=456  
Total recruited n=601 
Total for analysis n=592 
PlGF ≥ 5th centile n=505 PlGF <5th centile n=87 
SGA <3rd 
centile n=29   
No PlGF result n=5 
No plasma sample for analysis n=2 
Sample incorrectly labelled n=3 
No outcome data n=2 
No ultrasound scan data at 
enrollment n=2 
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Table 3.1: Characteristics of participants at booking.  Values given are 
median (quartiles) or n (%) as appropriate.  
 Women with 
SGA infant 












General maternal  
Age (years) 29.1  
(24.1 to 32.9) 
29.6  
(24.8 to 33.5) 
30.0  
(25.3 to 33.7) 
29.9  
(25.2 to 33.6) 
Body Mass Index at 
booking (kg/m2) † 
22.9  
(20.3 to 25.2) 
21.7  
(20.1 to 24.1) 
21.5  
(20.0 to 23.4) 
21.5  
(20.0 to 23.6) 
White ethnicity 52 (66.7) 122 (63.5) 266 (66.5) 388 (65.5) 
Primiparity  65 (83.3) 163 (84.9) 344 (86.0) 507 (85.6) 
Highest first trimester 
systolic BP (mmHg) 
105  
(100 to 114) 
105  
(100 to 114) 
104  
(100 to 112) 
105  
(100 to 112) 
Highest first trimester 
diastolic BP (mmHg) 
63  
(60 to 70) 
62  
(60 to 70) 
60  
(60 to 69) 
61  
(60 to 70) 
Smoking status 
Never smoked † 46 (59) 128 (66.7) 306 (76.5) 434 (73.3) 
Quit smoking before 
pregnancy 
9 (11.5) 22 (11.5) 31 (7.8) 53 (8.9) 
Quit smoking during 
pregnancy 
10 (12.8) 16 (8.3) 24 (6.0) 40 (6.7) 
Current smoker 13 (16.7) 26 (13.5) 39 (9.8) 65 (11.0) 
Drug use 
History of drug use *† 5 (6.4) 6 (3.1) 3 (0.8) 9 (1.5) 
Current drug user ** 1 (1.3) 2 (1.0) 0 (0.0) 2 (0.3) 
Previous medical history 
Pre-eclampsia with 
delivery <34/40 
0 (0) 0 (0) 1 (0.3) 1 (0.2) 
Chronic hypertension 0 (0) 1 (0.5) 1 (0.3) 2 (0.3) 
SLE/ APS 1 (1.3) 1 (0.5) 0 (0) 1 (0.2) 
Pre-existing diabetes  0 (0) 0 (0) 1 (0.3) 1 (0.2) 
Renal disease 0 (0) 0 (0) 0 (0) 0 (0) 
Self-report previous 
SGA  
9 (11.5) 22 (11.5) 27 (6.8) 49 (8.3) 
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BP, blood pressure 
 
* Drugs used before pregnancy: include cannabis, cocaine, ecstasy, 
amphetamines (speed, crystal meth), and heroin. 
 
** Drugs used during pregnancy: Cannabis only (rare or occasional)  
SLE/ APS, Systemic lupus erythematosus/ anti-phospholipid syndrome 
 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile   
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Table 3.2: Baseline characteristics of participants at study enrolment. 
Values given are median (quartiles) or n (%) as appropriate.  
 Women with 
SGA infant 

















(221 to 250) 
235 
(213 to 250) 
236  
(214 to 250) 
236  








(102 to 121) 
110 
(101 to 118) 
110 





(60 to 81) 
70 
(60 to 80) 
67 
(60 to 73) 
68 
(60 to 74) 
Dipstick proteinuria 
Not done 11 (14.1) 29 (15.1) 61 (15.3) 90 (15.2) 
Negative 58 (74.4) 148 (77.1) 322 (80.5) 470 (79.4) 
Present (+1 or 
greater) † 
9 (11.5) 15 (7.8) 17 (4.3) 32 (5.4) 
Complications in current pregnancy 
Gestational 
hypertension 
4 (5.1) 4 (2.1) 0 (0) 4 (0.7) 
Pre-eclampsia 0 (0) 1 (0.5) 1 (0.3) 2 (0.3) 
Gestational 
diabetes 




0 (0.0) 1 (0.5) 2 (0.5) 3 (0.5) 
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EFW < 10th 
centile † 
44 (57.9) 88 (47.1) 64 (16.3) 152 (25.9) 
Oligohydramni
os 




































† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile 
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Table 3.3: Characteristics of delivery and maternal and neonatal outcome. 
Values given are median (quartiles) or n (%) as appropriate.  
 



















(37.1 to 40.1) 
39.4 
(38.0 to 40.4) 
40.0 
(39.0 to 40.9) 
39.9 
(38.9 to 40.7) 
Maternal medications (at any point during pregnancy) 
Dexamethasone† 
5 (6.4) 7 (3.6) 4 (1.0) 11 (1.8) 
Betamethasone 
2 (2.6) 4 (2.1) 0 (0) 4 (0.7) 
Methyldopa 
2 (2.6) 2 (1.0) 0 (0) 2 (0.3) 
Labetalol † 
6 (7.7) 9 (4.7) 2 (0.5) 11 (1.8) 
Heparin 
1 (1.3) 2 (1.0) 3 (0.8) 5 (0.8) 
Nifedipine 
1 (1.3) 2 (1.0) 1 (0.3) 3 (0.5) 
Aspirin 
3 (3.8) 4 (2.1) 8 (2.0) 12 (2.0) 
Oral 
corticosteroids 
0 (0) 3 (1.6) 2 (0.5) 5 (0.8) 
Onset of 
labour 
    
Spontaneous † 24 (30.8) 99 (51.6) 300 (75.0) 399 (67.4) 




13 (16.7) 26 (13.5) 34 (8.5) 60 (10.1) 
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Spontaneous 48 (61.5) 125 (65.1) 279 (69.8) 404 (68.2) 
Assisted vaginal 
delivery 
8 (10.3) 23 (12.0) 66 (16.5) 89 (15.0) 
Caesarean 
section 




5 (6.4) 9 (4.7) 10 (2.5) 19 (3.2) 
Postpartum 
haemorrhage 
2 (2.6) 5 (2.6) 7 (1.8) 12 (2.0) 
Abruption 1 (1.3) 1 (0.5) 1 (0.3) 2 (0.3) 
HELLP 0 (0) 0 (0) 1 (0.3) 1 (0.2) 
Fetal      
Fetal death 0 (0) 0 (0) 1 (0.3) 1 (0.2) 


















4 (5.1) 6 (3.1) 7 (1.8) 13 (2.2) 
HELLP, haemolysis, elevated liver enzymes, low platelets. 
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* Adverse maternal outcome defined as presence of any of the following 
complications: Maternal death, Eclampsia, Stroke, Cortical blindness or retinal 
detachment, Hypertensive encephalopathy, Systolic blood pressure 
≥160mmHg, Myocardial infarction, Intubation (other than for caesarean section), 
Pulmonary oedema, Platelets <50×10⁹/L (without transfusion), Disseminated 
intravascular coagulation, Thrombotic thrombocytopenic purpura/ haemolytic 
uraemic syndrome, Hepatic Dysfunction (Alanine transaminase ≥70IU/L), 
Hepatic haematoma or rupture, Acute fatty liver of pregnancy, Creatinine >150 
µmol/L, Renal dialysis, Placental abruption, Major postpartum haemorrhage, 
Major infection. 
 
** Adverse perinatal outcome defined as presence of any of the following 
complications: Antepartum/ intrapartum fetal or neonatal death, Neonatal unit 
admission for >48 hrs at term, Intraventricular haemorrhage, Periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis. 
 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile 
(the main outcome) to women with infant ≥ 10th centile 
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Table 3.4: Maternal diagnosis according to birth weight and gestation at delivery  
                                            
1 Mild, severe, superimposed and atypical PE are defined in section 2.2.1. 
† indicates p value <0.05 for comparison of women with SGA infant <3rd centile (the main outcome) to women with infant ≥ 10th centile 
 Women with SGA infant 
<3rd centile (%) (n=78) 
Women with SGA infant 
<10th centile (%) (n=192) 
Women with infant ≥10th 
centile (%) (n=400) 








Delivery ≥ 37 
weeks (n=173) 
Delivery <37 
weeks  (n=16) 








9 (64.2) 59 (92.2) 14 (73.7) 159 (91.9) 13 (81.3) 369 (96.1) 27 (77.1) 528 (94.8) 
Gestational 
hypertension 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 8 (2.1) 0 (0) 8 (1.4) 
Chronic 
hypertension 
0 (0) 0 (0) 0 (0) 2 (1.2) 0 (0) 0 (0) 0 (0) 2  (0.4) 
Mild PE 0 (0) 0 (0) 0 (0) 0 (0) 2 (12.5) 1 (0.3) 2 (5.7) 1 (0.2) 
Severe PE 2 (14.3) 2 (3.1) 2 (10.5) 6 (3.5) 0 (0) 0 (0) 2 (5.7) 6 (1.1) 
Superimposed 
PE 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Atypical PE 2 (14.3) 2 (3.1) 2 (10.5) 2 (1.2) 0 (0) 0 (0) 2 (5.7) 2 (0.4) 
HELLP 
syndrome 
0 (0) 0 (0) 0 (0) 0 (0) 1 (6.3) 0 (0) 1 (2.9) 0 (0) 
Other dx 2 (14.3) 1 (1.6) 1 (5.3) 4 (2.3) 0 (0) 6 (1.6) 3 (6.1) 10 (1.8)1 
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Given the low frequency of maternal complications and adverse perinatal 
outcome it is unsurprising that average length of antenatal and postnatal 
admissions were less than one day (Table 3.5). Length of admission (including 
admission to neonatal unit) was slightly longer in those delivering an SGA infant 




Table 3.5: Health service usage according to birth weight centile; all 






















(0.6 to 2.7) 
0.6  
(0.4 to 1.2) 
0.2  
(0.1 to 0.2) 
0.3  




(2.1 to 3.1) 
2.0  
(1.8 to 2.3) 
1.4  




No of ultrasound 
assessments 
2.6  
(2.3 to 3.0) 
2.3  
(2.1 to 2.6) 
1.5  
(1.4 to 1.6) 
1.7  




(0.2 to 4.7) 
0.6  
(0.2 to 2.0) 
0.09  
(0.02 to 0.3) 
0.3  




(1.6 to 5.3) 
1.1  
(0.5 to 2.3) 
0.1  
(0.01 to 0.6) 
0.4  
(0.2 to 0.8) 
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Test performance statistics for PlGF and ultrasound parameters to determine 
delivery of an SGA infant <3rd and 10th customised centiles are given in Table 
3.6, with estimated fetal weight (EFW) <10th centile having the highest 
sensitivity and negative predictive power (sensitivity 57.9% and 47.1%; NPV 
92.6 and 77.2% for SGA <3rd and SGA <10th centiles) of all parameters 
assessed. Addition of PlGF to ultrasound parameters currently utilised to 
identify SGA antenatally, altered test sensitivity from 57.7 to 69.2% (NPV 91.3 
to 92.9%) in determining SGA <3rd centile and from 48.7 to 57.4% (NPV 76.6 to 
78.3%) in determining SGA <10th centile. ROC curve areas for all parameters in 
determining SGA <3rd centile are shown in Figure 3.2. EFW <10th centile, with a 
ROC area of 0.79 (95% CI 0.74 to 0.84), was greater than for low PlGF (0.70; 
95% CI 0.63 to 0.77). A combination of parameters increased the ROC area to 
0.82 (95% CI 0.77 to 0.86).  
 
In contrast to the findings of the PELICAN-PE study, there were no major 
differences in the results between women enrolled prior to 35 weeks’ gestation 
and those enrolled between 35+0 and 36+6 weeks’ gestation. The results of 
this study have therefore not been subdivided according to gestation at 
enrollment. 
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Table 3.6: Test performance statistics for PlGF and all ultrasound parameters (with 95% confidence intervals) to predict SGA 




(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV % 
(95% CI) n/N 
NPV % 
(95% CI) n/N 
Positive 
likelihood 
ratio (95% CI) 
Negative 
likelihood 
ratio (95% CI) 
SGA <3rd centile 
 
  
EFW <10th centile 57.9 
(46.0 to 69.1) 
44/76 
78.8 
(75.0 to 82.3) 
402/510 
28.9 
(21.9 to 36.8) 
44/152 
92.6 
(89.8 to 94.9) 
402/434 
2.73 
(2.12 to 3.53) 
0.53 
(0.41 to 0.70) 
Oligohydramnios  
(AFI < 5 cm) 
3.7 
(0.5 to 12.7) 
2/54 
99.0 
(97.0 to 99.8) 
289/292 
40.0 
(5.3 to 85.3) 
2/5 
84.8 
(80.5 to 88.4) 
289/341 
3.60 
(0.62 to 21.1) 
0.97 
(0.92 to 1.03) 
Umbilical artery 
Doppler PI >95th 
centile 
16.4 
(8.2 to 28.1) 
10/61 
96.0 
(93.5 to 97.7) 
381/395 
38.5 
(20.2 to 59.4) 
10/26 
88.2 
(84.8 to 91.1) 
381/432 
4.07 
(1.94 to 8.55) 
0.87 
(0.78 to 0.98) 
PlGF < 5th centile 37.2 
(26.5 to 48.9) 
29/78 
88.7 
(85.7 to 91.3) 
456/514 
33.3 
(23.6 to 44.3) 
29/87 
90.3 
(87.4 to 92.7) 
456/505 
3.29 
(2.26 to 4.80) 
0.71 
(0.60 to 0.84) 
Combinations   
Abnormal AFI or EFW 57.7 
 (43.2 to 71.3) 
30/52 
79.0 
(73.9 to 83.6) 
230/291 
33.0 
(23.5 to 43.6) 
30/91 
91.3 
(87.1 to 94.4) 
230/252 
2.75 
(1.99 to 3.80) 
0.54 
(0.39 to 0.74) 
Abnormal PlGF or AFI 
or EFW 
69.2 
(54.9 to 81.3) 
36/52 
72.2 
(66.6 to 77.2) 
210/291 
30.8 
(22.6 to 40.0) 
36/117 
92.9 
(88.8 to 95.9) 
210/226 
2.49 
(1.92 to 3.22) 
0.43 






(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV % 
(95% CI) n/N 
NPV % 
(95% CI) n/N 
Positive 
likelihood 
ratio (95% CI) 
Negative 
likelihood 
ratio (95% CI) 
SGA <10th centile 
 
EFW <10th centile 47.1 
(39.7 to 54.5) 
88/187 
84.0 
(80.0 to 87.4) 
335/399 
57.9 
(49.6 to 65.8) 
88/152 
77.2 
(72.9 to 81.1) 
335/434 
2.93 
(2.24 to 3.85) 
0.63 
(0.55 to 0.73) 
Oligohydramnios  
(AFI < 5 cm) 
3.4 
 (0.9 to 8.5) 
4/118 
99.6 
(97.6 to 100.0) 
227/228 
80.0 
(28.4 to 99.5) 
4/5 
66.6 
(61.3 to 71.6) 
227/341 
7.73 
(0.87 to 68.4) 
0.97 
(0.94 to 1.00) 
Umbilical artery 
Doppler PI >95th 
centile 
8.2 
(4.3 to 13.8) 
12/147 
95.5 
(92.6 to 97.5) 
297/311 
46.2 
(26.6 to 66.6) 
12/26 
68.8 
(64.1 to 73.1) 
297/432 
1.81 
(0.86 to 3.82) 
0.96 
(0.91 to 1.01) 
PlGF < 5th centile 24.5 
(18.6 to 31.2) 
47/192 
90.0 
(86.6 to 92.8) 
360/400 
54.0 
(43.0 to 64.8) 
47/87 
71.3 
(67.1 to 75.2) 
360/505 
2.45 
(1.67 to 3.60) 
0.84 
(0.77 to 0.92) 
Combinations   
Abnormal AFI or EFW 48.7 
(39.3 to 58.2) 
56/115 
84.6 
(79.3 to 89.1) 
193/228 
61.5 
(50.8 to 71.6) 
56/91 
76.6 
(70.9 to 81.7) 
193/252 
3.17 
(2.22 to 4.54) 
0.61 
(0.50 to 0.73) 
Abnormal PlGF or AFI 
or EFW 
57.4 
(47.8 to 66.6) 
66/115 
77.6 
(71.7 to 82.9) 
177/228 
56.4 
(46.9 to 65.6) 
66/117 
78.3 
(72.4 to 83.5) 
177/226 
2.57 
(1.92 to 3.42) 
0.55 
(0.44 to 0.69) 
 
SGA, small for gestational age; EFW, estimated fetal weight; AFI, amniotic fluid index; PI, pulsatility index; PlGF, placental growth factor.
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Figure 3.2: ROC areas for low PlGF, EFW <10th centile and combination of 
these parameters to predict delivery of an SGA infant <3rd birth weight 














0.00 0.25 0.50 0.75 1.00
1-Specificity
Combined indicator AUC = 0.82 (0.77 to 0.86)
Low PlGF AUC = 0.70 (0.63 to 0.77)
Low EFW AUC = 0.79 (0.74 to 0.84)
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To explore whether these predictive parameters improved if the interval 
between gestation at sampling to delivery was restricted, a subgroup analysis of 
267 women where delivery occurred within six weeks of PlGF sampling (Table 
3.7) was undertaken. ROC areas were 0.74 (95% CI 0.66 to 0.83), 0.76 (95% 
CI 0.69 to 0.84) and 0.81 (95% CI 0.72 to 0.88) for PlGF, low EFW, and a 
combination of both parameters respectively to predict delivery of an SGA infant 
with birth weight <3rd customised centile (Figure 3.3). These results were similar 
to those of the whole study population (Figure 3.2) suggesting that restricting 
sampling to delivery time had minimal effect in this study cohort. 
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Table 3.7: Test performance statistics for PlGF and ultrasound parameters (with 95 % confidence intervals) to predict SGA <3rd 




(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV % 
(95% CI) n/N 
NPV % 
(95% CI) n/N 
Positive 
likelihood 
ratio (95% CI) 
Negative 
likelihood 




EFW <10th centile 62.2  
(46.5 to 76.2) 
28/45 
73.0 
(66.6 to 78.7) 
162/221 
31.8 
(22.3 to 42.6) 
28/88 
90.5 
(85.2 to 94.4) 
162/179 
2.30 
(1.68 to 3.15) 
0.52 
(0.35 to 0.76) 
Oligohydramnios  
(AFI < 5 cm) 
5.9 
(0.7 to 19.7) 
2/34 
97.7 
(93.4 to 99.5) 
126/129 
40.0 
(5.3 to 85.3) 
2/5 
79.7 
(72.6 to 85.7) 
126/158 
2.53 
(0.44 to 14.54) 
0.96 
(0.88 to 1.05) 
Umbilical artery 
Doppler PI >95th 
centile 
22.2 
 (10.1 to 39.2) 
8/36 
96.0 
 (91.9 to 98.4) 
167/174 
53.3 
 (26.6 to 78.7) 
8/15 
85.6 
 (79.9 to 90.2) 
167/195 
5.52 
(2.14 to 14.27) 
0.81 
(0.68 to 0.97) 
PlGF < 5th centile 42.2 
(27.7 to 57.8) 
19/45 
86.6 
(81.4 to 90.8) 
194/224 
38.8 
(25.2 to 53.8) 
19/49 
88.2 
(83.2 to 92.1) 
194/220 
3.15 
(1.96 to 5.08) 
0.67 
(0.52 to 0.86) 
Combinations   
Abnormal AFI or 
EFW 
62.5 
(43.7 to 78.9) 
20/32 
67.2 
(58.3 to 75.2) 
86/128 
32.3 
(20.9 to 45.3) 
20/62 
87.8 
(79.6 to 93.5) 
86/98 
1.90 
(1.32 to 2.74) 
0.56 
(0.35 to 0.89) 
Abnormal PlGF or 
AFI or EFW 
70.0 
(50.6 to 85.3) 
21/30 
58.3 
(49.2 to 67.0) 
74/127 
28.4 
(18.5 to 40.1) 
21/74 
89.2 
(80.4 to 94.9) 
74/83 
1.68 
(1.23 to 2.29) 
0.51 






(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV % 
(95% CI) n/N 
NPV % 
(95% CI) n/N 
Positive 
likelihood 
ratio (95% CI) 
Negative 
likelihood 
ratio (95% CI) 
SGA <10th centile 
 
EFW <10th centile 57.6 
(46.9 to 67.9) 
53/92 
80.0 
(73.3 to 85.7) 
140/175 
60.2 
(49.2 to 70.5) 
53/88 
78.2 
(71.4 to 84.0) 
140/179 
2.88 
(2.04 to 4.06) 
0.53 
(0.41 to 0.68) 
Oligohydramnios  
(AFI < 5 cm) 
6.3 
(1.7 to 15.2) 
4/64 
99.0 
(94.5 to 100) 
98/99 
80.0 
(28.4 to 99.5) 
4/5 
62.0 
(54.0 to 69.6) 
98/158 
6.19 
(0.71 to 54.12) 
0.95 
(0.89 to 1.01) 
Umbilical artery 
Doppler PI >95th 
centile 
12.2 
(5.7 to 21.8) 
9/74 
95.6 
(90.6 to 98.4) 
130/136 
60.0 
(32.3 to 83.7) 
9/15 
66.7 
(59.6 to 73.2) 
130/195 
2.76 
(1.02 to 7.44) 
0.92 
(0.84 to 1.01) 
PlGF < 5th centile 27.4 
(18.7 to 37.5) 
26/95 
86.8 
(80.8 to 91.4) 
151/174 
53.1 
(38.3 to 67.5) 
26/49 
68.6 
(62.1 to 74.7) 
151/220 
2.07 
(1.25 to 3.42) 
0.84 
(0.73 to 0.96) 
Combinations       
Abnormal AFI or EFW 62.3 
(49.0 to 74.4) 
38/61 
75.8 
(66.1 to 83.8) 
75/99 
61.3 
(48.1 to 73.4) 
38/62 
76.5 
(66.9 to 84.5) 
75/98 
2.57 
(1.72 to 3.83) 
0.50 
(0.35 to 0.70) 
Abnormal PlGF or AFI 
or EFW 
67.8 
(54.4 to 79.4) 
40/59 
65.3 
(55.0 to 74.6) 
64/98 
54.1 
(42.1 to 65.7) 
40/74 
77.1 
(66.6 to 85.6) 
64/83 
1.95 
(1.41 to 2.70) 
0.49 
(0.33 to 0.73) 
 




Figure 3.3: ROC areas for low PlGF, EFW <10th centile and combination of 
these parameters to predict delivery of an SGA infant <3rd birth weight 














0.00 0.25 0.50 0.75 1.00
1-Specificity
Low PlGF AUC = 0.74 (0.66 to 0.83)
Low EFW AUC = 0.76 (0.69 to 0.84)
Combined indicator AUC = 0.81 (0.72 to 0.88)
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The test performance of PlGF to predict pre-eclampsia and SGA in women with 
suspected pre-eclampsia has previously been shown to be high when 
measured prior to 35 weeks’ gestation and performance diminishes at 
gestations beyond this. The test performance of PlGF and ultrasound 
parameters in women sampled prior to 35 weeks’ gestation were therefore 
calculated to evaluate whether restricting the timing of PlGF sampling improved 
the markers ability to determine delivery of an SGA infant. These results are 
summarised in Table 3.8, with EFW <10th centile having the highest sensitivity 
(55.6%) and NPV (93.1%) for delivery of an SGA infant <3rd birth weight centile. 
Whilst test sensitivity for PlGF to determine delivery of an SGA infant was lower 
than test performance of EFW <10th centile, it is marginally higher than when 
sampling is undertaken up to 37 weeks’ gestation. 
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Table 3.8: Test performance statistics for PlGF and ultrasound parameters (with 95 % confidence intervals) to predict SGA <3rd 





(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV %  
(95% CI) n/N 
NPV % 












(40.0 to 70.4) 
25/45 
79.7 
(75.0 to 83.9) 
271/340 
26.6 
(18.0 to 36.7) 
25/94 
93.1 
(89.6 to 95.8) 
271/291 
2.74 
(1.96 to 3.83) 
0.56 
(0.40 to 0.78) 
Umbilical artery 
Doppler PI >95th 
centile 
16.7 
(6.4 to 32.8) 
6/36 
96.6 
(93.6 to 98.4) 
252/261 
40.0 
(16.3 to 67.7) 
6/15 
89.4 
(85.2 to 92.7) 
252/282 
4.83 
(1.83 to 12.78) 
0.86 
(0.74 to 1.00) 
PlGF < 5th centile 39.1 
(25.1 to 54.6) 
18/46 
89.2 
(85.4 to 92.3) 
305/342 
32.7 
(20.7 to 46.7) 
18/55 
91.6 
(88.1 to 94.3) 
305/333 
3.62 
(2.26 to 5.80) 
0.68 
(0.54 to 0.86) 
Combinations   
Abnormal AFI or 
EFW 
56.3 
(37.7 to 73.6) 
18/32 
82.8 
(76.8 to 87.8) 
164/198 
34.6 
(22.0 to 49.1) 
18/52 
92.1 
(87.2 to 95.6) 
164/178 
3.28 
(2.13 to 5.05) 
0.53 
(0.35 to 0.79) 
Abnormal PlGF 
or AFI or EFW 
71.9 
(53.3 to 86.3) 
23/32 
77.3 
(70.8 to   82.9) 
153/198 
33.8 
(22.8 to 46.3) 
23/68 
94.4 
(89.7 to 97.4) 
153/162 
3.16 
(2.26 to 4.43) 
0.36 






(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV % 
(95% CI) n/N 
NPV % 
(95% CI) n/N 
Positive 
likelihood 









(34.9 to 53.5) 
52/118 
84.3 
(79.3 to 88.4) 
225/267 
55.3 
(44.7 to 65.6) 
52/94 
77.3 
(72.1 to 82.0) 
225/291 
2.80 
(1.99 to 3.95) 
0.66 
(0.56 to 0.79) 
Umbilical artery 
Doppler PI >95th 
centile 
7.9 
(3.2 to 15.5) 
7/89 
96.2 
(92.6 to 98.3) 
200/208 
46.7 
(21.3 to 73.4) 
7/15 
70.9 
(65.2 to 76.2) 
200/282 
2.04 
(0.76 to 5.47) 
0.96 
(0.90 to 1.02) 
PlGF < 5th centile 25.0 
(17.5 to 33.7) 
30/120 
90.7 
(86.5 to 93.9) 
243/268 
54.5 
(40.6 to 68.0) 
30/55 
73.0 
(67.9 to 77.7) 
243/333 
2.68 
(1.65 to 4.35) 
0.83 
(0.74 to 0.92) 
Combinations   
Abnormal AFI or 
EFW 
43.2 
(31.8 to 55.3) 
32/74 
7.2 
(80.9 to 92.0) 
136/156 
61.5 
(47.0 to 74.7) 
32/52 
76.4 
(69.5 to 82.4) 
136/178 
3.37 
(2.08 to 5.48) 
0.65 
(0.53 to 0.80) 
Abnormal PlGF 
or AFI or EFW 
54.1 
(42.1 to 65.7) 
40/74 
82.1 
(75.1 to 87.7) 
128/156 
58.8 
(46.2 to 70.6) 
40/68 
79.0 
(71.9 to 85.0) 
128/162 
3.01 
(2.03 to 4.47) 
0.56 
(0.43 to 0.72) 
 




Only 13 women had an adverse perinatal outcome which included one stillbirth, 
four cases of respiratory distress syndrome and nine cases of admission to the 
neonatal intensive care unit for greater than 48 hours at term. The ability of 
PlGF and ultrasound parameters to determine adverse perinatal outcome was 
assessed, with results displayed in Table 3.9. All parameters performed poorly 
in determining this endpoint with EFW <10th centile having the highest 
sensitivity (23.1%) and negative predictive value (97.7%). When a combination 
of abnormal EFW, AFI and PlGF was used to predict adverse perinatal 
outcome, sensitivity and NPV did improve to 66.7% and 99.1% respectively. 
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Table 3.9: Test performance statistics for PlGF and ultrasound parameters 






(95% CI)  
n/N 
Specificity % 
(95% CI)  
n/N 
PPV  % 
(95% CI)  
n/N 
NPV  % 





(5.0 to 53.8) 
3/13 
74.0 
(70.2 to 77.5) 
424/573 
2.0 
(0.4 to 5.7) 
3/152 
97.7 




(AFI < 5 cm) 
16.7 
(0.4 to 64.1) 
1/6 
98.8 
(97.0 to 99.7) 
336/340 
20.0 
(0.5 to 71.6) 
1/5 
98.5 







(0 to 28.5) 
0/11 
94.2  
(91.6 to 96.2) 
421/447 
0  
(0 to 13.2) 
0/26 
97.5  
(95.5 to 98.7) 
421/432 
PlGF < 5th 
centile 
15.4 
(1.9 to 45.4) 
2/13 
85.3 
(82.2 to 88.1) 
494/579 
2.3 
(0.3 to 8.1) 
2/87 
97.8 




AFI or EFW 
50.0 
(11.8 to 88.2) 
3/6 
73.9 
(68.9 to 78.5) 
249/337 
3.3 
(0.7 to 9.3) 
3/91 
98.8 
(96.6 to 99.8) 
249/252 
Abnormal 
PlGF or AFI 
or EFW 
66.7 
(22.3 to 95.7) 
4/6 
66.5 
(61.2 to 71.5) 
224/337 
3.4 
(0.9 to 8.5) 
4/117 
99.1 
(96.8 to 99.9) 
224/226 
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Very low concentrations of PlGF (<12 pg/ml, lower level of assay detection) 
have previously been correlated with poor outcome (Chappell et al., 2013). 16 
women in the study population had very low PlGF at enrolment and details of 
their pregnancies are given in Table 3.10.  Of these women, 11 delivered an 
SGA infant and seven had hypertensive disorders (7/16; 50% versus 17/577; 
3% in the rest of the cohort).  
 
The test performance of PlGF in a subgroup of 152 women who had EFW <10th 
centile at study enrolment was also assessed (Table 3.11). Sensitivity was 
similar in this subgroup (40.9% to determine SGA <3rd birth weight centile) to 
that displayed in Table 3.6, for the whole study population (37.2%) but NPV was 







Table 3.10: Maternal and neonatal outcomes for women with PlGF <12 


















A 30+0 33+6 1935 10.1 HELLP 
Syndrome 
B 31+4 33+3 1305 0 Severe pre-
eclampsia 
C 31+4 35+4 1825 1.2 Gestational 
diabetes 
mellitus 
D 34+2 39+3 2530 2.7 Atypical pre-
eclampsia 
E 35+2 37+0 2225 0.6 Severe pre-
eclampsia 
F 35+5 36+6 2905 38.5 None 
G 35+5 38+0 2330 2.6 None 
H 35+6 38+0 2260 9.5 Severe pre-
eclampsia 
I 36+0 36+4 2525 38.4 Mild pre-
eclampsia 
J 36+0 37+6 1958 0.1 None 
K 36+1 39+0 2765 8.8 None 
L 36+3 38+3 2600 17.4 None 
M 36+3 41+1 2710 1.3 None 
N 36+4 37+1 2000 0.3 None 
O 36+4 37+3 2398 6.0 Chronic 
hypertension 
P 36+6 40+2 3720 63.2 Gestational 
hypertension 
 
HELLP, haemolysis, elevated liver enzymes, low platelets. 
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Table 3.11: Test performance statistics for PlGF (with 95 % confidence 
intervals) to predict SGA <3rd and <10th centiles in women who had an 
EFW <10th centile at enrolment (n=152) 
 
PlGF Sensitivity % 
(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV %  
(95% CI) n/N 
NPV %  
(95% CI) n/N 
SGA <3rd  
centile 
40.9 
(26.3 to 56.8) 
18/44 
80.6 
(71.8 to 87.5) 
87/108 
46.2 
(30.1 to 62.8) 
18/39 
77.0 





(20.3 to 40.2) 
26/88 
79.7 
(67.8 to 88.7) 
51/64 
66.7 
(49.8 to 80.9) 
26/39 
45.1 
(35.8 to 54.8) 
51/113 
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In addition to assessing the ability of PlGF to determine delivery of an SGA 
infant, the possibility of identifying a high cut-off for PlGF measurement was 
explored, which would provide a threshold for use of PlGF as a “rule out” test. 
Table 3.12 shows the distribution of cases within the cohort according to PlGF 
centile and subdivides according to birth weight above or below the 3rd centile. 
There was no PlGF cut off that provided adequate performance to rule out 






Table 3.12: Distribution of cases across PlGF centiles.  
(Numbers and row percentages are shown).  
 
PlGF centile Birth weight 
≥3rd centile  
n (%) 
Birth weight 




<10th  93 (72.1) 36 (27.9) 129 
10th-20th  65 (89.0) 8 (11.0) 73 
20th-30th  48 (82.8) 10 (17.2) 58 
30th-40th  44 (86.3) 7 (13.7) 51 
40th-50th  32 (91.4) 3 (8.6) 35 
50th-60th  39 (95.1) 2 (4.9) 41 
60th-70th  42 (97.7) 1 (2.3) 43 
70th-80th  49 (94.2) 3 (5.8) 52 
80th-90th  55 (91.7) 5 (8.3) 60 
90th-100th  47 (94.0) 3 (6.0) 50 




Within the UK, current clinical practice relies on measurement of ultrasound 
parameters to identify pregnancies at risk of delivering an SGA infant. In this 
prospective, multicentre cohort study, recruiting women with reduced 
symphysis-fundal height (current UK referral tool to identify women at risk of 
SGA), these parameters had modest test performance for predicting delivery of 
an SGA infant. EFW <10th centile had the highest sensitivity and negative 
predictive value to predict delivery of an SGA infant <3rd birth weight centile 
(57.9% and 92.6% respectively). Quantification of maternal plasma PlGF in this 
cohort performed no better than ultrasound parameters (sensitivity 37.2% and 
negative predictive value 90.3% for SGA <3rd centile). This is in contrast to the 
findings of the PELICAN-PE study, where low plasma PlGF had high sensitivity 
(89.6%; 95% CI 81.7 to 94.9%) and negative predictive value (91.3%; 95% CI 
84.6 to 95.8%) to determine delivery of an SGA infant (birth weight <3rd 
customised centile). 
 
Whilst I have focused on the ability of ultrasound parameters and PlGF to 
predict delivery of an SGA infant I also investigated their ability to predict 
adverse perinatal outcome. However, only 13 pregnancies in the whole cohort 
experienced an adverse perinatal outcome, making firm conclusions regarding 
the predictive capability of PlGF and ultrasound parameters for this endpoint 
impossible. The single stillbirth reported in PELICAN FGR was not SGA and 
had a normal PlGF concentration at enrolment.  
I discuss possible explanations for differences observed between the PELICAN-
PE and PELICAN-FGR studies and implications of the study findings in Chapter 
4: Discussion.
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Chapter 4: Discussion 
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4.1 Principal findings 
 
4.1.1 PELICAN-PE study findings 
In this work, I have demonstrated that the angiogenic factor, PlGF accurately 
identifies pregnancies delivering an SGA infant in a high-risk cohort of women 
presenting in the second half of pregnancy with suspected pre-eclampsia 
(sensitivity 93.2%, negative predictive value 89.7%, ROC area 0.83 for SGA 
<3rd birth weight centile in women enrolled prior to 35 weeks’ gestation).  
 
4.1.1.1 Comparison of PlGF test performance to other individual 
biomarkers 
In women sampled before 35 weeks’ gestation, PlGF outperformed all other 
individual biomarkers assessed, with high-test performance to predict delivery 
of an SGA infant. However, test performance statistics for PlGF in women 
enrolled beyond 35 weeks’ gestation (ROC area 0.69 (95% CI 0.57 to 0.81) for 
SGA <3rd birth weight centile) were less impressive than those reported in 
women recruited prior to 35 weeks’ gestation. A possible explanation for this 
finding is the convergence of PlGF concentrations between normal and 
pathological pregnancies with advancing gestation.  
 
Of all 47 biomarkers assessed, the three markers with highest individual test 
performance to predict delivery of an SGA infant (PlGF, Endoglin and sFlt-1) 
were all angiogenic factors. Given that they are all involved in the same 
pathological process, this may explain why addition of Endoglin or sFlt-1 to 
PlGF did not improve overall test performance. The finding that the best 
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performing biomarkers for SGA in suspected pre-eclampsia are involved in the 
regulation of angiogenesis adds support to placental insufficiency being key to 
pathogenesis of FGR in these women. 
 
4.1.1.2 Test performance of individual versus combinations of biomarkers 
Due to the complex underlying pathophysiology of FGR, involving multiple 
pathological processes, I hypothesised that a panel of biomarkers reflecting 
differing pathways might improve test performance over individual biomarkers 
to predict delivery of an SGA infant.  
 
From the analysis of women enrolled to the PELICAN-PE study prior to 35 
weeks’ gestation, the best performing combination of biomarkers, derived from 
factor analysis and multiple logistic regression included PlGF, nephrin and CPA-
4 (ROC area of 0.84 for SGA <3rd birth weight centile). Nephrin is a protein 
essential for normal renal glomerular function and broadly reflects endothelial 
function, whilst CPA-4 is a metalloprotease, which cleaves angiotensin, a major 
component of the renin-angiotensin system, and essential for blood pressure 
homeostasis. Despite their diverse pathophysiology, addition of nephrin and 
CPA-4 to PlGF had little affect on overall test performance to determine SGA 
<3rd birth weight centile over that derived from PlGF measured in isolation. The 
high individual test performance of PlGF to determine SGA <3rd birth weight 
centile may explain why addition of other biomarkers (with modest individual 
test performance (ROC areas of 0.63 for SGA <3rd birth weight centile)) did not 
aid identification of the few cases undetected by PlGF alone.  
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In women sampled beyond 35 weeks’ gestation, isolated biomarkers performed 
less well to determine delivery of an SGA infant, possibly due to other 
processes in addition to placental disease contributing to delivery of an SGA 
infant near term. A combination of biomarkers reflecting other pathological 
processes may therefore be more useful in this group. The same combination 
of PlGF, nephrin and CPA-4 achieved the best test performance in determining 
subsequent delivery of an SGA infant in women sampled beyond 35 weeks’ 
gestation, but this combination achieved only modest improvements in test 
performance over PlGF alone (ROC area for combination of PlGF, Nephrin, 
CPA-4 0.77 (95% CI 0.66 to 0.88) for delivery of an SGA infant <3rd birth weight 
centile). 
 
Using single, rather than multiple biomarkers, has significant advantages when 
translating this work to a clinical setting. It is likely to be more cost effective and 
will reduce the overall error associated with using multiple assays. It will also 
facilitate future comparisons between datasets as reproducibility is likely to be 
easier. 
 
4.1.1.3 Comparison of PlGF test performance with ultrasound parameters 
to determine delivery of an SGA infant and predict adverse perinatal 
outcome in women presenting with suspected pre-eclampsia 
After identifying PlGF as the most promising biomarker for prediction of 
delivering an SGA infant in these high-risk women, I compared its test 
performance to currently utilised ultrasound parameters. I have shown that 
PlGF outperformed all ultrasound parameters in predicting subsequent delivery 
of an SGA infant in women presenting with suspected pre-eclampsia. PlGF also 
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had high sensitivity and negative predictive value to detect adverse perinatal 
outcome, which included stillbirth. A systematic review and meta-analysis of risk 
factors for stillbirth in high-income countries reported SGA as having the highest 
population attributable risk (23%) for this devastating outcome (Flenady et al., 
2011a). There were six cases of stillbirth in this cohort, with five cases 
delivering an infant with birth weight <3rd centile. Only three of these cases were 
detected antenatally by ultrasound scan but all had a low PlGF at study 
enrolment. This supports the hypothesis that PlGF measurement would aid 
identification of such cases early enough to allow appropriate surveillance and 
timely delivery, with the aim of avoiding this major adverse outcome.  
 
The high sensitivity of PlGF in this population is only slightly increased by 
addition of ultrasound parameters. However, ultrasound may give additional 
information that may aid decisions regarding timing of delivery, such as absent 
or reversed umbilical artery end-diastolic flow as PlGF is not yet validated as a 
predictor of stillbirth. Therefore, in women presenting with high risk features for 
pre-eclampsia, I propose combining PlGF and ultrasound data to generate a 
test that has very high negative predictive value. Addition of PlGF to current 
ultrasound parameters has the potential to increase detection of SGA in high-
risk women, allowing appropriate follow up and targeted intervention with the 




4.1.2 PELICAN-FGR study findings 
 
While PlGF has been shown to work well in high-risk women, it would be very 
advantageous for a biomarker to predict SGA in a more general antenatal 
population. I therefore investigated use of PlGF in women with reduced 
symphysis-fundal height measurement, a referral trigger for suspected SGA in 
the UK. I compared the test performance of PlGF to predict subsequent delivery 
of an SGA infant to the performance of ultrasound parameters used in current 
clinical practice. 
 
4.1.2.1 Comparison of PlGF test performance with ultrasound parameters 
to determine delivery of an SGA infant and predict adverse perinatal 
outcome  
In this work I demonstrated that ultrasound parameters used in current clinical 
practice to identify pregnancies at risk of delivering an SGA infant had modest 
test performance. EFW <10th centile had the best test sensitivity of all 
ultrasound parameters assessed but only identified 58% of cases antenatally 
who delivered an infant with a birth weight <3rd centile (sensitivity 57.9% and 
NPV 92.6%). This finding is similar to results of a systematic review and 
subsequent retrospective cohort study which both assessed the predictive 
capability of EFW <10th centile to determine delivery of an SGA infant in high 
risk populations (including women with suspected SGA), and published 
sensitivities of 33-89%, 68% and specificities of 54-91%, 89% respectively 
(Chang et al., 1992, De Jong et al., 2000). Sensitivity to detect SGA in 
unselected populations have been reported as lower than those seen in the 
PELICAN-FGR study (21-47%) (David et al., 1996, Ben-Haroush et al., 2007, 
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Souka et al., 2012). In contrast to the findings in the high-risk PELICAN-PE 
cohort, PlGF quantification performed no better than ultrasound parameters in 
predicting delivery of an SGA infant in this population (sensitivity 37.2% and 
NPV 90.3% for SGA <3rd centile).  
 
Whilst EFW <10th centile had the highest sensitivity and negative predictive 
values of all ultrasound parameters evaluated, oligohydramnios and umbilical 
artery Doppler PI >95th centile had high specificity for SGA (99% and 96% 
respectively for SGA <3rd birth weight centile). This corroborates the findings of 
a recent meta-analysis and systematic review evaluating the association of 
amniotic fluid index and adverse perinatal outcome, where there was a strong 
association between oligohydramnios and delivery of an SGA infant and 
mortality (Morris et al., 2014). However the predictive accuracy for perinatal 
outcome was poor. The very low sensitivities for oligohydramnios and umbilical 
artery Doppler >95th centile to predict delivery of an SGA infant <3rd birth weight 
centile (3.7% and 16.4% respectively) in the PELICAN-FGR cohort, limit their 
use in clinical practice as isolated predictors of SGA but their high specificity for 
identifying pregnancies delivering an SGA infant, makes them useful indicators 
for timing of delivery, as discussed in section 4.1.1.3. 
 
In addition to evaluating the ability of ultrasound parameters and PlGF to predict 
delivery of an SGA infant, I also investigated their ability to predict adverse 
perinatal outcome. Previously, three Cochrane systematic reviews evaluating 
symphysis-fundal height measurement (Neilson, 2000), routine ultrasound 
measurement (Bricker et al., 2008) and umbilical artery doppler assessment in 
normal pregnancies (Alfirevic et al., 2010) concluded that none of these 
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techniques reduced adverse perinatal outcome. However preliminary data from 
a recent large prospective cohort study reported increased sensitivity of 
screening (79%) vs. selective (32%) sonography in the third trimester in an 
unselected nulliparous population for prediction of severe SGA (Sovio et al., 
2014).  
 
The PELICAN-FGR study was powered for the primary endpoint of delivering 
an SGA infant, assuming a rate of SGA <3rd birth weight centile of 8% in women 
referred with suspected SGA (based on data from St Thomas’ Hospital, 
London). The incidence of SGA <3rd centile in the study cohort was higher than 
this at 13% but the low incidence of adverse perinatal outcome (a secondary 
outcome) in the study cohort (with only 13 cases) made conclusions regarding 
the ability of any of the parameters to determine adverse perinatal outcome 
impossible. This is in contrast to the PELICAN-PE study where 19% of the 
population had an adverse perinatal outcome, including nine cases of 
stillbirth/neonatal death. The single stillbirth reported in PELICAN-FGR was not 
SGA and had a normal PlGF concentration at enrolment. It is therefore unlikely 
that placental disease was the underlying pathological process in this case.  
 
4.2 Comparison of PELICAN-PE and PELICAN-FGR 
studies 
 
The PELICAN-PE study reported high-test performance statistics for the ability 
of low concentrations of maternal plasma PlGF to predict delivery of an SGA 
infant in women presenting with suspected pre-eclampsia (Chappell et al., 
 191 
2013). A previous study had reported similar test performance statistics for low 
plasma PlGF concentrations in women delivering an SGA infant with associated 
placental pathology (Benton et al., 2012). In both these studies placental 
dysfunction is the likely major underlying pathological process. PlGF is an 
angiogenic factor primarily released by trophoblast cells and concentrations 
reflect placental function. Therefore if placental dysfunction is the predominant 
pathological process contributing to delivery of an SGA infant, concentrations 
would be expected to closely correlate with presence and severity of SGA, as 
was observed in these studies.  
 
In the PELICAN-FGR study, I sought to investigate whether the findings of 
these two studies could be applied to a lower risk population presenting with 
reduced symphysis-fundal height measurement. Whilst acknowledging that 
other pathological processes maybe involved in subsequent delivery of an SGA 
infant in this population, I hypothesised that placental dysfunction was still likely 
to be the major pathological process resulting in SGA. Therefore, low plasma 
PlGF could still be a useful screening tool to identify pregnancies at risk of 
delivering an SGA infant in this cohort. However, the findings of the PELICAN-
FGR study did not support this hypothesis, with PlGF performing no better than 
ultrasound parameters utilised in current clinical practice to identify pregnancies 
at risk of delivering an SGA infant. Here I will discuss possible explanations for 
the contrasting findings of the PELICAN-PE and PELICAN-FGR studies.  
 
The primary aim of the PELICAN-PE study was to assess the diagnostic 
accuracy of PlGF to determine need for delivery for confirmed pre-eclampsia in 
women presenting with suspected pre-eclampsia. As a secondary outcome, the 
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ability of PlGF to predict delivery of an SGA infant with birth weight <3rd 
customised birth weight centile was assessed. The women enrolled in this study 
were high-risk, with 61% of those recruited prior to 35 weeks gestation 
developing pre-eclampsia (Chappell et al., 2013). This is in contrast to the low 
frequency of coexisting maternal complications of pregnancy in the PELICAN-
FGR study (555/592, 93% had no coexisting maternal complications of 
pregnancy), where only 4% were diagnosed with a hypertensive disorder. I 
have searched the literature for similar cohorts to that described in these 
studies and data for comparison is sparse. Anumba and colleagues reported an 
incidence of pre-eclampsia of 26% in women presenting to an obstetric day 
assessment unit with gestational hypertension (diastolic >90mmHg in 
community) (Anumba et al., 2010). This study excluded women presenting with 
coexisting FGR, diabetes mellitus and severe hypertension, which may give 
some explanation for the lower incidence than that reported in the PELICAN-PE 
study. The PELICAN co-investigator group anticipated that not all women 
enrolled with suspected pre-eclampsia would develop the disease, in line with 
the findings of Anumba et al. 
 
 
It has been suggested that different pathological processes may occur in the 
placentas of women with hypertensive disorders, especially if early onset 
compared to those who remain normotensive but deliver an SGA infant 
(Redline, 2008). Redline has described five chronic patterns of placental injury 
in placentas from pregnancies complicated by growth restriction, including; 
maternal vascular obstruction, fetal vascular obstruction, villitis of unknown 
aetiology, perivillous fibrin deposition and chronic abruption. He suggests that 
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maternal vascular disorders are more common in those pregnancies 
complicated by hypertensive disorders, whilst villitis of unknown aetiology is 
more common in those who remain normotensive but deliver an SGA infant. It 
is possible that concentrations of individual markers may vary in differing 
pathological processes therefore offering some explanation why the ability of 
PlGF to distinguish SGA in those with associated hypertensive disorders and in 
those who remain normotensive but deliver an SGA infant is not comparable.  
 
Whilst SGA was defined as birth weight less <3rd customised centile in both 
studies, in PELICAN-FGR this encompassed a more heterogeneous population 
whose underlying pathology was not necessarily restricted to placental disease. 
It is possible that the contribution of placental dysfunction in this study 
population was less than I anticipated, offering an explanation as to why PlGF, 
a marker of placental function, may not be as accurate a predictor of delivering 
an SGA infant in a population whose pathology is not limited to placental 
disease.  
 
Gestational age at sampling differed by three weeks between the two studies 
(average gestational age at sampling in those women delivering an SGA infant 
with birth weight <3rd centile was 31 weeks’ gestation in the PELICAN-PE study 
compared to 34 weeks’ gestation in PELICAN-FGR). In women delivering an 
infant with birth weight <3rd customised centile, gestational age at delivery was 
also markedly different in the two studies (33.8 weeks in the PELICAN-PE study 
(Table 2.6) and 38.7 weeks in the PELICAN-FGR study (Table 3.3). PlGF 
concentration peaks at approximately 32 weeks’ gestation and then declines 
towards term (Knudsen et al., 2012). The clinical application of PlGF appears 
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less efficacious if sampling occurs later in the third trimester and if women 
deliver closer to term, likely secondary to the convergence of values between 
normal and pathological pregnancies with advancing gestation (Knudsen et al., 
2012). 
 
4.3 Strengths and limitations of the studies 
 
The PELICAN-PE and PELICAN-FGR studies are the largest reported 
prospective multi-centre studies evaluating the ability of PlGF, measured in the 
third trimester, to predict delivery of an SGA infant in women presenting with 
suspected pre-eclampsia or reduced symphysis-fundal height respectively. The 
PELICAN-PE study evaluated a large panel of biomarkers chosen for their 
biological relevance to placental disease and pre-eclampsia and no previous 
studies have compared such a diverse panel of biomarkers to predict 
subsequent delivery of an SGA infant.  
 
Both studies were large multicentre, multinational prospective cohort studies 
enrolling women from diverse geographical and ethnic backgrounds, aiding 
generalisabilty of the findings. The entry criteria for both studies were chosen 
due to their clinical relevance, being common referral triggers for obstetric 
assessment within the United Kingdom. However, I acknowledge that in other 
healthcare settings symphysis-fundal height measurement is not part of routine 
antenatal care. In such settings, third trimester ultrasound assessment is 
offered in all pregnancies and therefore the findings of the PELICAN-FGR study 
may be less applicable. 
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The studies took a pragmatic approach, in order to evaluate the real life 
applications of these tests, and recruited women who were referred for obstetric 
assessment with either a broad range of signs or symptoms of suspected pre-
eclampsia or suspected SGA on symphysis-fundal height measurement and 
included women with underlying medical conditions. This approach was chosen 
in an attempt to more closely reflect the test performance in a clinical setting, 
rather than evaluating the test against normal healthy pregnant women, in a 
case-control design. However, use of reduced symphysis-fundal height as the 
inclusion criterion for the PELICAN-FGR study identified a heterogeneous 
group, with few cases complicated by placental disease (i.e. pre-eclampsia) and 
may explain why the performance of PlGF, an angiogenic factor, to predict 
delivery of an SGA infant, was lower that I anticipated. Using PlGF in a more 
targeted subgroup may be more appropriate.  
 
PlGF measurement was undertaken at the enrolling site as would occur if the 
test was to be adopted clinically and results were validated by paired sample 
testing at a central laboratory. All additional biomarkers in the PELICAN-PE 
study were measured at the same central laboratory. All final maternal 
diagnoses were made by a panel of senior clinicians, without prior knowledge of 
the PlGF result. All clinical and laboratory staff were masked to biomarker 
results until study completion.  
 
With the exception of PlGF, test results were not validated by a paired sample 
and there was no comparative testing at a second laboratory. In addition, both 
studies only measured PlGF at study enrolment. It could be informative to 
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evaluate serial measurements to assess whether longitudinal changes in PlGF 
concentrations correlate with evolving placental dysfunction. In the PELICAN-
PE study serial plasma sampling would also have had the added benefit of 
allowing testing of all additional biomarkers at advancing gestations, as some 
biomarkers may only become clinically significant closer to outcome. However, 
with regards to PlGF measurement in the PELICAN-PE study, despite varying 
timescales between plasma sampling and delivery, PlGF remained a strong 
indicator of subsequent delivery of an SGA infant.  
 
To allow comparison of ultrasound parameters to biomarkers measured at study 
enrolment, inclusion was restricted to women recruited to the PELICAN-PE 
study who had a recorded ultrasound scan at or within 14 days of study 
enrolment. Of the 397 women recruited prior to 37 weeks’ gestation less than 
half (n=179) had ultrasound scan data available within this timeframe and data 
relating to umbilical artery Doppler were limited to whether there was absent/ 
reversed end diastolic flow. In women enrolled prior to 35 weeks’ there was a 
disparity in the incidence of pre-eclampsia and delivery of an SGA infant with 
birth weight <3rd centile, with higher incidence of both in women who had 
ultrasound scanning (incidence of pre-eclampsia at delivery and SGA <3rd 
centile 74% and 46% respectively in women with ultrasound within 14 days 
compared to 36% and 10% in women with no ultrasound data). This has the 
potential to bias results. 
  
Absent/ reversed end diastolic flow in the umbilical artery Doppler was only 
present in 16 cases included in this analysis (13 prior to 35 weeks’ gestation 
and 3 cases enrolled between 35+0 and 36+6 weeks’ gestation). Absent/ 
 197 
reversed end diastolic flow in the umbilical artery Doppler is a relatively 
uncommon finding even in high-risk populations and occurs late in the 
pathological process. It is used as an end point to aid decisions regarding 
timing of delivery. It may have been more informative to record umbilical artery 
Doppler pulsatility index  (and then transformed them to allow for gestational 
age changes), as alterations in pulsatility index are usually observed prior to the 
development of absent/reversed end diastolic flow and raised pulsatility index 
can therefore be used as an earlier indicator of adverse outcome. These data 
were collected in the PELICAN-FGR cohort but there were only 26 cases with 
umbilical artery Doppler PI >95% centile in the whole cohort (n=592). Data of 
ultrasound scans conducted after enrolment were recorded but there were 
insufficient number of cases in both studies with additional ultrasound scan data 
to justify further analysis. As with serial PlGF measurements, serial ultrasound 
assessment would provide data to allow assessment as to whether longitudinal 
changes in ultrasound parameters can improve identification of pregnancies at 
risk of delivering an SGA infant.  
 
4.4 Significance of findings 
 
To date, no published studies have compared the performance of currently 
utlilised ultrasound parameters and such a diverse panel of biomarkers in the 
third trimester to predict delivery of an SGA infant. In this work I have 
demonstrated that third trimester PlGF quantification in a high-risk cohort of 
women accurately predicts delivery of an SGA infant. I have shown that PlGF 
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outperforms all other individual biomarkers evaluated. Combining the results of 
two or more biomarkers, regardless of their pathogenesis, add little to overall 
test performance. Given that impaired placental function contributes to a 
substantial proportion of cases of SGA (Redline, 2008), an angiogenic placental 
factor such as PlGF has biological plausibility for prediction.  
 
4.4.1 Comparison of PELICAN-PE study findings to other studies 
evaluating the ability of PlGF to predict delivery of an SGA infant 
Previous reports of the ability of PlGF to determine pregnancies at risk of 
delivering an SGA infant are conflicting. Most early studies concentrated on 
sampling in the first and second trimesters. Initial small case-control studies in 
the first half of pregnancy found no significant relationship between PlGF 
concentration and subsequent delivery of an SGA infant (Vandenberghe et al., 
2011, Steinberg et al., 2010, Bersinger and Odegard, 2005) but larger case-
control studies (Karagiannis et al., 2011, Asvold et al., 2011, Romero et al., 
2008, Thadhani et al., 2004) and several prospective cohort studies measuring 
PlGF in the first (Poon et al., 2013, Poon et al., 2008b) and second trimesters 
(Espinoza et al., 2007) have reported an association between low plasma PlGF 
concentrations and delivery of an SGA infant. The few small (n=21 or less) 
mainly case-control studies that have evaluated PlGF quantification in the third 
trimester (including at time of delivery) to predict delivery of an SGA infant 
agree with the findings of the PELICAN-PE study where low PlGF 
concentrations are associated with subsequent delivery of an SGA infant 
(Benton et al., 2012, Wallner et al., 2007, Shibata et al., 2005, Taylor, 2003).  
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Comparison between studies investigating the ability of PlGF to identify 
pregnancies at risk of delivering an SGA infant is further confounded by use of 
a variety of PlGF assays. The majority of studies discussed above used a PlGF 
assay marketed by R&D systems (USA), which is not automated. At present 
there are only two commercially available PlGF immunoassays, which could be 
implemented directly into clinical practice; the Triage placental growth factor 
assay (Alere, USA) and the Elecsys soluble Fms-like tyrosine kinase-
1/placental growth factor ratio (Roche Diagnostics, Germany). A small case 
control study, compared the performance of these two assays as diagnostic 
tests for pre-eclampsia, and reported superior performance for the former assay 
(Benton et al., 2011). The Alere Triage assay was used in the PELICAN-PE and 
PELICAN-FGR studies but was only used in one of the studies discussed 
above (Benton et al., 2012).  
 
4.4.2 PlGF as a predictor of adverse perinatal outcome in the 
PELICAN-PE study 
In addition to demonstrating the ability of third trimester PlGF sampling to 
predict delivery of an SGA infant in a high-risk cohort, low concentrations of this 
marker also identified cases complicated by adverse perinatal outcome. This 
finding is supported by two studies (Smith et al., 2007, Sibiude et al., 2012), but 
the first was a nested case-control study, measuring PlGF in the first trimester 
and the second reported a combined maternal and perinatal adverse outcome. 
Both studies included delivery of an SGA infant within their definitions of 
adverse outcome. In contrast, in the PELICAN-PE study, delivery of an SGA 
infant was a separate secondary endpoint. This allowed identification of an 
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association between low PlGF measurement and adverse perinatal outcome, 
independent of that demonstrated between low PlGF and delivery of an SGA 
infant. This finding has not previously been published in any study evaluating 
PlGF to predict delivery of an SGA infant. 
 
4.4.3 Comparing the performance of PlGF and other individual 
biomarkers and biomarker combinations/ ratios in the PELICAN-PE 
study to other studies investigating biomarker prediction of 
delivering an SGA infant  
Whilst many publications have linked altered concentrations of biomarkers with 
delivery of an SGA infant, there is a paucity of published data regarding the test 
performance of biomarkers, especially measured in the third trimester, to predict 
this endpoint. Most evidence has evaluated the ability of angiogenic biomarkers 
to determine delivery of an SGA infant but few studies have published test 
performance statistics to allow any comparison.  
 
With the exception of PlGF, s-Flt is one of the only markers with published test 
performance statistics for determining delivery of an SGA infant. Stepan et al. 
measured s-Flt in the second trimester of pregnancy in women with abnormal 
uterine artery Doppler flow and reported sensitivity of 64% with specificity of 
54% to predict delivery of an SGA infant with birth weight <5th centile (Stepan et 
al., 2007). Using a different definition for SGA, Bersinger et al. published a 
sensitivity of 56% (95% CI 27 to 81%) and specificity of 88% (95% CI 74 to 
95%) for s-Flt to predict delivery of an SGA infant (Bersinger and Odegard, 
2005). This study was limited by small sample size, (only nine cases of SGA) 
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which is likely to explain the wide confidence intervals quoted. In the PELICAN-
PE cohort the ROC area for s-Flt to predict delivery of an SGA infant with birth 
weight <10th centile was 0.69 (95% CI 0.63 to 0.76), lower than that of PlGF 
(0.79; 95% CI 0.73 to 0.84). The sample size of our study population was much 
greater than any previously published data regarding the performance of s-Flt 
as a predictor of delivering an SGA infant and therefore our data are likely to 
offer more accurate information regarding the ability of s-Flt to determine this 
outcome.  
 
Of the other angiogenic biomarkers discussed in detail in section 1.4.1, Asvold 
et al. have published test performance statistics for endoglin to predict delivery 
of an SGA infant with birth weight <2.5th centile in women without pre-eclampsia 
(Asvold et al., 2011). They report a sensitivity of 61% (95% CI 52 to 69%) and 
specificity of 67% (95% CI 60 to 73%) for endoglin to predict delivery of an SGA 
infant. In the PELICAN-PE cohort the ROC area for endoglin to predict delivery 
of an SGA infant with birth weight <3rd centile was 0.74 (95% CI 0.68 to 0.80), 
less than that for PlGF for the same endpoint (0.83; 95% CI 0.78 to 0.88). 
Asvold et al. sampled s-Flt in the second trimester, which may give some 
explanation for the differing results published compared to the PELICAN-PE 
data. 
 
A recent systematic review and meta-analysis investigating novel biomarkers 
for predicting intrauterine growth restriction concluded that PlGF was the most 
promising of all 37 biomarkers evaluated (Conde-Agudelo et al., 2013). This 
review included 53 studies mostly evaluating biomarker measurement in the 
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first and second trimesters to predict delivery of an SGA infant and no studies 
evaluated PlGF in a similar cohort to this study. Of the 13 studies in this review 
reporting test performance for PlGF to predict delivery of an SGA infant, only 
one used a commercially available automated immunoassay (Benton et al., 
2012) and only five recruited women over 20 weeks’ gestation. Within this 
review, a subgroup analysis including the five studies enroling women over 20 
weeks’ gestation reported a pooled sensitivity for PlGF (at various thresholds 
and using two different assays) for prediction of ‘IUGR’ (by differing definitions) 
of 49% (95% CI 44 to 53%). Given the considerable difference between studies 
included in this analysis and the fact that only one followed a cohort design, 
comparisons between studies was very difficult. In the single cohort study 
included in the subgroup analysis of women enrolled beyond 20 weeks’ 
gestation, delivery of an SGA infant was a secondary endpoint (primary 
outcome was pre-eclampsia). No cohort studies evaluating PlGF quantification 
in the third trimester were included in this review.  
 
The gross heterogeneity of the studies included in this systematic review with 
differing inclusion criteria, study design and use of various PlGF assays, gives 
some explanation as to why the findings were markedly different to that of the 
PELICAN-PE study and emphasise the importance of this study, being the only 
large prospective cohort study evaluating a wide range of third trimester 
biomarkers in predicting delivery of an SGA infant and adverse perinatal 
outcome.  
 
Subsequent to publication of this systematic review, a large prospective cohort 
study on an unselected population evaluated maternal plasma angiogenic 
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markers (PlGF, sFlt-1 and soluble endoglin) at a fixed time point (30-34 weeks’ 
gestation) to determine delivery of an SGA infant. This group reported an 
increased adjusted odds ratio for PlGF/sFlt-1 ratio of 5.5 (95% CI 2.3 to 13.1%) 
to determine delivery of an SGA infant <3rd birth weight centile. Unfortunately 
they did not publish any standard test performance statistics to allow 
comparison to the PELICAN-PE or PELICAN-FGR datasets (Chaiworapongsa 
et al., 2013). Interestingly, the data from the PELICAN-PE study showed that 
use of a PlGF/sFlt-1 ratio added nothing to PlGF measurement alone and in 
fact had a lower ROC area (0.80 (95% CI 0.75-0.85) Table 2.8) than PlGF 
measurement in isolation (0.83 (95% CI 0.78-0.88)) in predicting delivery of an 
SGA infant with birth weight <3rd centile.  
 
4.4.4 Significance of PELICAN-FGR study findings 
Whilst the results of the PELICAN-FGR study do not support extension of the 
findings of the PELICAN-PE study in a more general antenatal population, this 
study is the largest prospective cohort study to evaluate the diagnostic accuracy 
of currently used ultrasound parameters and maternal plasma PlGF 
concentration in women presenting with reduced symphysis-fundal height 
measurement. Publication of the results of the PELICAN-FGR study will ensure 
avoidance of inappropriate extrapolation of the findings of the PELICAN-PE 
study into an unselected population. I have demonstrated that currently utilised 
ultrasound parameters had only modest predictive ability for delivery of an SGA 
infant, in line with previous publications (David et al., 1996, De Jong et al., 
2000, Frøen et al., 2004, Chang et al., 1992). I have also shown that whilst 
oligohydramnios and umbilical artery Doppler >95% centile had low sensitivity 
for predicting delivery of an SGA infant, limiting their clinical utility as isolated 
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tools, they were both highly specific for this condition. This corroborates the 
findings of a recent meta-analysis and systematic review evaluating the 
association of amniotic fluid index and adverse perinatal outcome, where there 
was a strong association between oligohydramnios and delivery of an SGA 
infant and mortality (Morris et al., 2014). 
 
4.5 Clinical application of findings, unanswered 
questions and future research 
 
Whilst the results of my work do not support the widespread addition of PlGF to 
current ultrasound parameters to identify pregnancies at risk of delivering an 
SGA infant in an unselected population, its use as a screening tool in high- risk 
women presenting with signs and symptoms of pre-eclampsia is likely to be 
beneficial. However, in the work presented here I did not investigate whether 
adoption of PlGF into clinical practice would alter clinical outcome.  
 
4.5.1 Assessment of clinical utility of PlGF guided management in 
suspected pre-eclampsia 
I hypothesise that improved identification of those at greatest risk of delivering 
an SGA infant and associated adverse outcome will facilitate appropriate 
targeting of resources and timely intervention with subsequent improvements in 
maternal and neonatal outcome. A randomised controlled trial comparing 
current clinical practice to PlGF guided management should be performed to 
demonstrate effectiveness prior to widespread adoption of PlGF as a screening 
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tool for SGA in a high-risk population presenting with suspected pre-eclampsia. 
Such a study should include a comprehensive economic analysis to enable 
comparison to current care. We have recently received funding from the 
National Institute for Health Research, Research for Patient Benefit programme 
to perform a stepped wedge randomised trial comparing PlGF guided clinical 
management against current practice in women presenting with suspected pre-
eclampsia. All women will have plasma PlGF measured at study entry. The two 
study arms will follow either;  
 
1) current clinical practice according to NICE guidance with PlGF result being 
concealed from the clinician  
or  
 
2) PlGF guided management where the clinician would be informed of the PlGF 
result and if this is <12 pg/ml the patient should be treated according to NICE 
guidance on the management of pre-eclampsia, including close surveillance, 
irrespective of their clinical presentation. If PlGF result is >100 pg/ml then 
women will be offered outpatient consultant-led follow up.  
 
The primary outcome is the proportion of women in each arm with composite 
maternal adverse outcome. A full economic analysis is planned and the study is 
powered for neonatal outcome with delivery of an SGA infant with birth weight 
<3rd customised centile as a secondary endpoint. 
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4.5.2 Use of PlGF in maternal renal disease 
In section 1.1.3 I discussed the many risk factors contributing to the 
development of FGR and the particular importance of maternal factors, which 
mainly predispose to placental disease. Within the PELICAN-PE study I have 
demonstrated that PlGF accurately predicts delivery of an SGA infant in a high-
risk cohort of women with suspected pre-eclampsia. I hypothesise that PlGF 
may have similar ability to predict delivery of an SGA infant and adverse 
perinatal outcome in other high-risk cohorts at risk of placental disease, such as 
women with diabetes mellitus, renal and vascular disease. Diagnosis of pre-
eclampsia using conventional criteria is particularly challenging in women with 
pre-existing hypertension and proteinuria and if PlGF quantification in this group 
of women can identify those at most risk of developing pre-eclampsia and 
delivering an SGA infant, targeted intervention has a real opportunity to improve 
outcome.  
 
Whilst some women included in the PELICAN-PE study initial analysis (n=274) 
had pre-existing medical conditions including diabetes mellitus (n=6) and renal 
disease (n=19), numbers were insufficient to draw any substantive conclusions. 
Further prospective cohort studies investigating the utility of PlGF as a 
screening tool in these populations are warranted. Bramham et al. have 
recently presented data assessing the diagnostic accuracy of PlGF in 129 
women with chronic kidney disease or hypertension and suspected pre-
eclampsia to determine pre-eclampsia or superimposed pre-eclampsia. The 
ROC area for low PlGF for the diagnosis of pre-eclampsia was high (0.89 (SE 
0.07) for women with pre-existing hypertension and 0.98 (SE 0.02) for women 
with chronic kidney disease (with or without chronic hypertension) (Bramham et 
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al., 2014). The number of cases within this cohort, delivering an SGA infant was 
too small for further analysis. In future work, this group is evaluating the 
predictive value of PlGF for adverse pregnancy outcomes in women with 
chronic kidney disease and/or chronic hypertension.  
 
4.5.3 Use of PlGF in women with a previous history of pre-eclampsia 
or delivery of an SGA infant 
In addition to maternal factors highlighted above, women with a previous history 
of pre-eclampsia or delivery of an SGA infant are at increased risk of recurrence 
(Tejani, 1982). The absolute risk of delivering an SGA infant in subsequent 
pregnancies is likely to be lower than that observed in the high-risk cohort of the 
PELICAN-PE study but higher than that seen in the PELICAN-FGR study. 
Therefore, use of PlGF as a predictor of delivering an SGA infant in women who 
had previous pre-eclampsia or delivery of an SGA infant would require 
assessment as it may be a useful tool. Deciding the most appropriate gestation 
at which to measure PlGF is challenging, as sampling at earlier gestations has 
the benefit of identifying high-risk pregnancies for intensive monitoring, 
facilitating timely intervention. However, test performance diminishes with 
greater interval between sampling and delivery. 
 
It was not possible to assess the ability of PlGF to predict delivery of an SGA 
infant in women with a previous history of pre-eclampsia or delivery of an SGA 
infant witihin the PELICAN-FGR study as only one woman enrolled reported a 
previous history of pre-eclampsia and whilst 49 women reported delivering a 
previous SGA infant, in those where actual birth weights were available, few 
had a birth weight <10th customized birth weight centile for gestational age.  
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4.5.4 Use of PlGF in maternal obesity  
Maternal obesity is a growing problem, presenting multiple challenges for the 
clinician. Obesity in pregnancy is associated with many complications including 
pre-eclampsia. In obese pregnant women, identifying pregnancies at risk of 
FGR presents a particular challenge due to the difficulties with applying current 
techniques for screening and diagnosing SGA. Symphysis-fundal height is not 
an appropriate screening tool in obese women and whilst most local guidelines 
on the management of obesity in pregnancy recommend routine third trimester 
ultrasound scanning, obtaining optimal views for accurate measurement of 
ultrasound parameters is often very difficult. Unlike other biomarkers such as 
leptin, maternal weight does not have a significant effect on PlGF 
concentrations and therefore PlGF may offer a useful adjunct to ultrasound 
scan to identify pregnancies at risk of delivering an SGA infant. I propose 
further assessment of the ability of PlGF in an obese pregnant population to 
predict delivery of an SGA infant. 
 
4.4.5 Use of PlGF with Doppler assessment 
The UK National Screening Committee and Royal College of Obstetricians and 
Gynaecologists guidelines do not recommend routine uterine artery Doppler 
screening in mid-trimester for prediction of pre-eclampsia or FGR (UK National 
Screening Committee, 2011, Robson et al., 2013). However, as part of a 
research programme, some UK centres offer second trimester uterine artery 
Doppler assessment to all primiparous women. Whilst screening low-risk 
pregnancies using isolated uterine artery Doppler analysis has not been shown 
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to improve maternal or fetal outcome (Stampalija et al., 2010), its use in a 
combined screening programme with PlGF may be beneficial. Exploring the 
ability of combined second trimester uterine artery Doppler measurement and 
early third trimester PlGF quantification to predict delivery of an SGA infant in 
an unselected population would be an interesting area of future research. An 
economical analysis would be necessary as part of such an evaluation as 
introducing widespread measurement of uterine artery Doppler indices would 
have significant cost implications, although this could be incorporated into 
second trimester anomaly scanning. As the majority of centres enrolling women 
in the PELICAN-FGR study did not routinely undertake second trimester uterine 
artery Doppler screening, these data were not available for analysis.  
Within the UK, uterine artery Doppler assessment is only offered (outside a 
research setting) in pregnancies with pre-existing risk factors for delivery of an 
SGA infant. However, many women who subsequently deliver an SGA infant 
have no pre-existing risk factors. Accurately identifying those at risk of 
delivering an SGA infant remains challenging. Gardosi et al. suggest that wide 
spread implementation of a comprehensive growth assessment protocol (GAP), 
involving use of customised symphysis-fundal height measurement and growth 
charts, aids antenatal identification of pregnancies delivering an SGA infant 
(Gardosi et al., 2014). Umbilical artery Doppler measurement in high-risk 
pregnancies, including those with suspected SGA, has been shown to reduce 
perinatal death (Alfirevic and Neilson, 1995). Gardosi et al. suggests that by 
better identification of at risk pregnancies, allowing targeted monitoring with 
ultrasound and umbilical Doppler measurement; stillbirth rates are reduced 
(Gardosi et al., 2014). Prior to widespread implementation of these findings, I 
suggest they are verified in a large-scale randomised control trial. 
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Current national guidelines suggest that if Doppler measurement is abnormal 
then serial ultrasound and umbilical artery Doppler measurement should be 
conducted from 26-28 weeks’ gestation (Robson et al., 2013). Given the 
modest test performance of ultrasound parameters to predict delivery of an 
SGA infant, using PlGF quantification in this high-risk cohort might improve 




The results of the PELICAN-PE study suggest that PlGF measurement could be 
a useful adjunct to current ultrasound parameters in predicting subsequent 
delivery of an SGA infant in a high-risk cohort of women. However the findings 
of PELICAN-FGR do not support its use in a more generalised setting, where 
women presented with reduced symphysis-fundal height. Whilst current 
ultrasound parameters provide only modest prediction of delivering an SGA 
infant (EFW <10th centile, ROC area 0.79 for SGA <3rd centile), addition of PlGF 
to these parameters provided minimal improvement in test performance (PlGF 
and EFW<10th centile ROC area 0.82 for SGA <3rd centile), insufficient to 
recommend inclusion into clinical practice. The contrasting findings of 
PELICAN-PE and PELICAN-FGR emphasises the importance of not 
generalising the findings in one study population to another and highlights the 
need for caution regarding use of new biomarkers in clinical practice without 
validation in the appropriate setting. 
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Preeclampsia complicates 2% to 8% of all pregnancies and is characterized by placental and maternal vascular 
dysfunction and associated adverse outcomes.1 Diagnosis is 
based on traditional but unreliable and nonspecific clinical 
markers, most commonly blood pressure and urinary pro-
tein excretion; both are subject to observer error and poor 
test accuracy for identifying women and infants at risk of 
adverse outcome.2 This clinical uncertainty leads to overuse 
of ancillary testing and intervention, with associated expense 
of antenatal monitoring and inpatient admissions, placing 
considerable burden on pregnant women and their families. 
In the United States, preeclampsia is the most common reason 
for iatrogenic preterm delivery.3 Evaluation of biomarkers and 
imaging techniques has shown that none have adequate sensi-
tivity, specificity, and convenience for diagnosis or prediction 
of preeclampsia or complications,2,4 the majority identifying 
advanced disease with established end-organ damage.
Clinical Perspective on p 2131
Recent advances in understanding preeclampsia and fetal 
growth restriction have elucidated important biological 
roles for placentally derived angiogenic factors.5 In normal 
pregnancy, placental growth factor (PlGF), synthesized by 
syncytiotrophoblast,6 increases with gestation in maternal 
circulation, with concentrations peaking at 26 to 30 weeks7 
and declining toward term. PlGF is abnormally low in women 
with preeclampsia in comparison with gestational age-
matched controls8 and is reduced further in severe preeclamp-
sia.9 Development of a test for preeclampsia with the use of a 
pathophysiologically relevant biomarker, such as PlGF, may 
Background—Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and 
their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are 
tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker 
of associated placental dysfunction in preeclampsia, with known low plasma concentrations in the disease.
Methods and Results—In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF 
concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 
20 and 35 weeks’ gestation (and up to 41 weeks’ gestation as a secondary analysis). The outcome was delivery for 
confirmed preeclampsia within 14 days. Of 625 women, 346 (55%) developed confirmed preeclampsia. In 287 women 
enrolled before 35 weeks’ gestation, PlGF <5th centile had high sensitivity (0.96; 95% confidence interval, 0.89–0.99) 
and negative predictive value (0.98; 0.93–0.995) for preeclampsia within 14 days; specificity was lower (0.55; 0.48–0.61). 
Area under the receiver operating characteristic curve for low PlGF (0.87, standard error 0.03) for predicting preeclampsia 
within 14 days was greater than all other commonly used tests, singly or in combination (range, 0.58–0.76), in women 
presenting with suspected preeclampsia (P<0.001 for all comparisons).
Conclusions—In women presenting before 35 weeks’ gestation with suspected preeclampsia, low PlGF has high sensitivity 
and negative predictive value for preeclampsia within 14 days, is better than other currently used tests, and presents an 
innovative adjunct to management of such women.  (Circulation. 2013;128:2121-2131.)
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have advantages over blood pressure and urinary protein, 
which are the consequences of established disease. Because 
earlier gestation of preeclampsia onset is associated with 
greater maternal and perinatal risks,1 and the difference in 
PlGF concentrations between normal and preeclamptic preg-
nancies is most marked before 35 weeks, PlGF has potential 
to aid the diagnosis of hypertensive disorders of pregnancy 
at gestations critical to clinical outcome. The most clinically 
relevant test for health professionals would identify women 
with preeclampsia associated with deteriorating disease 
requiring iatrogenic delivery. Because women with suspected 
hypertensive disease are routinely monitored every 2 weeks, a 
Figure 1. Flow diagram of participants. 
*Details given in Figure 2. †Preeclampsia requiring 
delivery within 14 days. PlGF indicates placental 
growth factor. 
Figure 2. Flow diagram of participants in study 
enrolled after 35 weeks’ gestation. †Preeclampsia 
requiring delivery within 14 days.
 234 
  
Chappell et al  Placental Growth Factor in Suspected Preeclampsia  2123
test should be applicable for a subsequent 14-day window to 
impact management strategies.
The primary aim of this study was to evaluate the diagnostic 
accuracy of plasma PlGF concentrations in women presenting 
with suspected preeclampsia between 20 and 35 weeks’ gesta-
tion (up to 40+6 weeks as a secondary analysis) in determining 
the need for delivery for preeclampsia within 14 days of test-
ing (preeclampsia-D14).
Methods
This prospective observational study was undertaken between January 
2011 and February 2012 in 7 consultant-led maternity units in the 
Table 1. Characteristics at Booking and Enrollment
Gestation at Enrollment (weeks, days)
<35+0 35+0 to 36+6 ≥37+0
n=287 n=137 n=201
Age, y, median (IQR) 31.9 (27.0–35.9) 32.4 (27.5–35.4) 32.1 (27.5–36.0)
Body mass index, kg/m2, median (IQR) 28.6 (24.2–33.6) 28.6 (24.4–32.7) 26.9 (23.1–31.2)
Nulliparous 123 (43) 60 (44) 89 (44)

















Highest 1st trimester systolic BP, mm Hg, median (IQR) 120 (110–130) 118 (110–127) 120 (108–123)














  Previous preeclampsia







  Chronic hypertension 45 (17) 10 (7.9) 8 (4.5)
  Systemic lupus erythematosus/antiphospholipid syndrome 12 (4.5) 0 1 (0.6)
  Pregestational diabetes mellitus 6 (2.2) 4 (3.2) 0
  Renal disease 19 (7.1) 4 (3.2) 6 (3.4)
At enrollment in assessment unit
  Gestational age, wk, median (IQR) 31.0 (27.9–33.4) 36.0 (35.4–36.4) 38.4 (37.6–39.6)
  Signs/ symptoms of suspected preeclampsia (non exclusive)
   New onset of hypertension 155 (54) 92 (67) 133 (66)
   Worsening of underlying hypertension 56 (20) 21 (15) 39 (19)
   New onset of dipstick proteinuria 161 (56) 85 (62) 108 (54)
   Persistent epigastric/ right upper quadrant pain 18 (6) 8 (6) 13 (6)
   Headaches 84 (29) 44 (32) 77 (38)
   Suspected fetal growth restriction 25 (9) 4 (3) 2 (1)
Highest systolic BP, median (IQR) 144 (131–159) 144 (132–153) 145 (135–155)
Highest diastolic BP, median (IQR) 92 (82–100) 94 (86–100) 95 (87–100)
  Dipstick proteinuria
   Not done 38 (13) 19 (14) 15 (8)
   Negative 103 (36) 34 (25) 81 (40)
   Present (1+ or greater) 146 (51) 84 (61) 105 (52)
























Values are given as number (percentage) unless stated otherwise. BP indicates blood pressure; and IQR, interquartile range.
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United Kingdom and Ireland. Women were eligible if they presented 
or were referred with symptoms or signs of suspected preeclampsia 
between 20+0 and 40+6 weeks of gestation, had a singleton or twin 
pregnancy, and were ≥16 years of age. Symptoms or signs included 
headache, visual disturbances, epigastric or right upper quadrant pain, 
hypertension, dipstick proteinuria, or suspected fetal growth restric-
tion. Participants were included if the healthcare provider deemed 
that the woman required evaluation for suspected preeclampsia. Any 
woman already meeting diagnostic criteria for confirmed preeclamp-
sia at enrollment was not eligible. A woman could only be enrolled 
Table 2. Characteristics at Delivery for Women in Each Gestational Age Group
Gestation at Enrollment (weeks, days)
<35+0 35+0 to 36+6 ≥37+0
Total number of women n=287 n=137 n=201
Maternal characteristics
  Final diagnosis (exclusive), preeclampsia 176 (61) 81 (59) 89 (44)
  Final diagnosis (exclusive)
   Mild preeclampsia 25 (9) 24 (18) 40 (20)
   Severe preeclampsia 76 (26) 31 (23) 23 (11)
   Superimposed preeclampsia 40 (11) 10 (6) 7 (3)
   Atypical preeclampsia 32 (14) 15 (12) 19 (9)
   Eclampsia 1 (0) 1 (1) 0 (0)
   HELLP syndrome 2 (1) 0 (0) 0 (0)
   Gestational hypertension 27 (9) 14 (10) 42 (21)
   Chronic hypertension only 28 (10) 9 (7) 18 (9)
   Isolated proteinuria only 10 (3) 6 (4) 10 (5)
   Isolated SGA (<10th customized birthweight centile) 8 (3) 3 (2) 5 (2)
   Transient hypertension 14 (5) 17 (12) 24 (12)
   Normal 22 (8) 5 (4) 12 (6)
   Other 2 (1) 2 (1) 1 (0)
  Antihypertensive use
   1 drug 51 (18) 31 (23) 42 (21)
   2 drugs 53 (18) 9 (7) 16 (8)
   ≥3 drugs 19 (7) 8 (6) 7 (4)
   Magnesium sulfate use 6 (2) 4 (3) 0
  Onset of labor
   Spontaneous labor 42 (15) 25 (19) 59 (29)
   Induced labor 108 (38) 75 (55) 111 (55)
   Prelabor cesarean delivery 134 (47) 36 (26) 31 (16)
  Adverse maternal outcome* 122 (43) 44 (32) 53 (26)
Neonatal characteristics n=299 n=151 n=204
  Gestation at delivery, wk, median (IQR) 36.7 (33.6–38.6) 37.3 (36.6–38.4) 39.4 (38.6–40.3)
  Preterm delivery <37/40 158 (53) 55 (36) 0
  Mode of delivery
   Spontaneous vaginal delivery 72 (27) 54 (41) 98 (50)
   Assisted vaginal delivery 31 (11) 13 (9.9) 29 (15)
   Cesarean delivery 169 (62) 64 (49) 70 (35)
  Fetal death







  Birth weight, g, median (IQR) 2420 (1620–3125) 2820 (2340–3340) 3278 (2980–3560)
  SGA (<10th customized birth weight centile) 142 (47) 57 (38) 52 (25)
  SGA (<3rd customized birth weight centile) 108 (36) 39 (26) 25 (12)
  SGA (<1st customized birth weight centile) 78 (26) 19 (13) 15 (7.3)
  Adverse perinatal outcome† 69 (23) 13 (8.6) 13 (6.4)
Values are given as number (percentage) unless stated otherwise. HELLP indicates hemolysis, elevated liver enzymes, and low platelet count; IQR, interquartile range; 
and SGA, small for gestational age infant. 
*Defined in Table I in the online-only Data Supplement. 
†Defined in Table II in the online-only Data Supplement.
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once. Written informed consent was obtained, and baseline demo-
graphic and pregnancy-specific information was entered onto the 
study database (finalized before the first participant being enrolled). 
Fifteen milliliters of blood (additional to routine blood samples) were 
drawn into ethylenediamine tetra-acetic acid and transported to the 
laboratory within 1 hour, and plasma stored until analysis (−80°C). 
Pregnancy outcome details for mother and infant were obtained from 
case note and electronic database review. Participants were recruited 
until sufficient numbers in each prespecified gestational age range 
had been reached. The study was approved by East London Research 
Ethics Committee (ref. 10/H0701/117).
Definitions and outcomes were prespecified in the study proto-
col. The primary analysis was of diagnostic accuracy of low plasma 
PlGF (<5th centile for gestational age) to predict the need to deliver 
for preeclampsia within 14 days of testing in women with sus-
pected preeclampsia before 35 weeks’ gestation. The prespecified 
secondary analyses included women presenting later (35–36+6; ≥37 
weeks), or by using a lower threshold (<12 pg/mL). All hyperten-
sive disorders of pregnancy, including superimposed and severe 
preeclampsia, were defined according to the American College of 
Obstetricians and Gynaecologists practice bulletin; superimposed 
preeclampsia was defined as new-onset proteinuria in women with 
hypertension before 20 weeks, a sudden increase in proteinuria if 
already present in early gestation, a sudden increase in hyperten-
sion, or the development of hemolysis, elevated liver enzymes, and 
low platelet count (HELLP) syndrome.10 Atypical preeclampsia was 
defined by the International and Australasian Societies for the Study 
of Hypertension in Pregnancy11 as gestational hypertension without 
proteinuria but with other multiorgan involvement or fetal growth 
restriction (<10th customized birthweight centile). The latter12 was 
calculated by using the Gestation Related Optimal Weight method by 
freely available software.13
The final adjudicated diagnosis of pregnancy outcome was the refer-
ence standard for evaluating PlGF test accuracy. This was determined by 
2 independent senior physicians requiring documentation of end points 
required to fulfill the diagnostic criteria; disagreement was resolved by 
a third adjudicator. All adjudicators were masked to PlGF values when 
assigning a final diagnosis; PlGF measurements were not revealed until 
all subject adjudication was complete. Ten percent of database records 
were verified against source data by an independent assessor.
Plasma samples were tested, using the Triage PlGF Test (Alere, 
San Diego, CA), at each study center according to the manufacturer’s 
instructions. All meters were programmed for study duration to pro-
duce a masked result, determining satisfactory test completion only, 
without revealing the value. All laboratory staff were unaware of clin-
ical outcomes. To determine assay reproducibility, replicate samples 
were also tested at a central laboratory. The assay uses fluorescently 
labeled recombinant murine monoclonal antibodies and detects PlGF 
specifically and quantitatively, in the range of 12 to 3000 pg/mL, in 
≈15 minutes. The Total Precision (coefficient of variation) on plasma 
controls at concentrations of 85 and 1300 pg/mL is 12.8% and 13.2%, 
respectively, based on the manufacturer’s package insert generated 
before the study.
As prespecified, women were classified according to the gestation 
of the test, <35, 35 to 36+6, and ≥37 weeks; the test result, normal 
(≥5th centile for gestation), low (<5th centile), and very low (<12 pg/
mL); and the principal outcome, preeclampsia-D14. A positive test 
was PlGF concentration <5th centile for gestational age for normal 
controls (calculated from 247 women with normal pregnancies con-
tributing 1366 samples between 20 and 40 weeks’ gestation).14 Test 
performance was evaluated as sensitivity, specificity, positive and 
negative predictive values, positive and negative likelihood ratios, 
and receiver operating characteristics (ROC) areas. Kaplan-Meier 
survival curves of gestational age at delivery were produced, treat-
ing data as left-censored before the gestation at which the test was 
conducted or at 24 weeks (to avoid very low numbers at gestation 
of the first delivery). The curves represent the probability of deliv-
ery conditional on no delivery before the gestation of the earliest test. 
Median and interquartile ranges for the time from PlGF test to deliv-
ery were calculated. Logistic regression was used to consider whether 
the utility of PlGF was limited to women delivering small for gesta-
tional age infants. Comparison of PlGF with other standard tests for 
preeclampsia (systolic and diastolic blood pressure, proteinuria, uric 
acid, alanine transaminase) was performed for the primary outcome 
by using unadjusted PlGF concentrations. The 4 tests (excluding 
proteinuria, which amounts to confirmation of diagnosis) were com-
bined into a single predictor by using logistic regression, and ROC 
areas were compared for the prediction of the primary end point. For 
implementation to clinical practice in women <37 weeks’ gestation, 
an exploratory analysis was conducted with the aim of identifying a 
single threshold (independent of gestation) with test performance sta-
tistics similar to 5th centile, while retaining the properties of a clini-
cally relevant test (high sensitivity, high negative predictive value). We 
evaluated test biochemical reproducibility by analyzing all samples a 
second time in 1 central laboratory. The required sample sizes were 
calculated for accurate estimation of the sensitivity (within 10%) and 
specificity (within 6%) of PlGF in determining the primary end point. 
We assumed a sensitivity of 0.90, specificity 0.90, and 95% confidence 
intervals (2-tailed), requiring 62 preeclampsia cases and 150 nonpre-
eclamptic women. Because adjudication of the final diagnosis (after 
delivery) lagged behind enrollment, 287 women were recruited before 
35 weeks’ gestation before enrollment was stopped. Statistical analysis 
was performed in the statistical package Stata (version 11.2), College 
Station, TX. The study is reported in accordance with STAndards for 
the Reporting of Diagnostic accuracy studies (STARD) guidelines.
Results
Between January 2011 and February 2012, 649 women were 
recruited (Figures 1 and 2). We recruited all those who were 
approached, eligible, and consented but did not document 
women who declined to take part. Of consented women, 24 
did not have a valid baseline sample (17) or were lost to fol-
low-up (7). The characteristics of the remaining 625 women 
are shown in Table 1, maternal and infant outcomes are in 
Table 2, details of adverse maternal and perinatal outcomes 
Table 3. PlGF Concentrations in Women by Final Diagnosis 
and by Adverse Events, Stratified by Gestational Age Group
Gestation at enrollment (weeks, days)
<35+0 35+0 to 36+6 ≥37+0
Total number of women n=287 n=137 n=201
By diagnosis
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The values stated are PlGF concentrations (pg/mL), median (IQR). IQR 
indicates interquartile range; and PlGF, placental growth factor.
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are in Tables I and II in the online-only Data Supplement, 
respectively, and unadjusted PlGF concentrations by final 
diagnosis are shown in Table 3.
The diagnostic accuracy of PlGF for predicting preeclamp-
sia-D14 (primary outcome) is shown in Table 4, with the use 
of prespecified thresholds of <5th centile and <12 pg/mL. 
Table 4. Test Performance Statistics for Low PlGF in Prediction of Adverse Outcomes
Gestation at Enrollment (weeks, days)
<35+0 35+0 to 36+6 ≥37+0
n=287 n=137 n=201

































  Positive likelihood ratio 2.1 (1.8–2.5) 2.0 (1.4–2.8) 2.4 (1.7–3.5)
  Negative likelihood ratio 0.07 (0.02–0.22) 0.46 (0.31–0.71) 0.56 (0.43–0.73)

































  Positive likelihood ratio 6.4 (4.1–9.9) 2.6 (1.1–6.3) 2.3 (1.2–42)
  Negative likelihood ratio 0.41 (0.30–0.55) 0.85 (0.73–0.98) 0.84 (0.73–0.97)
Preeclampsia requiring delivery


























  Positive likelihood ratio 2.2 (1.9–2.6) 1.4 (1.2–1.6)
  Negative likelihood ratio 0.07 (0.02–0.22) 0.16 (0.04–0.64)


























  Positive likelihood ratio 2.0 (1.7–2.3) 1.9 (1.4–2.4)
  Negative likelihood ratio 0.14 (0.06–0.3) 0.2 (0.03–1.2)
PlGF indicates placental growth factor. 
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All values, including outliers, were included. Low PlGF <5th 
centile had high sensitivities and negative predictive values 
for women tested before 35 weeks, declining at later gesta-
tions. For implementation into clinical practice for women 
presenting before 37 weeks’ gestation, an exploratory analysis 
determined that a PlGF threshold of <100 pg/mL predicted 
preeclampsia-D14 or before 37 weeks’ gestation (which-
ever was sooner) with sensitivity and negative predictive 
values similar to diagnostic accuracy estimates obtained by 
using a <5th centile cutoff (Table III in the online-only Data 
Supplement). Raw values of PlGF had higher ROC areas for 
determination of preeclampsia-D14 than PlGF categorized by 
centiles in women before 35 weeks’ gestation (Figure I in the 
online-only Data Supplement).
PlGF <5th centile also had good test accuracy for pre-
dicting subsequent delivery of a small for gestational age 
infant <1st centile (not restricted to diagnosis within 14 days 
of testing). The sensitivity of PlGF for determining pre-
eclampsia-D14 was similar if the infant was subsequently 
born appropriate-for-gestational age (before 35 weeks 0.94 
[0.71–0.99]; 35+0 to 36+6 weeks 0.88 [0.73–0.97]). There was 
no interaction between PlGF and small for gestational age as 
a predictor of preeclampsia-D14 on formal testing with the 
use of logistic regression.
For women presenting before 35 weeks’ gestation, there 
were 3 cases with false-negative results (≥5th centile), all with 
an additional indication for early delivery; 4 cases with PlGF 
<12 pg/mL were delivered after 37 weeks with severe pre-
eclampsia, 3 of whom delivered infants ≤5th customized birth-
weight centile, suggesting placental disease (Table 5). PlGF 
was <5th centile in all cases and <12 pg/mL in 4 of the 7 cases 
of antepartum fetal death (occurring after enrollment; Table 5). 
PlGF <5th centile predicted intrauterine fetal death with sen-
sitivity 1.00 (95% confidence interval, 0.71–1.00); specificity 
0.48 (0.44–0.52); positive predictive value 0.03 (0.02–0.05); 
negative predictive value 1.00 (0.99–1.00). In 5 cases, testing 
at enrollment predated Doppler ultrasound abnormalities by 7 
to 39 days and predated the stillbirth by 10 to 53 days.
The area under the ROC curve for low PlGF in predicting 
preeclampsia-D14 was greater than all other commonly used 
tests, either singly or in combination (P<0.001 for all compar-
isons; Figure 3). The addition of blood pressure or other blood 
tests currently used did not increase the ROC area further in 
comparison with PlGF alone. PlGF was a consistently good 
predictor of preeclampsia-D14 in women with and without ≥ 
1+ dipstick proteinuria. The times (in days) to delivery for the 
3 PlGF groups are presented for women with all diagnoses 
and for preeclampsia cases (Figure 4).
Table 5. False Negatives, Cases With Very Low PlGF and Term Delivery, and Antepartum Deaths in Women Presenting 
<35 Weeks’ Gestation
Subject Gestation (Sampling) Gestation (Delivery) [PlGF], pg/mL Birth Weight BW Centile
Final Adjudicated Diagnosis  
and Other Details
False negative (PlGF normal and delivered within 14 days of sampling with final diagnosis of preeclampsia)
A 28+2 29+5 1224 1330 29 Superimposed preeclampsia; SPPROM, 
spontaneous labor, cesarean delivery
B 29+6 30+0 160 1095 1 Atypical preeclampsia; reduced fetal 
movements and prelabor cesarean 
delivery
C 33+2 34+4 218 2020 5 Severe preeclampsia; previous history of 
early-onset preeclampsia
PlGF very low and not delivered preterm <37/40
D 33+6 37+5 <12 2900 34 Severe preeclampsia
E 34+1 38+1 <12 2350 3 Severe preeclampsia
F 34+2 37+0 <12 2310 5 Severe preeclampsia
G 34+2 37+2 <12 1805 0 Severe preeclampsia
Antepartum deaths
H 23+0 23+1 <12 374 0 Severe preeclampsia
I 25+3 26+6 <12 690 0.5 Severe preeclampsia with placental 
abruption
J 27+5 29+4 <12 570 0 Superimposed preeclampsia
K 28+0 30+2 59 480 0 Twin pregnancy; severe preeclampsia, 
and discordant FGR
L 28+0 35+4 17 2210 1.7 Chronic hypertension with increase 
in blood pressure; FGR not suspected 
antenatally
M 30+4 35+5 <12 2220 12 Chronic hypertension with placental 
abruption
N 33+2 38+6 39 1900 0 Gestational hypertension; FGR not 
suspected antenatally
BW indicates birth; FGR, fetal growth restriction; and SPPROM, spontaneous preterm prelabor rupture of membranes.
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For test reproducibility, 595 paired samples were measured 
both at the study site and at the central laboratory (30 results 
were unevaluable owing to error codes, or mismatched sam-
ple identifications). Four hundred twenty-five were in-range 
(between 12 and 3000 pg/mL) on both evaluations and had 
a Pearson correlation coefficient of 0.950. For all 595 PlGF 
test pairs (including out-of-range values), the Spearman (rank) 
correlation coefficient was 0.948. A Bland-Altman plot is pre-
sented in Figure II in the online-only Data Supplement. Of 
women evaluated, 85.4% would receive the same classifica-
tion in both laboratories; 11.1% moved between low and very 
low (in either direction), and a further 3.5% moved between 
low and normal. No woman moved between very low and nor-
mal. The sensitivity and specificity of the test in predicting the 
primary outcome were changed by <1% when 29 twin preg-
nancies were excluded. There were no adverse events associ-
ated with the collection of the blood necessary for performing 
PlGF testing.
Discussion
This study suggests that PlGF testing presents a realistic and 
innovative adjunct to the management of women with sus-
pected preeclampsia, especially those presenting preterm. 
Low PlGF concentration (<5th centile or ≤100 pg/mL) has 
high sensitivity and negative predictive value in determin-
ing which women presenting with suspected disease at <35 
weeks’ gestation are likely to need delivery for preeclampsia 
within 14 days. A previous review has highlighted the need 
for a test with high sensitivity in this setting, because there is 
greater preference for minimizing false negatives when con-
sidering overall benefits and harms and in ensuring appropri-
ate resource use.15 Time to delivery is markedly different for 
women with very low, low, and normal PlGF values, facilitat-
ing stratified management strategies with appropriate surveil-
lance. PlGF was more predictive of the need for delivery than 
other commonly used signs and tests, either singly or in com-
bination, in current clinical practice. Sensitivity and negative 
predictive values were also high for delivery of an small for 
gestational age infant <1st centile; this indicator is most likely 
to equate to fetal growth restriction of placental origin and 
to be associated with adverse perinatal outcomes. Although 
diagnostic accuracy is greatest for women presenting before 
35 weeks’ gestation, the test may still benefit those presenting 
up to 37 weeks’ gestation (using a threshold of <100 pg/mL) 
for whom stratified surveillance is also advantageous and the 
risks/benefits of delivery remain uncertain.
The strengths of this study include the use of multiple cen-
ters encompassing a wide demographic and ethnic profile and 
a pragmatic approach to enrollment with minimal exclusion 
criteria, enabling generalizability. The main research question 
was chosen to be clinically relevant, with the use of a primary 
outcome where delivery was indicated for the mother or infant, 
despite being preterm. Final diagnoses were independently 
adjudicated by 2 senior clinicians following database record 
review with the use of strict criteria. PlGF concentrations 
were not revealed until all diagnoses had been adjudicated, 
so that the test result could not influence decisions for deliv-
ery. Laboratory staff were also unaware of the diagnosis. The 
analysis followed prespecified methods and outcomes, with 
subsequent transparent evaluation of a single PlGF threshold 
(rather than using a variable 5th centile threshold dependent on 
gestational age) to enable easier adoption into clinical practice.
The optimal choice of primary outcome was difficult. When 
the study was planned, there was no validated composite mea-
sure of adverse outcome for women with preeclampsia. The 
fullPIERS model subsequently published used a composite 
outcome determined by iterative Delphi consensus16; com-
ponents of this composite (other than blood transfusion) are 
reported in our study. Maternal plasma PlGF normally declines 
in the latter part of the third trimester, reducing test perfor-
mance at >35 weeks’ gestation; an ideal test would maintain 
separation between preeclamptic cases and other women, 
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Figure 3. ROC areas (standard error) for PlGF compared with 
5 other signs/tests (systolic and diastolic blood pressure, uric 
acid, alanine transaminase, and proteinuria) in determining 
preeclampsia requiring delivery within 14 days in 176 women 
presenting before 35+0 weeks gestation with all tests measured 
using parameters singly (A) or in combination (B). ALT indicates 
alanine transaminase; DBP, diastolic blood pressure; PlGF, 
placental growth factor; ROC, receiver operating characteristics; 
and SBP, systolic blood pressure. 
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all gestations. More accurate determination of very low PlGF 
values (less than the current limit of detection of 12 pg/mL) 
could be useful; however, the high clinical sensitivity reported 
in this study relates to the prespecified threshold of <5th centile 
(low PlGF, or PlGF <100 pg/m:) rather than very low PlGF.
This is the largest, and the first prospective multicenter, 
study to evaluate PlGF in women with suspected preeclampsia. 
Other studies have evaluated PlGF and other factors includ-
ing soluble Flt-1 (sFlt-1; soluble fms-like tyrosine kinase-1), 
a trophoblast derived antiangiogenic factor that is increased in 
plasma from preeclamptic women. A case-control study7 and a 
small prospective observational study17 using the Triage assay 
reported promising test performance. A more recent study 
using a different assay for sflt-1/PlGF ratio (Elecsys platform, 
Roche, Penzburg, Germany) found considerably lower sensi-
tivity (0.73) and negative predictive value (0.87) at high speci-
ficity (0.94) in predicting maternal adverse outcome in women 
presenting at <34 weeks’ gestation,18 a level of sensitivity that 
is unlikely to be useful in clinical practice. Direct compari-
son of assays in 128 pregnant women (44 with preeclampsia) 
confirmed higher sensitivity of the Triage test than the sflt-1/ 
PlGF ratio (Elecsys) in diagnosing early-onset preeclampsia,19 
which may relate to different target epitopes of PlGF used in 
the Triage test. Other studies have not reported sensitivity and 
specificity (recommended measures of diagnostic accuracy), 
making direct comparison difficult,20,21 have compared assays 
in women with established disease22 or have tested at a fixed 
time point rather than at presentation.23,24
Suspected preeclampsia is the most frequent clinical pre-
sentation to obstetric day care assessment units, and those 
with early-onset disease are at the greatest risk. Current signs 
and tests do not perform well in predicting need for delivery 
or adverse outcomes.25–27 We hypothesize that adding PlGF 
measurement to current clinical assessment of women with 
All participants (n=287)














All pre-eclampsia cases (n=87)





Interval from test to delivery (days)
Figure 4. Time to delivery (median, IQR) stratified 
by PlGF concentration for all participants and for 
preeclampsia cases. Red line indicates very low 
PlGF (<12 pg/mL); orange line, low PlGF (<5th 
centile); green line, normal PlGF (≥5th centile). 
The numbers in the table below relate to the figure 
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suspected preeclampsia before 37 (and particularly before 35) 
weeks’ gestation could improve risk stratification, achieve an 
earlier diagnosis based on underlying pathophysiology, enable 
individualized management of women with the disease, with 
the potential to reduce associated maternal morbidity and 
unnecessary health service usage. There may be a double 
benefit: targeting of resources to those at highest risk, while 
minimizing excessive assessment and intervention in women 
at lower risk. One decision-analytic modeling analysis has 
estimated $1400 cost saving associated with the introduction 
of PlGF testing (based on a sensitivity of 0.82) for the man-
agement of pregnant women in a UK setting.28 Cost savings 
may be greater when the Triage platform has been adapted 
to test whole blood at the point-of-care. We would propose 
that further assessment of PlGF should be undertaken in the 
context of a randomized, controlled trial, as recommended for 
all new diagnostic tests, to measure the impact on the health 
of mother and infant through changing diagnostic/ treatment 
decisions, time to treatment, and potential harms, as well.29
Hypertensive disorders of pregnancy remain a challenge 
worldwide, as indicated by the recent Global Burden of 
Disease Study30 ;improved detection and management have 
also been strongly recommended for reduction of stillbirths.31 
Although current strategies focus on blood pressure measure-
ment and assessment of end-organ damage, this study pro-
vides evidence for the recently proposed concept that better 
diagnosis results from measuring secondary rather than ter-
tiary features of preeclampsia.32
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CLINICAL PERSPECTIVE
Current management of women who present with hypertension in pregnancy or other features of suspected preeclampsia is 
hampered by the use of signs (high blood pressure) or tests (proteinuria, abnormal platelets, uric acid, alanine transaminase) 
that reflect end-organ disease and are poorly predictive of subsequent adverse outcomes. In our study, we report the first pro-
spective multicenter study of a biomarker in which we evaluated the diagnostic accuracy of placental growth factor (PlGF) 
in women presenting with suspected preeclampsia between 20 and 41 weeks’ gestation. In women presenting before 35 
weeks, low PlGF (<5th centile) had high sensitivity (0.96; 95% confidence interval, 0.89–0.99) and negative predictive value 
(0.98; 0.93–0.995) in determining delivery for confirmed preeclampsia within 14 days. The area under the receiver operating 
characteristics curve for low PlGF (0.87, standard error 0.03) was greater than all other commonly used tests, singly or in 
combination (range, 0.58–0.76). Suspected preeclampsia is the most frequent clinical presentation to obstetric assessment 
units, and those with early-onset disease are at greatest risk. We hypothesize that adding the PlGF measurement to the current 
clinical assessment of women with suspected preeclampsia before 37 (and particularly before 35) weeks’ gestation could 
improve risk stratification, achieve an earlier diagnosis based on underlying pathophysiology, enable individualized manage-
ment of women with the disease, with the potential to reduce associated maternal morbidity and unnecessary health service 
usage. There may be double benefit: targeting of resources to those at highest risk, while minimizing excessive assessment 
and intervention in women at lower risk.
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Abstract  
Objectives: To assess the diagnostic accuracy of placental growth factor (PlGF) 
and ultrasound parameters to predict delivery of a small-for-gestational-age 
(SGA) infant in women presenting with reduced symphysis-fundal height (SFH).  
Methods: Multicentre, prospective observational study recruiting 601 women 
with singleton pregnancies and reduced SFH between 24-37 weeks’ gestation 
across 11 sites in UK and Canada. Plasma PlGF concentration <5th centile, 
estimated fetal weight (EFW) <10th centile, umbilical artery Doppler pulsatility 
index >95th centile and oligohydramnios (Amniotic Fluid Index <5cm) were 
compared as predictors for a SGA infant <3rd customised birth weight centile 
(SGA-3) and adverse perinatal outcome. Test performance statistics were 
calculated for all parameters in isolation and combination. 
Results: 592 women were analysed. For predicting delivery SGA-3 (n=78), 
EFW <10th centile had 58% sensitivity (95%CI 46 to 69%) and 93% negative 
predictive value (NPV) (95%CI 90 to 95%), PlGF had 37% sensitivity (95%CI 27 
to 49%) and 90% NPV (95%CI 87 to 93%); in combination, PlGF and EFW 
<10th centile had 69% sensitivity (95%CI 55 to 81%) and 93% NPV (95%CI 89 
to 96%). The equivalent ROC areas were 0.79 (95%CI 0.74 to 0.84) for EFW 
<10th centile, 0.70 (95%CI 0.63 to 0.77) for low PlGF and 0.82 (95%CI 0.77 to 
0.86) in combination. 
Conclusions: In women presenting with reduced SFH, ultrasound parameters 
had modest test performance for predicting delivery of SGA-3. PlGF performed 
no better than EFW <10th centile in determining delivery of a SGA infant.   
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Introduction 
Fetal growth restriction (FGR) is a failure to fulfill growth potential, associated 
with increased risk of stillbirth1, neonatal morbidity2, 3 and mortality4-7. 
Complications can extend into adult life, with greater risk of cardiovascular 
disease and type 2 diabetes mellitus8. Evaluation of birth weight centile 
identifies small for gestational age (SGA) infants (typically defined as birth 
weight below the 3rd or 10th birth weight centile); these include constitutionally 
small infants and those with FGR, and as a group these pregnancies are at 
increased risk of adverse neonatal outcome9. 
Identifying the SGA infant remains challenging in the low-risk population, relying 
on imprecise techniques such as SFH measurement10. If SGA is suspected, UK 
national guidance recommends ultrasound measured abdominal circumference 
(AC) or estimated fetal weight (EFW) <10th centile to diagnose an SGA fetus11, 
12. However, a large proportion of SGA infants are not detected antenatally 
(32% of 215 high-risk women1 and 82% of 195 stillbirths with SGA13).  
UK national guidance11 does not advocate routine ultrasound measurement in 
the third trimester as a screening tool for SGA, due to poor prediction 
(sensitivity 38-51%)14-17 and no evidence of improved neonatal outcome18. 
However, preliminary results from a recent large prospective cohort study 
reported increased sensitivity of screening (79%) vs. selective (32%) 
sonography in the third trimester in an unselected nulliparous population for 
prediction of severe SGA19.  
Whilst the pathophysiology of FGR is multifactorial, placental insufficiency is 
causative in many cases. Markers of placental function could provide adjuncts 
to current techniques to identify high-risk pregnancies. Multiple biomarkers have 
been proposed to aid detection but none have sufficient accuracy for 
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incorporation into clinical practice20. However, low maternal Placental Growth 
Factor (PlGF) concentrations can distinguish placental SGA from 
constitutionally small fetuses (sensitivity 100%; specificity 86%)21 and in a high-
risk cohort with suspected preterm pre-eclampsia can predict pre-eclampsia 
and delivery of an SGA infant (birth weight <1st centile) with high sensitivity22. 
We performed a large, prospective, multicentre, cohort study in women with 
suspected SGA (reduced SFH measurement) with the aim of assessing the 
diagnostic accuracy of PlGF and ultrasound parameters to predict delivery of an 




Participants and sampling: 
Women were enrolled from eleven consultant-led units across the United 
Kingdom and Canada between December 2011 and July 2013 (approximate 
number of deliveries per year: St Thomas’ Hospital London: 6650; St Marys’ 
Hospital Manchester: 8200; Oxford: 6550; Leeds: 9550; Sheffield: 7000; St 
Georges’ Hospital London: 4950; St Michael’s Hospital Bristol: 5500; Lewisham: 
4000; West Middlesex Hospital: 4700; Sunderland: 3200; Vancouver, Canada; 
7000). Local audit data at St Thomas’ Hospital London in the year prior to the 
study starting (2011) showed that approximately 1300 women were referred 
with reduced symphysis fundal height measurement; of these women, 8% 
delivered an SGA infant with customised birth weight less than the 3rd centile for 
gestational age. Ethical approval was granted by East London Research Ethics 
Committee (ref. 10/H0701/117).  
Women were eligible if they were aged 16 years or over, with a singleton 
pregnancy, between 24+0 and 36+6 weeks’ gestation and referred with 
suspected SGA by either: 1) SFH measuring more than 2 cm (i.e. 3 cm or more) 
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under that expected for any given gestational age in completed weeks (e.g. 
measuring 33cm or less at 36 weeks’ gestation) or 2) SFH < 10th centile on 
customised SFH chart. Women with with multiple pregnancies, SGA already 
confirmed (EFW <10th customised centile), major fetal anomaly (fetal 
malformations that affect viability and/ or the quality of life of the fetus and 
require intervention23) or confirmed rupture of amniotic membranes were 
excluded.  
Written informed consent was obtained from participants. A study specific 
database was designed and finalised prior to recruitment of the first participant. 
On the same day as the ultrasound scan, baseline demographic and pregnancy 
specific data were entered into the database and PlGF testing was performed. 
Blood was drawn into ethylenediamine tetra-acetic acid and labeled with a 
study-specific coded identifier. Samples were transported to the laboratory at 
the recruiting site and spun for 10 minutes at 3000 rpm. Plasma was extracted 
from each sample and stored at -80˚C until analysis. All samples were analysed 
for PlGF at the recruiting site using the Triage®
 
PlGF Test (Alere, San Diego, 
CA) according to manufacturer’s instructions. All laboratory staff received 
standardised training in sample processing delivered by the study monitor. All 
meters were programmed to produce a masked result, determining satisfactory 
test completion only, without revealing the value. All laboratory staff were 
masked to the clinical diagnosis. The assay uses fluorescently-labeled 
recombinant murine monoclonal antibodies and detects PlGF specifically and 
quantitatively, in the range of 12-3000 pg/mL, in approximately 15 minutes. The 
lower limit of detection of the assay is 12 pg/mL and PlGF results were 
classified as normal (PlGF ≥ 5th centile for gestational age), low (<5th centile) 
and very low (<12 pg/mL). To determine assay reproducibility, replicate 
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samples were also tested at a central laboratory. The Total Precision 
(coefficient of variation) on plasma controls at concentrations of 85 pg/mL and 
1300 pg/mL was 12.8% and 13.2%, respectively.  
All case outcomes were adjudicated by two independent senior physicians, 
without knowledge of PlGF concentrations. SGA was defined as delivery of an 
infant with a birth weight less than the 3rd (or 10th, as a secondary analysis) 
customised birth weight centile calculated using the Gestation Related Optimal 
Weight (GROW) method software24. A final maternal diagnosis was assigned 
using definitions from the American College of Obstetricians and Gynecologists’ 
practice bulletin for maternal hypertensive disorders 25 and the International and 
Australasian Societies for the Study of Hypertension in Pregnancy for atypical 
pre-eclampsia, as predefined in the study protocol 26. 
Any hospital attendances subsequent to enrolment were recorded in the study 
database, including repeat ultrasound assessments, details of delivery and 
adverse maternal and perinatal outcomes. Adverse maternal outcome was 
predefined as the presence of any of the following complications: maternal 
death, eclampsia, stroke, cortical blindness or retinal detachment, hypertensive 
encephalopathy, systolic blood pressure ≥160mmHg, myocardial infarction, 
intubation (other than for caesarean section), pulmonary oedema, platelets 
<50×109/l (without transfusion), disseminated intravascular coagulation, 
thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome, hepatic 
dysfunction (alanine transaminase ≥70iu/l), hepatic haematoma or rupture, 
acute fatty liver of pregnancy, creatinine >150 µmol/l, renal dialysis, placental 
abruption, major postpartum haemorrhage, major infection. Adverse perinatal 
outcome was defined as presence of any of the following complications: 
antepartum/ intrapartum fetal or neonatal death, neonatal unit admission for >48 
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hrs at term, intraventricular haemorrhage, periventricular leucomalacia, seizure, 
retinopathy of prematurity, respiratory distress syndrome, bronchopulmonary 
dysplasia or necrotising enterocolitis. An independent data monitor conducted 
regular data monitoring at all sites. 
Sample size and power:  
The study was powered on the basis of the number of cases needed to reliably 
distinguish good (80%) from moderate (60%) sensitivity. 55 cases were needed 
for 90% power and 5% significance. This number was met for all endpoints by 
recruiting 601 women, giving 78 cases of SGA <3rd birth weight centile.   
Statistical analysis: 
The predefined primary outcome (reference standard) was delivery of a SGA 
infant < 3rd customised birth weight centile, calculated using version 6.7 of 
Gestation Related Optimal Weight (GROW) calculator. SGA < 10th centile, and 
adverse perinatal outcomes were considered as secondary outcomes.  
Gestational-adjusted centiles for PlGF from a large low-risk antenatal population 
were used.27 An abnormal result was taken as maternal PlGF concentration 
below the 5th centile, as this has previously been shown to offer a combination 
of high sensitivity and acceptable specificity for pre-eclampsia and SGA, with a 
high negative predictive value.22 PlGF and three ultrasound parameters (EFW 
<10th centile, oligohydramnios, defined as an amniotic fluid index <5 cm and 
umbilical artery Doppler pulsatility index >95th centile) were compared, both in 
isolation and in combination, as predictors of delivery of an SGA infant <3rd and 
<10th customised centiles. Gestation adjusted centiles were calculated for each 
observed value of umbilical artery Doppler pulsatility index (UAPI) based on a 
mean value of 0.405 -0.0134 x gestational age in weeks’, and a standard 
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deviation of 0.0794 for the log10 UAPI 28. Sensitivity, specificity and positive and 
negative predictive values were calculated with 95% confidence intervals. 
Receiver operator characteristic (ROC) curve areas were also calculated for 
each individual parameter and combinations, and in a pre-defined subgroup 
who delivered within six weeks of PlGF sampling. Fisher’s exact test was used 
to compare the event rate in women with normal and low PlGF measurements. 
Statistical analysis was carried out in the Stata statistical package (version 11.2, 
StataCorp, College Station, Texas, USA).  
This study is reported in accordance with the STAndards for the Reporting of 




601 women presenting with suspected SGA between 24+0 and 36+6 weeks’ 
gestation were recruited across 11 sites between December 2011 and July 
2013. We recruited all women who were approached, eligible and consented 
but did not document women who declined to participate. No outcome data 
were available for two participants and five women did not have PlGF results 
generated by the test meter. A further two women had no ultrasound data at 
enrolment available. After exclusion of these nine cases, 592 women were 
included in this analysis. Of these women, 192 delivered an SGA infant with 
birth weight <10th customised centile and 78 had a birth weight <3rd customised 
centile (Figure 1). 
Characteristics of participants at booking are given in Table 1; higher rates of 
smoking were observed in women who delivered an SGA infant. Table 2 
displays baseline characteristics at study enrolment. Details of maternal and 
neonatal outcomes and final adjudicated maternal diagnoses are shown in 
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Table 3. The majority of women (n=555) experienced no maternal complications 
during their pregnancy. Whilst the number of cases complicated by pre-
eclampsia was small (n=16) most of these women delivered an SGA infant 
(n=12). Of 13 cases with adverse perinatal outcome there was one stillbirth, 
four cases of respiratory distress syndrome and nine infants admitted to the 
Neonatal Unit at term for greater than 48 hrs. 
Induction of labour and caesarean section occurred more frequently in 
pregnancies delivering an SGA infant, compared to those with birth weights 
appropriate for gestational age. Maternal and perinatal adverse outcomes were 
reported in 3.2% and 2.2% of women and infants respectively. Both 
complications were higher in pregnancies with delivery of an SGA infant (4.7% 
and 3.1% respectively).  
The median concentration of PlGF according to birth weight was 94.5 pg/ml 
(Interquartile Range (IQR) 36.3 to 324 pg/ml) for SGA <3rd centile, 253 pg/ml 
(IQR 125 to 631 pg/ml) for SGA <10th centile and 311 pg/ml (IQR 131 to 742 
pg/ml) for birth weight ≥ 10th centile. The diagnostic accuracy of PlGF and 
ultrasound parameters to determine SGA <3rd and <10th centile are shown in 
Table 4, with EFW having the highest sensitivity and negative predictive value 
of all parameters assessed. Addition of PlGF to currently utilised ultrasound 
parameters altered test sensitivity from 58% to 69% (NPV 93 to 93%) in 
determining SGA <3rd centile and from 47% to 57% (NPV 77 to 78%) in 
determining SGA <10th centile. For women presenting prior to 37 weeks’ 
gestation in whom EFW was measured as ≥10th centile, low PlGF 
concentrations at the time of scanning (<5th centile) would have detected an 
additional nine women with subsequent SGA <3rd centile. This difference in 
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SGA <3rd centile between those with normal PlGF (5.9%; 23/390) compared to 
those with low PlGF (20.5%; 9/44) is significant (p=0.002 by Fisher’s exact test). 
In the whole cohort, the ROC area was higher for EFW <10th centile (0.79; 95% 
CI 0.74 to 0.84) than for low PlGF (0.70; 95% CI 0.63 to 0.77) for prediction of 
SGA < 3rd centile; in combination this increased to 0.82 (95% CI 0.77 to 0.86) 
(Figure 2A). In a planned subgroup analysis of 267 women where delivery 
occurred within six weeks of PlGF sampling (Table S2), ROC areas were 0.76 
(95% CI 0.69 to 0.84) 0.74 (95% CI 0.66 to 0.83) and 0.81 (95% CI 0.72 to 
0.88) for EFW <10th centile, low PlGF and a combination of both parameters 
respectively (Figure 2B).  
The outcomes of 16 participants with a very low PlGF concentration (<12 pg/ml, 
lower level of assay detection) at enrolment, are shown in Table S3. Seven 
women had hypertensive complications of pregnancy (7/16; (44%) versus 
17/577; (3%) in the rest of the cohort) and 11 women delivered an SGA infant 
with birth weight <10th customised centile. 





In this multicentre, prospective cohort study of women presenting with reduced 
SFH measurement, currently utilised ultrasound parameters including EFW 
<10th centile had modest test performance for predicting delivery of an SGA 
infant. Maternal PlGF measurement performed no better than these ultrasound 
parameters and provided only minimal increments in overall test performance 
when used in combination. This contrasts with the findings of our previous 
study, assessing the diagnostic accuracy of PlGF in women with suspected pre-
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eclampsia, which reported excellent performance of PlGF (sensitivity 93% and 
NPV 96%) in predicting SGA in women presenting before 35 weeks’ 
gestation22.  
There are several possible explanations for differences observed in these 
studies. The majority of women recruited to this study reported here had no 
maternal complications of pregnancy (556/592; 93%) and only 24 (4%) had a 
hypertensive disorder. This contrasts with our previous high-risk cohort, where 
61% of women enrolled before 35 weeks’ gestation developed pre-eclampsia22. 
Differing pathological processes may occur in the placentas of pregnancies 
complicated by hypertensive disease, particularly if early onset, and those who 
remain normotensive but deliver an SGA infant29. The gestation at delivery of 
SGA infants <3rd centile in this study was 38.7 weeks (with 5% adverse 
perinatal outcome), compared to 33.8 weeks (with 39% adverse perinatal 
outcome) in the previous study, emphasizing the likely different placental 
pathophysiology. The average gestational age was 34 weeks at PlGF sampling 
and 40 weeks at delivery. PlGF appears to have limited clinical utility in women 
presenting late in pregnancy and delivering near term. This may reflect 
convergence of PlGF measurements between normal and pathological 
pregnancies with advancing gestation27 and the heterogeneous aetiology of 
SGA even when categorised as birth weight <3rd customised centile. PlGF is an 
angiogenic factor produced principally by trophoblast cells. Low maternal 
plasma PlGF concentrations reflect placental dysfunction and have been 
described in early onset pre-eclampsia and SGA associated with abnormal 
placental pathology21. 
It is particularly notable that adverse perinatal outcome occurred infrequently 
(2.2%) in this study; this makes conclusions regarding the ability of PlGF to 
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determine adverse outcomes impossible. The single case of stillbirth had 
normal PlGF concentration and was not SGA, therefore placental insufficiency 
is an unlikely aetiology. The neonatal characteristics (Table 3) are markedly 
different to that described in the previous PlGF study, in which nine (2.1%) 
cases of stillbirth/neonatal death were reported with adverse perinatal outcome 
in 19%22. 
This is the largest reported prospective study evaluating the ability of third 
trimester PlGF to predict delivery of an SGA infant in women presenting with 
reduced SFH. Recruitment from 11 centres across the UK and Canada 
provided a diverse ethnic and geographical population. PlGF was measured at 
the recruiting site, as would occur if adopted into clinical practice. PlGF results 
were concealed until assignment of a final maternal diagnosis at study 
completion. The study entry criterion, reduced SFH, was selected for clinical 
relevance, reflecting current referral practice in the UK. A primary endpoint of 
delivering an infant < 3rd customised birth weight centile was selected as it 
includes fewer constitutionally small infants and has a stronger association with 
perinatal mortality7.  
This study only included PlGF measurement at study enrolment. Serial 
measurements to assess whether longitudinal changes in PlGF correlate with 
evolving placental dysfunction could be informative. Where routine antenatal 
third trimester ultrasound in low risk women is performed, the findings of this 
study may be less applicable. 
A systematic review evaluating biomarkers for predicting FGR identified 13 
studies that reported test performance for PlGF in predicting delivery of an SGA 
infant20. In a subgroup of studies recruiting women after 20 weeks’ gestation, 
the pooled PlGF sensitivity (at various thresholds) for prediction of intrauterine 
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growth restriction (by differing definitions) was 49% (95% CI 44-53%). 
Comparisons were difficult due to heterogeneity between studies. The majority 
were case-control studies with only two cohort studies recruiting women over 20 
weeks’ gestation. Of these, one was in an abnormal population (abnormal 
uterine artery Doppler waveforms at 20 weeks’ gestation) while in the other, 
delivery of an SGA infant was a secondary endpoint. No cohort studies 
recruiting in the third trimester were evaluated. A recent study evaluated 
maternal PlGF concentration at a fixed time point (30-34 weeks’ gestation) and 
reported increased adjusted odds ratio for PlGF combined with other 
angiogenic factors in prediction of delivering an SGA infant but did not provide 
test performance statistics to enable comparison30. 
The capabilities of current standard ultrasound parameters to determine 
delivery of an SGA infant must also be considered. A large study published a 
sensitivity of 27% for SFH measurement to predict delivery of an SGA infant10. 
Reported test performance of EFW <10th centile to predict pregnancies 
delivering an SGA infant (sensitivity 21-46%; NPV 90-94%)14, 17. are similar to 
those published in this cohort (sensitivity 48%; NPV 77%). Three Cochrane 
systematic reviews evaluating SFH31, routine ultrasound measurement 
(including EFW)18 and fetal and umbilical artery doppler assessment in low-risk 
pregnancy32 concluded that none of these techniques reduced adverse 
perinatal outcome. Use of customised SFH charts and EFW centiles, which 
adjust for maternal characteristics, may improve SGA detection33, prediction of 
delivering an SGA infant13, 34 and adverse outcome, including stillbirth35 and 
neonatal death36. Implementation of customised charts in conjunction with 
accredited training is associated with reduction in stillbirth rates in areas of high 
uptake37 but has not been validated in a randomised control trial.   
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A systematic review and meta-analysis assessing amniotic fluid index reported 
strong correlation between oligohydramnios and delivering an SGA infant (birth 
weight <10th centile) and mortality but the predictive accuracy for perinatal 
outcome was poor38. This agrees with our findings of high specificity for delivery 
of an SGA infant (99.6%, 95%CI 97.6-100%) but low sensitivity (3.4% 95% CI 
0.9-8.5%), limiting clinical application without incorporating other clinical factors. 
Novel ultrasound parameters such as the cerebroplacental ratio have been 
reported as potentially useful in predicting neonatal unit admission and 
validation is awaited39.   
We previously suggested PlGF measurement as a useful adjunct to current 
clinical practice in women with suspected preterm pre-eclampsia, but the 
findings from this study cannot support its use in women with reduced SFH. 
Whilst EFW < 10th centile has only modest test performance for prediction of 
SGA, addition of PlGF measurement does not significantly improve test 
performance. This study highlights the need for caution in generalising findings 
from one population to another and alerts against overenthusiastic adoption of 
novel biomarkers without appropriate evaluation. 
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Table 1: Characteristics of participants at booking. Values given are median 
(quartiles) or n (%) as appropriate.  













    
Age (years) 29.1  
(24.1 to 32.9) 
29.6  
(24.8 to 33.5) 
30.0  
(25.3 to 33.7) 
29.9  
(25.2 to 33.6) 




(20.3 to 25.2) 
21.7  
(20.1 to 24.1) 
21.5  
(20.0 to 23.4) 
21.5  
(20.0 to 23.6) 
White ethnicity 52 (66.7) 122 (63.5) 266 (66.5) 388 (65.5) 





(100 to 114) 
105  
(100 to 114) 
104  
(100 to 112) 
105  





(60 to 70) 
62  
(60 to 70) 
60  
(60 to 69) 
61  
(60 to 70) 
Smoking status     
Never smoked 46 (59) 128 (66.7) 306 (76.5) 434 (73.3) 
Quit smoking 
before pregnancy 
9 (11.5) 22 (11.5) 31 (7.8) 53 (8.9) 
Quit smoking 10 (12.8) 16 (8.3) 24 (6.0) 40 (6.7) 
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during pregnancy 
Current smoker 13 (16.7) 26 (13.5) 39 (9.8) 65 (11.0) 
Drug use     
History of drug 
use*  
5 (6.4) 6 (3.1) 3 (0.8) 9 (1.5) 
Current drug user 
† 
1 (1.3) 2 (1.0) 0 (0.0) 2 (0.3) 
Previous 
medical history 




0 (0) 0 (0) 1 (0.3) 1 (0.2) 
Chronic 
hypertension 
0 (0) 1 (0.5) 1 (0.3) 2 (0.3) 
SLE/ APS 1 (1.3) 1 (0.5) 0 (0) 1 (0.2) 
Pre-existing 
diabetes mellitus  
0 (0) 0 (0) 1 (0.3) 1 (0.2) 




9 (11.5) 22 (11.5) 27 (6.8) 49 (8.3) 
BP, blood pressure, SLE/ APS, Systemic lupus erythematosus/ anti-
phospholipid syndrome 
*Drugs used before pregnancy: include cannabis, cocaine, ecstasy, 
amphetamines (speed, crystal meth) and heroin. 
†Drugs used during pregnancy: Cannabis only (rare or occasional)  
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Table 2: Baseline characteristics of participants at study enrolment. Values 
given are median (quartiles) or n (%) as appropriate.  
















(221 to 250) 
235 
(213 to 250) 
236  
(214 to 250) 
236  
(213 to 250) 
Maternal BP     





(102 to 121) 
110 




BP (mmHg)  
70 
(60 to 81) 
70 
(60 to 80) 
67 
(60 to 73) 
68 
(60 to 74) 
Dipstick 
proteinuria 
    
Not done 11 (14.1) 29 (15.1) 61 (15.3) 90 (15.2) 
Negative 58 (74.4) 148 (77.1) 322 (80.5) 470 (79.4) 
Present (+1 or 
greater) 
9 (11.5) 15 (7.8) 17 (4.3) 32 (5.4) 
Complications in 
current pregnancy 
    
Gestational 
hypertension 
4 (5.1) 4 (2.1) 0 (0) 4 (0.7) 
Pre-eclampsia 0 (0) 1 (0.5) 1 (0.3) 2 (0.3) 










0 (0.0) 1 (0.5) 2 (0.5) 3 (0.5) 
Fetal      
EFW < 10th centile 44 (57.9) 88 (47.1) 64 (16.3) 152 (25.9) 
Oligohydramnios 
































Table 3: Characteristics of delivery and maternal and neonatal outcome. Values 
given are median (quartiles) or n (%) as appropriate.  
 













at delivery (weeks) 
38.7 
(37.1 to 40.1) 
39.4 
(38.0 to 40.4) 
40.0 
(39.0 to 40.9) 
39.9 
(38.9 to 40.7) 
Maternal 
diagnosis 
    
No new maternal 
disease in 
pregnancy 
68 (86.3) 173 (89.2) 382 (95.5) 555 (93.4) 
Pre-eclampsia 8 (10.0) 12 (6.2) 4 (0.99) 16 (2.7) 
Gestational 
hypertension 
0 (0) 0 (0) 8 (1.9) 8 (1.3) 
Chronic 
hypertension 
0 (0) 2 (1.0) 0 (0) 2 (0.3) 
Other diagnosis 2 (2.5) 5 (2.6) 6 (1.5) 11 (1.8) 
Maternal 
medications 
    
Dexamethasone 5 (6.4) 7 (3.6) 4 (1.0) 11 (1.8) 
Betamethasone 2 (2.6) 4 (2.1) 0 (0) 4 (0.7) 
Methyldopa 2 (2.6) 2 (1.0) 0 (0) 2 (0.3) 
Labetalol 6 (7.7) 9 (4.7) 2 (0.5) 11 (1.8) 
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Heparin 1 (1.3) 2 (1.0) 3 (0.8) 5 (0.8) 
Nifedipine 1 (1.3) 2 (1.0) 1 (0.3) 3 (0.5) 
Aspirin 3 (3.8) 4 (2.1) 8 (2.0) 12 (2.0) 
Oral 
corticosteroids 
0 (0) 3 (1.6) 2 (0.5) 5 (0.8) 
Onset of labour     
Spontaneous 24 (30.8) 99 (51.6) 300 (75.0) 399 (67.4) 
Induced 41 (52.6) 67 (34.9) 66 (16.5) 133 (22.5) 
Pre-labour 
caesarean section 
13 (16.7) 26 (13.5) 34 (8.5) 60 (10.1) 
Mode of delivery     
Spontaneous 48 (61.5) 125 (65.1) 279 (69.8) 404 (68.2) 
Assisted vaginal 
delivery 
8 (10.3) 23 (12.0) 66 (16.5) 89 (15.0) 
Caesarean section 22 (28.2) 44 (22.9) 55 (13.8) 99 (16.7) 
Adverse maternal 
outcome ‡ 
5 (6.4) 9 (4.7) 10 (2.5) 19 (3.2) 
Postpartum 
haemorrhage 
2 (2.6) 5 (2.6) 7 (1.8) 12 (2.0) 
Abruption 1 (1.3) 1 (0.5) 1 (0.3) 2 (0.3) 
HELLP 0 (0) 0 (0) 1 (0.3) 1 (0.2) 
Fetal      
Fetal death 0 (0) 0 (0) 1 (0.3) 1 (0.2) 












2610) 2854) 3470) 3329) 
Adverse perinatal 
outcome § 
4 (5.1) 6 (3.1) 7 (1.8) 13 (2.2) 
 
HELLP, haemolysis, elevated liver enzymes, low platelets. 
‡ Adverse maternal outcome defined as presence of any of the following 
complications: Maternal death, Eclampsia, Stroke, Cortical blindness or retinal 
detachment, Hypertensive encephalopathy, Systolic blood pressure 
≥160mmHg, Myocardial infarction, Intubation (other than for caesarean section), 
Pulmonary oedema, Platelets <50×109/L (without transfusion), Disseminated 
intravascular coagulation, Thrombotic thrombocytopenic purpura/ haemolytic 
uraemic syndrome, Hepatic Dysfunction (Alanine transaminase ≥70IU/L), 
Hepatic haematoma or rupture, Acute fatty liver of pregnancy, Creatinine >150 
µmol/L, Renal dialysis, Placental abruption, Major postpartum haemorrhage, 
Major infection. 
§ Adverse perinatal outcome defined as presence of any of the following 
complications: Antepartum/ intrapartum fetal or neonatal death, Neonatal unit 
admission for >48 hrs at term, Intraventricular haemorrhage, Periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis.  
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Table 4: Test performance statistics for PlGF and ultrasound parameters (with 




(95% CI)  
n/N 
Specificity % 
(95% CI)  
n/N 
PPV %  
(95% CI) n/N 
NPV %  
(95% CI)  
n/N 
SGA <3rd centile     
EFW <10th centile 57.9 
(46.0 to 69.1) 
44/76 
78.8 
(75.0 to 82.3) 
402/510 
28.9 
(21.9 to 36.8) 
44/152 
92.6 
(89.8 to 94.9) 
402/434 
Oligohydramnios  
(AFI < 5 cm) 
3.7 
(0.5 to 12.7) 
2/54 
99.0 
(97.0 to 99.8) 
289/292 
40.0 
(5.3 to 85.3) 
2/5 
84.8 
(80.5 to 88.4) 
289/341 
Umbilical artery 
Doppler PI >95th 
centile 
16.4 
(8.2 to 28.1) 
10/61 
96.0 
(93.5 to 97.7) 
381/395 
38.5 
(20.2 to 59.4) 
10/26 
88.2 
(84.8 to 91.1) 
381/432 
PlGF <5th centile 37.2 
(26.5 to 48.9) 
29/78 
88.7 
(85.7 to 91.3) 
456/514 
33.3 
(23.6 to 44.3) 
29/87 
90.3 
(87.4 to 92.7) 
456/505 
Combinations     
Abnormal AFI or 
EFW 
57.7 
(43.2 to 71.3) 
30/52 
79.0 
(73.9 to 83.6) 
230/291 
33.0 
(23.5 to 43.6) 
30/91 
91.3 
(87.1 to 94.4) 
230/252 
Abnormal PlGF or 
AFI or EFW 
69.2 
(54.9 to 81.3) 
36/52 
72.2 
(66.6 to 77.2) 
210/291 
30.8 
(22.6 to 40.0) 
36/117 
92.9 
(88.8 to 95.9) 
210/226 
SGA <10th centile     
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EFW <10th centile 47.1 
(39.7 to 54.5) 
88/187 
84.0 
(80.0 to 87.4) 
335/399 
57.9 
(49.6 to 65.8) 
88/152 
77.2 
(72.9 to 81.1) 
335/434 
Oligohydramnios  
(AFI <5 cm) 
3.4 
 (0.9 to 8.5) 
4/118 
99.6 
(97.6 to 100) 
227/228 
80.0 
(28.4 to 99.5) 
4/5 
66.6 
(61.3 to 71.6) 
227/341 
Umbilical artery 
Doppler PI >95th 
centile  §§ 
8.2 
(4.3 to 13.8) 
12/147 
95.5 
(92.6 to 97.5) 
297/311 
46.2 
(26.6 to 66.6) 
12/26 
68.8 
(64.1 to 73.1) 
297/432 
PlGF <5th centile 24.5 
(18.6 to 31.2) 
47/192 
90.0 
(86.6 to 92.8) 
360/400 
54.0 
(43.0 to 64.8) 
47/87 
71.3 
(67.1 to 75.2) 
360/505 
Combinations     
Abnormal AFI or 
EFW 
48.7 
(39.3 to 58.2) 
56/115 
84.6 
(79.3 to 89.1) 
193/228 
61.5 
(50.8 to 71.6) 
56/91 
76.6 
(70.9 to 81.7) 
193/252 
Abnormal PlGF or 
AFI or EFW 
57.4 
(47.8 to 66.6) 
66/115 
77.6 
(71.7 to 82.9) 
177/228 
56.4 
(46.9 to 65.6) 
66/117 
78.3 
(72.4 to 83.5) 
177/226 
EFW, Estimated fetal weight <10th centile; PI, pulsatility index; PlGF, placental 
growth factor 
Footnote: AFI and umbilical artery Doppler were not recorded for all subjects 
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1 Identify the article as a study of diagnostic 
accuracy (recommend MeSH heading 
'sensitivity and specificity'). 
Title page 1 
INTRODUCTION 2 State the research questions or study aims, 
such as estimating diagnostic accuracy or 
comparing accuracy between tests or across 
participant groups. 
Page 7 
METHODS    
Participants 3 The study population: The inclusion and 
exclusion criteria, setting and locations where 
data were collected. 
Page 7&8 
 4 Participant recruitment: Was recruitment based 
on presenting symptoms, results from previous 
tests, or the fact that the participants had 
received the index tests or the reference 
standard? 
Page 5 
 5 Participant sampling: Was the study population 
a consecutive series of participants defined by 
the selection criteria in item 3 and 4? If not, 




 6 Data collection: Was data collection planned 
before the index test and reference standard 
were performed (prospective study) or after 
(retrospective study)? 
Page 5 
Test methods 7 The reference standard and its rationale. Pages 6 & 
7 
 8 Technical specifications of material and 
methods involved including how and when 
measurements were taken, and/or cite 
references for index tests and reference 
standard. 
Pages 8&9 
 9 Definition of and rationale for the units, cut-offs 
and/or categories of the results of the index 
tests and the reference standard. 
Pages 8&9 
 10 The number, training and expertise of the 
persons executing and reading the index tests 
and the reference standard. 
Page 8 
 11 Whether or not the readers of the index tests 
and reference standard were blind (masked) to 
the results of the other test and describe any 





12 Methods for calculating or comparing measures 
of diagnostic accuracy, and the statistical 
methods used to quantify uncertainty (e.g. 95% 
confidence intervals). 
Page 10 




RESULTS    
Participants 14 When study was performed, including beginning 
and end dates of recruitment. 
Page 12 
 15 Clinical and demographic characteristics of the 
study population (at least information on age, 
gender, spectrum of presenting symptoms). 
Table 1 
 16 The number of participants satisfying the criteria 
for inclusion who did or did not undergo the 
index tests and/or the reference standard; 
describe why participants failed to undergo 
either test (a flow diagram is strongly 
recommended). 
Figure 1 
Test results 17 Time-interval between the index tests and the 
reference standard, and any treatment 
administered in between. 
Tables 2 & 
3 
 18 Distribution of severity of disease (define 
criteria) in those with the target condition; other 
diagnoses in participants without the target 
condition. 
Table 3 
 19 A cross tabulation of the results of the index 
tests (including indeterminate and missing 
results) by the results of the reference standard; 
for continuous results, the distribution of the test 




 20 Any adverse events from performing the index 





Estimates 21 Estimates of diagnostic accuracy and measures 
of statistical uncertainty (e.g. 95% confidence 
intervals). 
Table 4 and 
figure 2 
 22 How indeterminate results, missing data and 
outliers of the index tests were handled. 
Figure 1 
 23 Estimates of variability of diagnostic accuracy 
between subgroups of participants, readers or 
centers, if done. 
Not 
applicable 
 24 Estimates of test reproducibility, if done.      Page 9 





Table S2: Test performance statistics for PlGF and ultrasound parameters (with 
95% confidence intervals) to predict SGA <3rd centile when PlGF sampled 




(95% CI) n/N 
Specificity % 
(95% CI) n/N 
PPV %  
(95% CI) n/N 
NPV %  




(46.5 to 76.2) 
28/45 
73.0 
(66.6 to 78.7) 
162/221 
31.8 
(22.3 to 42.6) 
28/88 
90.5 
(85.2 to 94.4) 
162/179 
Oligohydramnios  
(AFI < 5 cm) 
5.9 
(0.7 to 19.7) 
2/34 
97.7 
(93.4 to 99.5) 
126/129 
40.0 
(5.3 to 85.3) 
2/5 
79.7 
(72.6 to 85.7) 
126/158 
Umbilical artery 
Doppler PI >95th 
centile 
22.2 
(10.1 to 39.2) 
8/36 
96.0 
(91.9 to 98.4) 
167/174 
53.3 
(26.6 to 78.7) 
8/15 
85.6 
(79.9 to 90.2) 
167/195 
PlGF < 5th 
centile 
42.2 
(27.7 to 57.8) 
19/45 
86.6 
(81.4 to 90.8) 
194/224 
38.8 
(25.2 to 53.8) 
19/49 
88.2 
(83.2 to 92.1) 
194/220 
Combinations  
Abnormal AFI or 
EFW 
62.5 
(43.7 to 78.9) 
20/32 
67.2 
(58.3 to 75.2) 
86/128 
32.3 
(20.9 to 45.3) 
20/62 
87.8 
(79.6 to 93.5) 
86/98 
Abnormal PlGF 
or AFI or EFW 
70.0 
(50.6 to 85.3) 
21/30 
58.3 
(49.2 to 67.0) 
74/127 
28.4 
(18.5 to 40.1) 
21/74 
89.2 
(80.4 to 94.9) 
74/83 
EFW, Estimated fetal weight <10th centile; PI, pulsatility index; PlGF, placental 
growth factor 
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Table S3: Maternal outcomes for women with very low PlGF (<12 pg/mL) at 


















A 30+0 33+6 1935 10.1 HELLP 
Syndrome 
B 31+4 33+3 1305 0 Severe pre-
eclampsia 
C 31+4 35+4 1825 1.2 Gestational 
diabetes 
mellitus 
D 34+2 39+3 2530 2.7 Atypical pre-
eclampsia 
E 35+2 37+0 2225 0.6 Severe pre-
eclampsia 
F 35+5 36+6 2905 38.5 None 
G 35+5 38+0 2330 2.6 None 
H 35+6 38+0 2260 9.5 Severe pre-
eclampsia 
I 36+0 36+4 2525 38.4 Mild pre-
eclampsia 
J 36+0 37+6 1958 0.1 None 
K 36+1 39+0 2765 8.8 None 
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L 36+3 38+3 2600 17.4 None 
M 36+3 41+1 2710 1.3 None 
N 36+4 37+1 2000 0.3 None 
O 36+4 37+3 2398 6.0 Chronic 
hypertension 
P 36+6 40+2 3720 63.2 Gestational 
hypertension 
 
HELLP, haemolysis, elevated liver enzymes, low platelets. 
 
 
 
